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Abstract 
The HPV vaccine was first made available to girls and women in 2006. Despite 
support for the vaccine from health care professionals and governments, vaccination rates 
remain lower than anticipated. This study had two goals: (1) To investigate factors that 
predict actual and intended vaccinations, and (2) to test a model of HPV vaccination 
intentions.  An adapted Health Belief Model was used as the theoretical framework to 
guide this study. The model components assessed in this study were: Perceived severity, 
perceived susceptibility, perceived barriers, perceived benefits, cues to action, self-
efficacy, knowledge, and subjective norms. Each model component was assessed by at 
least one variable, with some model components being assessed with multiple variables. 
Participants were 374 women, aged 18 to 30, residing in Canada. Data were collected 
using an online questionnaire.  
Logistic regression analyses revealed that actual vaccination decisions were 
directly influenced by the following model components and variables: Perceived severity 
(severity of treatment), perceived barriers (vaccine safety concerns, fear of doctor stigma, 
insurance coverage), and cues to action. Multiple regression analyses revealed that 
vaccination intentions were influenced by: Perceived benefits (vaccine positive beliefs, 
vaccine effectiveness), barriers (vaccine safety concerns), cues to action, self-efficacy, 
and subjective norms. A structural equation model to assess HPV vaccination intentions 
was tested. With a few modifications, support for the model was found. This model 
revealed that all of the theoretical components measured in this study contributed directly 
or indirectly to vaccination intentions. 
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This study revealed that actual and intended HPV vaccinations are predicted by 
different variables. In addition, it also found support for a complex model of vaccination 
intentions. A unique contribution was the finding that women’s fear of experiencing 
stigma from doctors by asking for the vaccine impacted actual vaccination decisions. 
Vaccine safety concerns were also found to impact actual uptake. Finally, healthcare 
professionals may also benefit from understanding that cues to action were found to be 
predictive of behaviours, suggesting that women who are exposed to more cues are more 
likely to get vaccinated.   
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Chapter I 
Introduction  
In 2006 the first vaccine for Human Papillomavirus (HPV), the common sexually 
transmitted infection (STI) that can cause genital warts and cervical cancer, was made 
available to girls and women in Canada and the USA (Gillison, 2008; Krishnan, 2008; 
McKaig, Barie, & Olshan, 1998; National Advisory Committee on Immunization , 2007). 
The announcement of the release, and subsequently, of government plans to begin mass 
school-based vaccination programs for girls, was not met with unanimous public support. 
Instead, many news stories and internet communications about the vaccine were negative 
in tone, describing possible risky side-effects and fears about the influence of the vaccine 
on teen sexual behaviour.  Media titles about the HPV vaccine included: Our girls are not 
guinea pigs: Is an upcoming mass inoculation of a generation unnecessary and 
potentially dangerous? (Gulli, 2007), Experts raise worries about HPV vaccine (ctv.com, 
July 2007), Schoolgirl dies after cervical cancer vaccination (Adetunji, 2009), and 
Defusing the War Over The “Promiscuity” Vaccine (Gibbs, 2006). It should be noted that 
an inquiry into the death of the school-aged girl from the United Kingdom revealed that 
she did not die as a result of the HPV vaccine.  
 Although many initial media stories about the HPV vaccine were negative, the 
benefit of vaccination is widely recognized by health professionals. School-based 
vaccination programs are offered in every province in Canada, and public health 
departments continue to support the vaccine. For instance, the Public Health Agency of 
Canada and the US Department of Health and Human Services both endorse the HPV 
vaccine on their websites. To combat negative media stories about the vaccine, Canada’s 
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Chief Public Health Officer issued a public statement refuting a negative story published 
by MacLean’s magazine (Public Health Agency of Canada, 2007). Although the negative 
public discourse about the HPV vaccine eventually ceased, HPV vaccination rates have 
not reached anticipated goals in some school based programs in Canada, and very few 
women outside of school based programs have been vaccinated. Why? 
Although health professionals may recognize the benefits of HPV vaccination, the 
general public may not. While HPV is a common STI that infects approximately 50-80% 
of individuals at some point in their lifetime (Henderson, Yasgur, & Warshowsky, 2002; 
National Advisory Committee on Immunization , 2007), individuals may not recognize 
the benefits of vaccination. This may be a result of the way in which the vaccine is 
promoted in popular advertisements, namely, as a defence against cervical cancer. A 
description of other benefits, such as protection from genital warts, is often lacking. 
Cervical cancer, however, is not a common illness within Canada. Approximately 1400 
women are diagnosed with it a year, with 400 women dying from it (Health Canada, 
1999).  Because of these statistics (low in comparison to other cancers), girls and women 
in Canada may not feel susceptible, and thus may not feel that the HPV vaccine is 
necessary or beneficial.  
For women who do recognize that they are at risk of HPV infection, and wish to 
avoid possible negative health effects, social and psychological factors may influence 
their actual vaccination behaviour. Women may want the vaccine but may have concerns 
about its safety, especially after the attention paid to this subject in the popular media. 
Related to the fear of negative side-effects, a general distrust of doctors or pharmaceutical 
companies may also influence perceptions of the HPV vaccine. If women distrust the 
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advice of those in the medical field, they may not be willing to act on their prompts to be 
vaccinated. In addition to these possible barriers, HPV’s sexually transmitted infection 
(STI) status may also impede women from obtaining the vaccine. Because STIs are 
viewed negatively by society, women may be uncomfortable asking for a STI vaccine. 
While it is possible that these variables influence HPV vaccination decisions, research 
into some of these factors has not yet been conducted. Because of this, investigating how 
physician and pharmaceutical distrust, as well as comfort with sexuality and the STI 
status of HPV, influences vaccination decisions, was one of the main objectives of the 
current study.   
Of course, in addition to these possible predictors of HPV vaccination decisions, 
past research has also investigated the relationship between HPV vaccinations and 
various other factors. These include: feelings of susceptibility to HPV infection (Kuitto, 
Pickel, Neumann, Jahn & Metelmann, 2010), a fear of needles (Gottvall, Larsson, 
Hoglund & Tyden, 2009), HPV knowledge (Woodhall et al., 2007), a fear of side-effects 
(Burke, Vail-Smith, White, Baker & Mitchell, 2010), perceived benefits of vaccination 
(Dempsey, Zimet, Davis & Koutsky, 2006), cost (Kahn, Rosenthal, Jin, Huang, 
Namakydoust & Zimit, 2008), feelings of self-efficacy (Buchanan, 2008; Kahn et al., 
2008), and health care provider cues to action (Caskey, Lindau & Alexander, 2009).  
While direct relationships between a host of predictor variables and HPV 
vaccination decisions have been examined in previous research, a comprehensive 
understanding of how the types of variables interact with each other to predict decisions 
is still lacking. Thus, another main objective of the current study was to develop a 
comprehensive understanding of these relationships. This was done by testing a 
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theoretically based model of vaccination intentions that included many of the variables 
that had been used in previous research. To date, one of the most comprehensive 
theoretically guided studies of HPV vaccination intentions was conducted by Buchanan 
(2008) for her dissertation. She compared two theoretical models, the Health Belief 
Model and the Theory of Planned Behaviour, to see which would better explain HPV 
vaccination intentions. Her sample was comprised of American university students, and 
the study was conducted soon after the release of the vaccine. Buchanan found that  an 
integrated model that used variables from each theory was actually more predictive of 
intentions than either theory alone. While Buchanan’s research was a good first step to 
developing a model of HPV vaccination decisions, in her study the components of each 
model were simply tested to see if they had direct relationships with the outcome 
variable. How the various model components may influence each other was not 
investigated. In order to build upon this, the current study took the testing of a theoretical 
model one step further, by developing and testing a more complex model of the decision 
process.  
In summary then, the objectives of this study were to investigate factors related to 
actual and anticipated vaccinations in a sample of young women residing in Canada. 
Direct relationships between possible predictor variables and vaccination outcomes were 
investigated. In addition, a proposed model of HPV vaccination intentions was tested. 
While these were the main objectives of this study, this study also makes an important 
contribution to the area of HPV research because it is one of the first studies to be 
conducted in Canada with young adult women. Because many studies have been 
conducted in the US, where the health-care system is different from Canada, and where 
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the cultural values of some segments of society may be quite different, it will be 
advantageous to investigate possible predictors of HPV vaccinations in Canada. Finally, 
this study was also important because of the timing of this research. Many earlier studies 
about the HPV vaccine had to investigate intentions to vaccinate because they were 
conducted prior to the release of the vaccine. Because the vaccine had been available for 
five years at the time this study was conducted, actual vaccination behaviours, as well as 
intentions, were able to be investigated.  
Background: What is Human Papillomavirus (HPV)? 
 Human Papillomaviruses are a family of over 100 viruses, at least 40 of which 
have been found to infect the genital region (National Advisory Committee on 
Immunization, 2007). Genital HPV infection can lead to the development of genital warts 
when individuals are infected with low risk strains such as types 6 or 11, or abnormal 
changes in squamous epithelial cells, such as the skin or mucosae, that can lead to certain 
genital and head and neck cancers when people are infected with high risk strains such as 
types 16 and 18 (Henderson, et al., 2002; National Advisory Committee on 
Immunization, 2007).  
Prevalence. HPV is often cited as the most common STI in the world, with 50 to 
80% of people being infected with it at some time in their lives (Henderson, et al., 2002; 
Krishnan, 2008; National Advisory Committee on Immunization, 2007). Canadian 
studies have found that the proportion of women infected with HPV at any one time is 
estimated to be between 10 - 29%, although studies have found that rates vary by region, 
age and ethnicity (National Advisory Committee on Immunization , 2007). Sellors et al. 
(2000), in a study investigating HPV infection rates in Ontario, found that 24% of women 
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aged 20 to 24 had HPV, with the rate declining as women aged. For example, 16.4 % of 
women aged 25 to 29 had HPV, 12.3% of those aged 30 to 34 had it, and 9.6% of women 
aged 35 to 39 were positive for HPV. Data were presented for women up to the age of 50. 
Another study, conducted in Montreal, examined rates of infection for both high risk and 
low risk strains of HPV. The study found that 21.8% of young women had high risk HPV 
infections, and 14.8% had low risk infections (Richardson et al., 2003). The women in 
this sample had a mean age of 23 years. Although the HPV virus can be found in many 
women, the majority will never notice that they are infected. In most cases the virus 
spontaneously clears the body without causing any adverse physical effects (Krishnan, 
2008; The Society of Obstetricians and Gynaecologists of Canada, 2007). However, a 
proportion of women and men will go on to experience physical symptoms of HPV 
infection.  
Within Canada, studies investigating the prevalence of genital warts are lacking, 
although a study in Ontario found that 1.1% of women who attended health clinics had 
genital warts (National Advisory Committee on Immunization, 2007; Sellors et al., 
2000). Rates from the United Kingdom and the United States of America estimate that 
approximately 1.5 people per 1000 have them. Younger individuals are more likely to 
have genital warts. For instance, six in 1000 women aged 20-24, and five in 1000 men 
aged 25-29 were found to have genital warts (National Advisory Committee on 
Immunization, 2007). For most individuals, the condition resolves within one to two 
years, although the virus can remain in the body indefinitely, making future outbreaks 
possible (National Advisory Committee on Immunization, 2007). 
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 When looking at cervical dysplasia and cervical cancer in particular, Henderson, 
et al. (2002) reported that 10% of women infected with high risk HPV strains will go on 
to develop abnormal cervical cell changes. The Canadian Women’s Health Network 
(2007) states that 8% of the 4 million Pap tests done in Canada each year (approximately 
325,000) require follow-up due to abnormal results. From the time risky (high grade) cell 
changes begin, it can take up to 10 years for cervical cancer to develop. However, in a 
small minority of cases, cervical cancer can develop very quickly, in less than a year 
(National Advisory Committee on Immunization, 2007). Cervical cancer normally peaks 
in women in their 40s, and then again over the age of 70 (National Advisory Committee 
on Immunization, 2007), although the Public Health Agency of Canada (2009) notes that 
67% of cervical cancer occurs in women aged 30-59. In Canada in 2001, approximately 
1450 cases of cervical cancer were diagnosed, and 420 women died (Shah, 2003). 
Fortunately, the treatment for cervical cancer, if caught early, is quite effective. For those 
women diagnosed with cervical cancer, 74% will still be alive five years post-diagnosis 
(Public Health Agency of Canada, 2009). This is a result of the various types of treatment 
that are available to women who are diagnosed, such as chemotherapy, radiation, and 
hysterectomy.  
Pap testing has also been a powerful tool to prevent deaths from cervical cancer. 
Since Pap testing began in the 1960s, rates of cervical cancer have declined greatly. 
Regular Pap smear testing allows cervical cell changes to be detected early on, in most 
cases before the development of cancer. Unfortunately, not all women obtain regular Pap 
testing, so some women remain at risk for developing cervical cancer. There is also a 
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small minority of women who develop cervical cancer very quickly, before pre-cancerous 
cell changes can be caught through tests. 
Reactions to HPV infection. While regular testing can allow the majority of 
women to avoid the most severe outcome of an HPV infection, it does not protect women 
from other negative effects such as psychological distress and potentially painful 
treatments. Research into women’s reactions to being told they have HPV or an abnormal 
Pap smear test has shown that the majority of these women experience adverse 
psychological reactions such as anxiety and distress (Biro, Rosenthal, Wildey & Hillard, 
1991; Doherty, Richardson, Wolfe & Raju, 1991; Juraskova, Butow, Sharpe & Campion, 
2007; Karasz, McKee & Roybal, 2003; McCaffery, Waller, Forrest, Cadman, Szarewki & 
Wardle, 2004; Perrin et al., 2006). For example, in a study of English women attending a 
colposcopy clinic after an abnormal Pap test (N=102), 90% of participants reported 
feelings of fear and worry as an initial response, while 67% reported feelings of 
depression (Gath, Hallam, Mynors-Wallis, Day & Bond, 1995).  A recent study 
conducted in Canada also found that women had negative reactions to abnormal Pap 
smears (Drolet et al., 2012). This study found that 46% of women with an abnormal test 
felt anxiety/depression, with 35% of women still having clinically significant anxiety 12 
weeks after diagnosis (Drolet et al., 2012).  
Women’s sexuality has been found to be greatly impacted by HPV infection in a 
negative fashion, with some women reporting a decreased desire to have sex  (Biro, 
Rosenthal, Wildey & Hillard, 1991; Campion, Brown, McCance, Atia, Edwards, Cuzick 
& Singer, 1988; Gath, Hallam, Mynors-Wallis, Day & Bond, 1995), decreased sexual 
enjoyment (Filiberti, Tamburini, Stefanon, Merola, Bandieramonte, Ventafridda & De 
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Palo, 1993; Gath, Hallam, Mynors-Wallis, Day & Bond, 1995), and less arousal and 
orgasm (Campion, Brown, McCance, Atia, Edwards, Cuzick & Singer, 1988). In 
addition, some women who have received medical treatment of the cervix report 
discomfort during sex and increased negative feelings toward sex, even five months after 
diagnosis and treatment (Campion, Brown, McCance, Atia, Edwards, Cuzick & Singer, 
1988).   
Perceptions of past and future sexual or romantic partners are also influenced by 
diagnosis. For example, women who had abnormal Pap tests reported feeling worse about 
past sexual relationships after they were diagnosed with HPV (McCaffery, Waller, 
Forrest, Cadman, Szarewki & Wardle, 2004). In another study, a worsening of the 
emotional relationship between romantic partners was reported (Filiberti et al., 1993). 
Not only are perceptions of past relationships tainted by diagnosis, but fear for future 
relationships is also reported as a concern of patients by college health care providers 
(Linnehan & Groce, 1999).  
Fear of developing cancer is also a common reaction after an abnormal Pap test or 
HPV diagnosis (Gath, Hallam, Mynors-Wallis, Day & Bond, 1995; Juraskova, Butow, 
Sharpe & Campion, 2007; Karasz, McKee & Roybal, 2003; Maissi, Marteau, Hankins, 
Moss, Legood & Gray, 2004). Interviews with women who had cervical abnormalities 
found that before treatment, 16 of the 21 women interviewed had fears about the 
possibility of developing cancer (Juraskova, Butow, Sharpe & Campion, 2007). These 
fears remained post-treatment for nine of the women, indicating that treating the 
immediate threat does not ease some women’s worries.  Health care providers also 
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recognize that their patients experience a fear of cancer, with providers reporting that 
patients communicate these fears to them (Linnehan & Groce, 1999). 
 In addition to negative psychological reactions, women also experience concerns 
related to their physical bodies. For example, women experience fears of HPV treatment 
(Doherty, Richardson, Wolfe and Raju, 1991), and concerns that the virus will negatively 
affect their fertility (Juraskova, Butow, Sharpe & Campion, 2007). These concerns are 
justified, as medical treatments can be uncomfortable and painful. In addition, knowledge 
that the health of the cervix may be compromised, now or in the future, would not 
surprisingly cause women to ponder  about future childbearing.  
As the above research highlights, women have multiple negative reactions to 
being diagnosed with HPV or having an abnormal Pap test. Thus, while Pap testing is an 
important and vital component of ensuring women’s health, a vaccine that would enable 
women to avoid HPV infections altogether would ensure that women do not have to 
experience these varied negative reactions to symptomatic infections and treatment. It is 
important to recognize that many of the negative reactions that women have to diagnosis 
are likely related to HPV’s STI status. While previous research has not investigated this 
link, the current study examined whether a relationship does exist. Findings from HPV 
research that has found that women feel anxious and depressed after diagnosis, and that 
they have concerns about past and future relationships, may indirectly demonstrate how 
the stigma of STIs negatively influence women.  
Risk factors. There are various risk factors that are associated with HPV 
infection. Demographically, groups of women in Canada who tend to have the highest 
rates of infection are younger women (with highest rates for men and women under the 
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age of 25) and Aboriginal women (Krishnan, 2008; National Advisory Committee on 
Immunization, 2007). For all women, factors that are related to an increased risk of 
contracting HPV are: number of lifetime sexual partners, having unprotected sex, 
engaging in activities that lead to sexual risk taking (e.g., substance abuse), younger age 
at first intercourse (through its link to number of partners, cervical development, and 
risky behaviours), and having a sexual partner who has had multiple partners (Henderson, 
et al., 2002; Krishnan, 2008).  
Unfortunately, knowledge of these risk factors does little to decrease the stigma of 
individuals infected with an STI. A girl or woman reading these risk factors may notice 
that they describe behaviours typically labelled as amoral by society. In order to avoid 
association with a group often deemed undesirable, girls or women may tell themselves 
they are not at risk of HPV infection, thus having an impact on their desire to obtain the 
vaccine. In addition, if women do recognize that they are at risk of HPV infection, be it 
regular risk or high risk, they may be reluctant to ask for a vaccine for a virus known to 
infect those who engage in risky sexual behaviours more frequently. To do so may be to 
open oneself up to experiencing stigma.  
Disadvantaged women. Individuals who are socially disadvantaged experience 
an increased incidence of various diseases, cervical cancer included (Raphael, 2009). The 
over-representation of poor, rural, isolated, under-educated, immigrant, and/or minority 
women (McGibbon, 2009; Rimer, McBride and Crump, 2001; Shah, 2003; Tiersma et al., 
2004) in those who are diagnosed with cervical cancer, or more severe forms of cervical 
dysplasia, highlights how social determinants of health impact these women. Women 
who belong to one or more of these groups may have limited access to appropriate or 
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reliable health care, and they may have a limited ability to engage in health promotion 
and protection activities. For example, African American women were found to be 
diagnosed with cervical cancer at a later stage, to be less likely to receive treatment in 
comparison to Caucasian women, and to be more likely to die as a result of cervical 
cancer (McGibbon, 2009). Sadly, the factors that contribute to disadvantaged women’s 
lack of Pap testing are also likely to have an impact on their ability to obtain the HPV 
vaccine. This argument is often made to demonstrate how the HPV vaccine will not 
necessarily save the lives of women living in Canada or the USA. While this is an 
important point that must be addressed, be it with more funding for Pap testing for 
disadvantaged women or free HPV vaccinations for those in need, the importance of the 
HPV vaccine in protecting women’s health should not be dismissed.  
Background: The HPV Vaccine 
 So far, this paper has discussed the HPV vaccine without providing detail about 
when it was developed and vaccination goals. The first HPV vaccine was released for 
females in 2006. In 2010 it was also approved for males. The vaccine protects against 4 
strains of HPV that cause 70% of cervical cancers and 90% of genital warts (Krishnan, 
2008). In Canada, the vaccine was first approved for girls and women aged nine to 26, 
and the National Advisory Committee on Immunization recommends that women up to 
the age of 26 be vaccinated (2007). The Public Health Agency of Canada (2011) 
“recommend[s] the vaccine for females 14 to 26 years of age as there still is the potential 
for benefit regardless of previous sexual activity, Pap abnormalities, cervical cancer, 
anogenital warts or a known HPV infection.”  Currently, grade eight girls in Canada may 
receive the HPV vaccine for free. Outside of grade eight, other girls and women are 
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responsible for payment of the three-dose vaccine, either personally or through their 
insurance providers if they are eligible.   
The vaccine has been widely touted by professionals as a promising tool to 
combat HPV infection. Initial models created to assess clinical population effects of 
widespread vaccination defined the best-case scenario as vaccination uptake levels of 70-
100% of the targeted population (Dempsey & Mendez, 2010). It was assumed in initial 
modelling that these targets would be reached within a few years of vaccine introduction, 
although these goals may have been too idealistic given the nature of the vaccine and the 
target population  (Dempsey & Mendez, 2010).  
For an HPV vaccination program to be successful, the majority of girls and 
women (and now boys and men) must be vaccinated. Unfortunately, although many 
preliminary studies found that a majority of parents would approve the vaccine for their 
daughters, or that young women and girls believed that they would accept the HPV 
vaccine when it became available, actual vaccination rates are lower than expected.      
Anticipated rates of vaccine acceptance. Prior to 2006, even though the 
introduction of an HPV vaccine was considered controversial in some circles, the 
majority of individuals for whom permission to vaccinate was required, namely mothers 
of daughters and young women, appeared to accept the idea of the vaccine, or to be open 
to learning more about it. For example, despite a general lack of public awareness of the 
impending availability of an HPV vaccine in 2003, a study conducted by Kahn, 
Rosenthal, Hamann and Bernstein (2003) found that the majority of study participants (52 
young women with a mean age of 25) had positive attitudes toward an HPV vaccine, with 
89% of them believing that it would be a good idea to get vaccinated. Jones and Cook 
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(2008) found similar high rates of acceptance. They examined the vaccination intentions 
of male and female college students, and found that 88.6% of women and 77.5% of men 
would get the vaccine (Jones and Cook, 2008). Kahn et al. (2008) found slightly lower 
levels of acceptance with a younger sample. Their results indicated that 66% of their 
sample of 409 sexually experienced girls and women aged 13-26 intended to get the HPV 
vaccine. This lower rate is likely influenced by the responses of the younger girls in the 
sample who may not be sexually experienced, and thus may not feel at risk for acquiring 
an STI. The one Canadian study that examined HPV vaccine acceptance found similar 
rates to those above, where 89% of their adult male and female sample would recommend 
the HPV vaccine to daughters or nieces (Sauvageau, Duval, Cilca, Lavoie & Ouakki, 
2007). A number of other studies have also found similar results (Brewer & Fazekas, 
2007; Christian, Christian & Hopenhayn, 2009; Constantine & Jerman, 2007; Lenselink 
et al., 2008; Marshall, Ryan, Roberton & Baghurst, 2007; Woodhall et al., 2007). As 
previous research has demonstrated then, a majority of individuals reported that they 
would accept or support an HPV vaccine. Unfortunately, perceptions do not appear to 
predict real-world behaviours in this situation.  
Actual rates of vaccine acceptance. Although initial interest in the HPV vaccine 
appeared positive, actual vaccine uptake rates after the 2006 release were surprisingly 
low, ranging from 50-85% for school based programs and 10-30% for non-school-based 
programs. Initial cost-benefit studies predicted vaccination uptake rates of 70-100% 
within five years (Dempsey & Mendez, 2010; Kim & Goldie, 2008). Dempsey and 
Mendez (2010) have described how various policy decisions impact uptake rates. They 
Factors that influence HPV vaccinations  15 
 
predicted that with a mandated school-based program 70% coverage could be obtained in 
8 years, but with no mandated program this rate would not be reached for 23 years.  
Research has consistently found that acceptance rates do differ depending upon 
the setting/target group (i.e., school based programs versus non-school based programs). 
For Canadian school-based vaccination programs, rates of receipt range from 50% to 
85% depending upon the province, with east coast provinces having the highest uptake 
rates and Ontario, Alberta and Manitoba the lowest (Canadian Women’s Health Network, 
2008; Graveland, 2009). In Canada, school-based vaccination programs for girls began in 
some provinces in 2007 and expanded into others in 2008. After the first year school-
based vaccination programs were available in Nova Scotia, Prince Edward Island, and 
Newfoundland, uptake of the HPV vaccine was at 80% and above (Canadian Women’s 
Health Network, 2008). Graveland (2009) reported that in Nova Scotia and Prince 
Edward Island rates were 80% for school-based programs, in Newfoundland they were 
83%, and in Quebec rates ranged from 84-87%. Rates in Ontario were lower, where 
approximately 50% of girls received the vaccine through school-based programs 
(Graveland, 2009; The Canadian Women’s Health Network, 2008). In the West, 66% of 
girls were vaccinated in British Columbia, while in Alberta and Manitoba 50-55% had 
received vaccines through school programs (Graveland, 2009). 
 Uptake among girls and women not eligible for school-based program is even 
lower than the lowest school-based rates, with only 10% to 30% of females obtaining the 
vaccine (Caskey, Lindau and Alexander, 2009; Gottlieb et al., 2009).  For example, 
Caskey et al. (2009) conducted a large nationally representative study of American girls 
and women (n = 1011) and found that 30% of 13 to 17 year olds, and 9% of 18 to 26 year 
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olds reported that they had received at least one of the three required HPV vaccine shots. 
A smaller study of university women found that of 64 participants, only 4 had received 
the HPV vaccine and of those who had not been vaccinated, only 65% were interested in 
getting it (Gerend & Magloire, 2008). Not surprisingly perhaps, age influences HPV 
vaccine usage. Gottlieb et al. (2009) found that only 10% of their study sample had 
actually gotten the HPV vaccine, even though the sample was located in an area with 
elevated cervical cancer rates. Age was a factor, with 17.5% of 16-18 year olds getting 
the vaccine, compared to 6.4% of 10 to 12 year olds. As these results indicate, it is clear 
that non-school-based HPV vaccination efforts as they currently exist are largely 
ineffective at encouraging girls and women to obtain the vaccine (Rouzier & Giordanella, 
2010).  
Age, vaccine acceptance, and the current study. While the success of school-
based HPV vaccination programs depends largely on the views and support of school 
boards and parents, grade-eight girls themselves are likely to have little decision-making 
power, or interest, in whether they receive the HPV vaccine or not. The group of women 
who have the most control over their own inoculation are those over the age of 18. While 
vaccination at younger ages (before girls are sexually active) is the most effective way to 
prevent HPV infection, promoting and vaccinating older girls and women can also be 
important. The Public Health Agency of Canada (2011) reports that while there is no 
official recommendation to vaccinate women over the age of 26, that the use of the 
vaccine for women over this age can still be considered.  
 In addition to the official age recommendations provided by governing health 
bodies, it is also important to understand the HPV vaccination beliefs and behaviours of 
Factors that influence HPV vaccinations  17 
 
women in their twenties (and beyond), because of current societal dating and marriage 
trends. Canadians are marrying later (Clark & Crompton, 2008), and thus dating longer, 
suggesting that many women may still be exposed to new sexual partners well past their 
26th birthdays. In addition, divorce is fairly common; consequently, women can find 
themselves dating again at the end of a marriage or long-term relationship.  The average 
age of a second marriage is 39 years (Clark & Crompton, 2008). Although statistics on 
cohabitation are not available, the divorce and dating pattern for individuals in common-
law relationships is most likely similar to that of individuals who marry, with some 
statistics indicating that common-law relationships are even more unstable (Clark & 
Crompton, 2008). As these statistics demonstrate, then, many women, including those 
over the age of 26 or who may be deemed at low-risk due to their current relationship 
status, can still benefit from the HPV vaccine.      
In light of the need for women over the age of 18 to be vaccinated against HPV 
infection, the current study examined the vaccination beliefs of women aged 18 to 30. 
These are women who currently fall within the recommended vaccination age range of 14 
to 26, or who did fall within this age range when the vaccine was first approved in 2006. 
Vaccination in Canada: Conclusions. As the research described in the sections 
above indicates, although intentions to become vaccinated against HPV appeared high 
before the release of the vaccine, once it became available, actual rates of receipt were 
lower than anticipated. While some school-based programs in Canada are effective 
(obtaining over 80% vaccination rates), other school-based programs, and all non-school 
based efforts, have been much less effective at encouraging the majority of girls and 
women to obtain the HPV vaccine. The reasons for this lack of uptake need to be 
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investigated fully if the HPV vaccine is to be successful in protecting all women from 
HPV infections and their resulting negative physical and psychological effects. Gaining 
an understanding of the complex factors that influence the receipt of a vaccine for an STI 
is also important because other STI vaccines are also needed and in development. 
 It is evident that there are notable differences in HPV vaccination rates. Cost and 
ease of access appear to impact uptake rates as free, school-based programs are the most 
effective means of vaccine delivery. However, the variance observed between uptake 
rates by province, and even between women who are not eligible for school-based 
programs, indicates that factors more complex than cost and accessibility are at play. 
There are various psychological, social, and practical reasons for why some girls and 
young women do not obtain the HPV vaccine. These reasons are discussed in the 
following sections.  
Distrust of the Medical Establishment and How it Can Impact Vaccinations 
 In the 1970s and 1980s, research on the growing distrust of the medical 
establishment began to appear (Betz & O’Connell, 1983; Shontz, 1974 ). Betz and 
O’Connell (1983) published an article discussing the growing distrust of professionals in 
North American society, stating that a Harris poll conducted in 1976 found that 
confidence in the medical institution declined from 72% to 43% between 1966 and 1975. 
Unfortunately, this distrust may still be present. Armstrong et al. (2006) found that 
distrust in the health care system is relatively high in the United States. Their sample was 
composed of 961 primarily Caucasian individuals, 80% of whom had health insurance. 
Eighty-two percent of their participants believed that people die every day because of 
mistakes made by the health care system, 58% believed that if a mistake was made in 
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their health care that the health care system would try to hide it, and 71% believed that 
there are ingredients in medicines that people are not informed about. While distrust in 
institutions or organizations appears to be high, Hall, Dugan, Zhang, Michra (2001) in 
their review of physician trust, have stated that individuals may have different 
perceptions of trust of individual doctors in comparison to health care systems or 
organizations. They report that “90% or more of patients express some level of trust in 
their physician, and two-thirds express strong trust” (p. 626). These researchers also note 
that in comparison to physicians, trust in health care establishments such as hospitals and 
insurance companies is lower. In light of these varying perceptions of trust, the current 
study examined participant perceptions of trust in physicians, as well as their trust in a 
larger health entity and key player in the vaccine industry, pharmaceutical companies. 
This was done in order to determine current levels of trusts in Canada, and whether 
perceptions of trust are related to HPV vaccination behaviours or intentions. 
Medical distrust has been linked to various health related behaviours. A study that 
looked at the construct of trust in the healthcare system and the use of preventative 
medical services in a sample of 1681 older adults found that having trust in one’s 
personal physician was related to use of preventative health services, with higher levels 
of distrust being associated with lower rates of health service usage (Musa, Schulz, 
Harris, Silverman & Thomas, 2004). Not only are levels of trust related to healthcare 
usage, but also to perceptions of actual health. One study found that distrust in the health 
care system was significantly related to worse self-reported health (Armstrong et al., 
2006). As this research reveals, then, the concept of trust in the healthcare field is 
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important, as a lack of trust can be expected to lead to negative health outcomes, such as 
lack of vaccination behaviours. 
How has medical distrust arisen? Betz and O’Connell (1983) proposed that 
distrust in doctors rose in the 1970s because the doctor-patient relationship had become 
more impersonal, short-lived, and specialized as individuals saw various doctors rather 
than relying on one family physician. The bureaucracy associated with medicine, as well 
as increased feelings of social distance and increased population mobility (and the result 
that many individuals do not know or have community connections to their doctors) were 
also discussed as contributing to increased physician distrust.  
More recently, high-profile medical mistakes or adverse research findings may 
have had a negative impact on public perceptions of the medical establishment as well. 
For instance, stories about dangerous drugs or supplements such as the diet drug Fen 
Phen, which can cause heart damage; the diabetes medication Avandia, which also has 
been found to damage the heart; and Accutane, the acne medication which has now been 
linked to Crohn’s disease and Colitis, may all impact the public’s trust. One of the most 
high-profile and emotionally-charged health-related controversies however, is that of a 
proposed link between childhood vaccinations and autism. This controversy, along with 
its impact on vaccination rates and the anti-vaccine movement in general, will be 
discussed in the next section.       
Anti-vaccine sentiment. The first vaccines were created over a century ago, and 
since that time immunizations have played an important role in maintaining population 
health, so much so that vaccines are touted as one of the most important medical 
advances in history to date (Link, 2005). Although the majority of individuals believe in 
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the benefit of vaccines (Heller, 2008), an anti-vaccine sentiment has gained popularity. 
Allen (2007), a writer and journalist, reports in his well-received book on vaccines that 
the latest controversy surrounding vaccines developed over the last decade. He reports 
that this was due to a number of factors: (1) the removal of a number of pharmaceuticals 
from shelves due to safety concerns, and a resulting suspicion of the safety of all 
pharmaceuticals, (2) distrust in those who regulate medicines, and (3) the popularity of 
the theory that the Measles Mumps Rubella (MMR) vaccine causes autism.  
The idea that vaccines cause autism began in the late 1990s and gained popularity 
in the early 2000s (Allen, 2007). The idea came from a study that was published in the 
esteemed medical journal, the Lancet, in 1998. The study, led by Andrew Wakefield, 
stated that a possible link between the Measles Mumps Rubella (MMR) vaccine and 
autism may exist. In 2004, 10 of the original 12 authors of the article issued a statement 
in the Lancet that they wanted to retract the interpretation that there may be a link 
between the vaccine and autism from the original article (Murch et al., 2004).  The 
journal article itself has since been retracted (The Editors of The Lancet, 2010), and in 
2011, the British Medical Journal reported that the study was a deliberate fraud. Before 
the official retraction, various studies were conducted in order to investigate the possible 
relationship between vaccines and autism. One of these studies was conducted in Quebec, 
and like the others, found that no link exists (Fombonne, Zakarian, Bennett, Meng & 
McLean-Heywood, 2006).  
While the Lancet article was eventually retracted, damage to the public’s trust in 
vaccines had already been done. Some individuals now feared vaccinations and the 
potential side effects the public feared they could produce. Popular media both 
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propagated this fear and tried to calm it. Articles from popular media included titles such 
as:  An Epidemic of Fear: How Panicked Parents Skipping Shots Endangers Us All 
(Wallace, 2009), H1N1 Flu Shot: 3 Major Fears Debunked (Biba, 2009), The Autism 
Debate: Who’s Afraid of Jenny McCarthy? (Greenfeld, 2010), The Vaccine-Autism link 
an Elaborate Fraud (MacLeans, 2011), Autism, Vaccines and Fear (Wente, 2010), and 
Swine Flu Fiasco: Everyone Needs the Vaccine. Few Plan to Get it. What you Need to 
Know. What You Need to Do (Gulli, 2009). A Canadian study that was conducted to 
investigate attitudes toward vaccines found that while the majority of respondents had 
positive views of the effectiveness of vaccines, 62% of participants were reluctant to 
dismiss anti-vaccine positions (Ritvo et al., 2003). Surprisingly, 45% of participants 
reported that they did not have enough knowledge about the safety of vaccines to 
comment on the topic. The authors noted that participants’ lack of knowledge about 
vaccines may cause them to be susceptible to anti-vaccine messages, a concern they 
believed public health should take seriously in the event of an emergency that would 
require vaccinations. 
Not only have some people internalized fears about vaccines, but actual 
behaviours have also changed. Some countries experienced actual drops in vaccination 
rates. For instance, in the USA in the early 2000s only 2% of parents refused to vaccinate 
their children, but throughout the 2000s vaccination rates decreased in some areas, with 
vaccine exemption rates in some communities doubling and tripling (Allen, 2007).  For 
example, by 2004, vaccination rates in one Colorado community had fallen so much that 
1200 cases of Whooping Cough were reported, the highest rate of the illness since 1964 
(Allen, 2007). The United Kingdom also experienced drops in immunization rates. In the 
Factors that influence HPV vaccinations  23 
 
mid-nineties the vaccination rate for the MMR vaccine was above 90%. This fell to a low 
of 80% in 2003-2004, although it is currently increasing again (rates were 88% for 2009-
2010). Rates have yet to reach their mid-1990s levels however, or the World Health 
Organization goal of 95% uptake (National Health Service, 2010). In Canada, while 
drops in childhood immunization rates haven’t been as large as those of the USA., 
England, or Ireland for example, immunization rates for many viruses and illnesses are 
still lower than target levels. The Influenza vaccine, for instance, while becoming more 
popular over the last decade, was still only obtained by 34% of the population in 2005 
(Statistics Canada, 2008). During the H1N1 vaccine program of 2009, when all 
Canadian’s were urged to obtain the vaccine for this particularly severe flu strain, only 
41% of Canadians were vaccinated (Gilmour & Hofmann, 2010).  
Research has been conducted to investigate how fears of vaccine safety and 
distrust in the medical establishment influences immunization decisions. Prislin, Dyer, 
Blakely and Johnson (1998) conducted in-person interviews with 4832 parents. They 
found that while external barriers (e.g., cost, logistical considerations) play a part in 
influencing whether parents have children vaccinated, factors such as beliefs about 
natural immunity, distrust of health professionals, and vaccine safety concerns also play a 
role. Research has also revealed a potential paradox, where individuals believe in medical 
science, but distrust health professionals. Gullion, Henry and Gullion (2008) conducted 
interviews with 25 parents who consciously chose to forgo or delay childhood 
vaccinations. Themes that arose from these interviews showed that parents place a high 
value on scientific knowledge, while at the same time voicing their distrust of the medical 
community. Some participants reported that they were suspicious of the reasons 
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physicians supported vaccines, stating that they believed doctors had specific agendas 
such as being rewarded financially. Some participants also mentioned that they do believe 
that physicians have good intentions, but that they are too busy to stay current with new 
medical developments. Thus, these parents believed that by doing their own research they 
could gain more knowledge about vaccinations than their physicians. To explain this 
distrust, the authors of the study discussed the current nature of physician visits. They are 
often short, and physicians do not have time to devote to explaining medical procedures 
or decisions. This means that individuals often do not have their medical information 
needs met, resulting in fears or concerns that are not addressed by doctors (Gullion, 
Henry and Gullion, 2008). Because of this, individuals begin seeking out their own 
medical information.  
Fear of the HPV vaccine. Given the anti-vaccine sentiment that grew in the 
2000s, it may not be surprising that when the HPV vaccine was released in 2006 that it 
was met with controversy and fear by some. As the media articles mentioned earlier in 
this document highlight, some individuals feared potential side effects from the HPV 
vaccine, and others feared its impact on girls’ sexuality. When beliefs about the safety of 
the HPV vaccine were actually investigated, it was found that while a majority of 
individuals believe the vaccine is safe, a portion of people are uncertain. For example, a 
study by Rosenthal et al. (2008) found that 57% of parents agreed that the HPV vaccine 
was safe, 33% were unsure, and 10% did not think that it would be safe to give to their 
children. In another study of 52 women aged 18 to 30 that investigated factors associated 
with HPV vaccination, 75% of the sample reported that they believed the HPV vaccine 
was very or extremely safe (Kahn, Rosenthal, Hamann and Bernstein , 2003). This 
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suggests that 25% of the sample were either uncertain, or did not believe this.  Concerns 
about HPV vaccine safety, if administered to the self or a daughter, were also found in 
others studies where the rates of participants who had safety concerns were 24% (Caskey, 
Lindau & Alexander, 2009), 7% (Constantine & Jerman, 2007), and 5% (Marshall, Ryan, 
Roberton and Baghurst, 2007), and the rates of concern about side-effects were 66% 
(Marshall et al., 2007). A Canadian study conducted in British Columbia that investigated 
predictors of school-based HPV vaccine acceptance found that fear of the safety of the 
vaccine was a predictor of parent’s decisions to have their daughters’ vaccinated, with 
29.2% of the sample reporting this as a reason for not having their daughter vaccinated in 
the school-based program (Ogilvie et al., 2010). 
While concerns about the safety of the HPV vaccine may be related to fears of 
vaccines in general, concerns about sexuality, or other factors, the newness of the HPV 
vaccine and thus a lack of data on side effects may have contributed to the relatively high 
rates of concern reported for this specific vaccine. In fact, in a study of parental attitudes 
towards HPV vaccination, Gerend, Weibley and Bland (2009) found that 50% of the 
parents in their sample of 82 individuals felt reluctant to give the new HPV vaccine to 
their daughters. They reported that they would feel more secure if the vaccine had been 
safely on the market for three years or longer. The current study was able to investigate if 
concerns about vaccine safety impact HPV vaccinations, along with an examination of 
the many other factors that may influence vaccine uptake.  
While it is obvious that concerns about the vaccine do exist, do such concerns 
actually influence uptake? Research has examined how a fear of side effects influences 
HPV vaccination behaviours, and some studies have found that concerns do influence 
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acceptance (Kahn et al., 2008; Woodhall et al., 2007). For instance, a study by Woodhall 
et al. (2007) found that of 727 parents surveyed, of those who were resistant to having 
their child vaccinated, 13% rated their concern about the safety of the HPV vaccine as 
high, and 57% rated their concern as medium. Kahn et al. (2008) also conducted  a study 
investigating HPV vaccination rates and factors that influence intentions to receive it. 
Their sample was comprised of 409 sexually experienced women aged 13 to 26.  
Questionnaires assessed HPV vaccination history, demographics, behaviours, knowledge, 
beliefs, and gynaecologic history. The results of the study indicated that only 5% of the 
sample had received one of the HPV vaccine shots and that various factors were related 
to future HPV vaccination intentions. Concerns about the safety of the vaccine was one 
factor. Others included practical barriers like cost, knowledge, norms, and perceived 
severity and benefits. While it is obvious that concerns about side effects influence 
acceptance of the vaccine, it is important that other possible concerns also be 
investigated. Concerns that were investigated in the present study include: trust in 
physicians, trust in pharmaceutical companies, concerns about the STI status of the 
vaccine and associated stigma, along with many other variables.  
It is important to note here, that the safety of the HPV vaccine has been widely 
demonstrated through research (Harper et al., 2006; Munoz, 2009). In a study conducted 
by Medina et al. (2010), 1035 girls from 12 countries were administered the HPV 
vaccine, while 1032 girls were administered the hepatitis A vaccine. The hepatitis group 
was used as a control group. The HPV vaccine was not found to lead to more  serious 
adverse event reports than the hepatitis vaccine. Only one reported adverse event from 
the HPV group was deemed to be related to vaccination. This reaction was a urinary tract 
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infection in conjunction with elevated liver enzymes (the participant recovered). Other 
serious medical events that were reported by the HPV group were not related to 
vaccination, as any adverse medical event that occurred in the months after vaccination 
was recorded. These serious adverse events included things such as: pneumonia, 
enterobiasis, gastroenteritis, upper respiratory tract infection, gunshot wound, 
dehydration, abdominal pain, bronchitis, and injury. Individuals in the HPV group did 
report more headache, fatigue, muscle pain, and rash than those in the control group, 
however. 
Distrust and safety concerns and the current study. In summary, the goals of 
the current research as they pertain to the concept of medical distrust, included an 
examination of: (1) perceptions of the safety of the HPV vaccine, (2) beliefs in the 
trustworthiness of physicians, and (3) beliefs in the trustworthiness of pharmaceutical 
companies, and how these variables were related to HPV vaccination decisions.  
The STI Status of HPV And How It Can Impact Vaccination 
When investigating factors that impact HPV vaccination behaviours, it is 
important to recognize that the HPV vaccine is not just a regular vaccine. The sexually 
transmitted nature of the human papillomavirus means that there are unique social and 
psychological factors tied up in perceptions of the vaccine. As Casper and Carpenter 
(2008) state in their examination of the HPV vaccine and notions of sexuality, the HPV 
vaccine “provokes longstanding controversies swirling around sex, gender and women’s 
bodies” (p.896). While little research has examined how the sexually transmitted nature 
of the human papillomavirus influences actual vaccine acceptance, it is likely that factors 
such as STI stigma and shame, embarrassment, and sexual comfort or discomfort may 
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influence actual or anticipated HPV vaccine receipt. It is important to note that Zimet, 
Liddon, Rosenthal, Lazcano-Ponce and Allen (2006), reported in their review of factors 
that influence vaccinations that the STI status of the HPV vaccine should not impact 
uptake. They based this belief on research that investigated young adults’ interest in the 
vaccine and the finding that a large majority of youth were interested in obtaining it, even 
when it was described as an STI vaccine. We now know, however, that HPV vaccine 
uptake has not reached anticipated levels. It is the belief of this author that the STI status 
of HPV does have an impact on participants’ vaccination decisions.  
Heller (2008) outlined the unique challenges that face vaccines for sexually 
transmitted infections in a discussion about the potential development of an HIV vaccine. 
He outlined how negative social perceptions about HIV and the “type” of people who 
acquire it, hampers public support for HIV preventative measures such as a vaccine. 
Because of the manner in which HIV is spread, either through unprotected sexual contact, 
intravenous drug use, or blood transfusions, individuals infected with it are blamed for 
their infections, Heller notes (2008). While part of the negative reaction to the HIV 
vaccine is likely related to homophobia, as HIV was first described as a disease of gay 
men, stigma is associated with all STIs, due to the sexually transmitted nature of the 
viruses, and the perceptions of the people who get them. Because of this, vaccines for any 
STI may face backlash. For example, Allen (2007) described how protests of school-
based Hepatitis vaccination programs arose in the 1990s. Religious organizations and 
their supporters protested the use of the vaccine, in part due to its status as a virus that 
could be spread by sex or intravenous drug use (Allen, 2007).  
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Due to the negative perceptions that people have of STIs, there are likely various 
barriers that impede individuals from wanting to obtain a vaccine for an STI. First, people 
may not believe they are at risk of STI infection because they think that they are not the 
“type” of person who would get an STI (e.g., promiscuous, risky, likely to have infected 
partners). Second, individuals may blame those who do acquire STIs for their own 
infections, and thus may not support preventative measures. Third, even if individuals do 
believe in STI vaccination and that they are at risk for acquiring an STI, they may fear 
stigma from health professionals, friends or romantic partners if they obtain the vaccine. 
And finally, individuals may simply be too embarrassed to discuss sexually related topics 
with healthcare providers. As this list demonstrates, there are many STI-related reasons 
why an individual may not want the HPV vaccine, or may not feel comfortable asking for 
it. While all individuals in North American society do not hold prejudicial attitudes 
towards sex, STIs, or those who are infected with them, prejudices are held by some 
individuals, and thus fears of STIs and associated stigma abound. Research findings 
concerning STI associated stigma will be discussed next.  
STIs, stigma and shame. Research has consistently found that STIs are viewed 
negatively. For example, Smith, Mysak and Michael (2008) conducted a study using 
vignettes that described the diagnosis of a target with either a sexually transmitted 
infection or another illness, in which symptoms and prognosis were held constant. 
Results indicated that targets who were described as having a STI were rejected more by 
study participants. Interestingly, although gender was hypothesized to influence target 
perceptions, with women being perceived more negatively, no differences were found. 
The authors note that this is in line with more recent research, and may indicate that 
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sexual double standards are decreasing. Thus, STI stigma is a concern for both men and 
women. Another study, conducted by East, Jackson, Peters and O’Brien (2010) using 
online interviews, also found that participants admitted to viewing those who had STIs 
negatively, even though the participants had recently been diagnosed with an STI 
themselves. The study authors proposed that these individuals were experiencing self-
blame and shame, and were attempting to deal with their diagnosis by denying and 
minimizing their infections to themselves and to others (and thus not identifying with 
others who have STIs).  Some participants did indicate that they felt shame because of 
their infection, and that it lead to their denial.   
Feelings of stigma and shame by those infected with STIs were also found in 
other studies. In an  interview study of 60 individuals with either HPV or Genital Herpes 
that was conducted to investigate the impact of STI infection on individuals and their 
relationships, the majority of participants stated that “the stigma associated with having 
an STI made them feel depressed, sad or upset” (Newton & McCabe, 2008, p. 866). 
Consistent with the Newton and McCabe study that had a sample in which half of its 
members had HPV (30 individuals had HPV, and 30 had herpes), other studies 
investigating perceptions of HPV infection have also found that individuals do perceive 
an HPV infection as stigmatizing (Kahn et al., 2007; Perrin et al., 2006).  
The negative associations that individuals hold of STIs and the people who get 
them are not only detrimental because of the psychological and social effects they have 
on individuals, but also because these STI fears can act as a barrier to seeking STI testing 
or treatment, and thus may lead to negative physical outcomes as well. For example, a 
study of 594 youth revealed that youth who view STIs as stigmatizing have a decreased 
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likelihood of being tested for STIs (Cunningham, Kerrigan, Jennings & Ellen, 2009). 
This finding was true for both males and females. Interestingly, this relationship was not 
found when perceptions of STIs as shameful were assessed in this study. However, 
Cunningham et al. noted that shame was found to influence STI testing in another study. 
Similar results were also found in a large study (N = 1973) by Fortenberry et al. (2002), 
who found that feelings of STI stigma and shame acted as barriers to STI testing, 
although STI stigma appeared to have the largest influence. A relationship between 
stigma and STI testing was also found by Barth et al. (2002). They investigated factors 
that influenced whether youth would seek STI testing and found that a fear of stigma was 
one of the reasons individuals did not get tested.  More specifically, participants reported 
that they feared being perceived negatively by others (e.g, as  dirty, stupid, or loose), 
being embarrassed or gossiped about, and feeling shame, guilt or other negative 
emotions. Finally, Balfe et al. (2010) conducted interviews with 35 Irish women, asking 
about perceptions of individuals with an STI. Participants viewed women with 
Chlamydia, or who needed testing for Chlamydia, as irresponsible and sexual risk-takers, 
quite different from how the participants viewed themselves, indicating that people who 
acquire STIs are others. Participants viewed being tested for Chlamydia negatively, and 
reported that doing so would open them up to stigma and social ostracism. To 
participants, not getting tested for the STI was a positive thing which enabled the women 
to maintain their sense of being a “good” person. As the research outlined above exhibits, 
negative perceptions of STIs do influence whether individuals will undertake 
preventative health measures (e.g., STI testing, STI vaccinations).  
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Even when the time for prevention has passed and treatment is needed, fear and 
stigma may still lead to a lack of treatment seeking. For example, Lichtenstein (2003) 
conducted focus groups with 42 participants to investigate how STI related stigma 
impacts individuals’ willingness to seek treatment in the southern USA. Findings from 
the focus groups confirmed that STI related stigma did impact participant willingness to 
seek treatment for STIs. Four types of stigma concerns were revealed in the focus groups. 
Individuals feared stigma because of: religious reasons, concerns about their privacy, 
fears of being the target of gossip, and concerns having to do with race. As this study 
demonstrates, STIs and how they are perceived by society has a very large impact on 
individual behaviour.  
Sexual comfort, sexual activity, and the HPV vaccine. While the stigma and 
shame associated with STIs is widely shown to influence STI-related health behaviours, it 
is likely that other sexually related factors such as comfort with sexual communication 
and conservatism also influence sexual health behaviours, and thus HPV vaccine 
acceptance. Comfort communicating with a health professional about the HPV vaccine 
may be important for women who want to obtain the vaccine. When speaking with health 
care providers, the topic of the vaccine may also come up in conjunction with 
conversations about other sexual behaviours, and thus comfort engaging in these 
conversations may prove to be important to HPV vaccine acceptance. Research that has 
investigated comfort discussing sexuality and STI vaccine behaviours is limited. 
However, Gamble, Klosky, Parra and Randolph (2010), wrote a review article about 
factors associated with family HPV vaccine decision-making. In it they recognized that 
sexual communication may be an important factor related to HPV vaccine acceptance. In 
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their article, their discussion focused on parent-child sexual communication, and how 
comfort in engaging in this type of talk is important for adolescent sexual health. They 
recommended that more research be conducted in this area.  
Conservatism may influence how individuals feel about sex and STIs in general. 
For instance, sexual and social conservatism were found to be associated with higher 
scores on STI stigma and shame measures in a Canadian study of 218 male and female 
university students (Foster & Byers, 2008). Sexual conservatism has definitely been 
found to influence some parents’ perceptions of the HPV vaccine. When the HPV 
vaccine was released in the USA in 2006 conservative parents protested, often stating that 
mandatory vaccination of young girls was immoral and compromised family values 
(Krishnan, 2008). Opponents to mandatory HPV vaccine programs stated that because the 
virus is spread sexually, and not through uncontrollable transmission methods like 
surface germs or sneezing, that parents should have the choice to vaccinate their children. 
For parents with sexual concerns, one of the most publicized criticisms of the HPV 
vaccine was the belief it would encourage teen girls to have sex or to be promiscuous, 
either because having parents approve an STI vaccine would be seen as synonymous with 
giving consent for sex, or because teens would believe that they were now protected 
against other STIs as well.  
 In light of the controversy surrounding the HPV vaccine launch, researchers 
investigated whether parents and youth really did believe that the HPV vaccine would 
increase sexual activity, and whether these beliefs would influence decisions to vaccinate. 
A Canadian study comprised of 471 adults aged 19 to 69 investigated various 
demographic factors associated with Pap testing and HPV vaccine beliefs and practises. 
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When results were examined, it was found that 12% of individuals believed the HPV 
vaccine would encourage early sexual activity, and that 19% of individuals somewhat 
believed that it would (Sauvageau et al., 2007). Luckily, in spite of these beliefs, 89% of 
the sample would recommend the vaccine to their daughters or nieces. Interestingly, this 
study found that opinions about the influence of vaccine receipt on sexual activity varied 
with age (Sauvageau et al., 2007). Older individuals were more likely to believe that the 
vaccine would encourage an earlier onset of sexual activity than did younger individuals, 
with 19% of male and female participants under the age of 30 believing that the vaccine 
would encourage earlier sex, and 47% of participants aged 60-69 believing it would do 
so. Other studies have also found that some individuals believe that HPV vaccinations 
would encourage early sexual activity, although these individuals are usually the 
minority. A study that looked at factors associated with HPV vaccine acceptance in a 
sample of California mothers found that 18% of their sample would not vaccinate their 
daughters, and that of these mothers, 11% would not vaccinate their daughters because 
they had either moral or pragmatic concerns about the effect vaccination would have on 
their daughters’ sexual behaviour (Constantine & Jerman, 2007). The majority of study 
participants (75%) did support immunization by age 13 however, and stated they did so 
for health and safety reasons. A study by Bernat et al. (2009) found a similar proportion 
of parents who believed that the HPV vaccine would impact sexuality. They found that 
12.8 % of parents believed that the HPV vaccine would cause increased sexual activity. 
Marshall, Ryan, Roberton and Baghurst (2007) also found similar results, with 5% of 
their Australian parent sample (N = 2002) reporting concerns about the HPV vaccine 
leading to promiscuity.  
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Although research does show that a small proportion of individuals believe that 
the HPV vaccine will impact sexual behaviour, it does not show that it increases sexual 
activity in youth or that vaccination leads to risky sexual practices (e.g., not using 
condoms, not getting Pap tests).  Kahn, Rosenthal, Hamann and Bernstein (2003) studied 
52 young women between the ages of 18 and 30, and found that most of their study 
participants reported that they would not engage in more risky sexual behaviours if they 
got the HPV vaccine. Related to this, after the release of the HPV vaccine, Caskey, 
Lindau and Alexander (2009) conducted a study of 1011 women. In order to investigate 
perceptions of the HPV vaccine, participants were asked a variety of questions about it. 
When asked about the need to use condoms after vaccination, women who had received 
the vaccine correctly responded in 98% of cases that condoms were still necessary. 
Meanwhile, 18% of non-vaccinated women did not know if women would need to use 
condoms after vaccination or not. When asked about the need to get Pap tests after 
vaccination, 19% of women who had been vaccinated were not sure if they still had to get 
them, while 24% of women who had not been vaccinated did not know if women would 
still need to get them if they were vaccinated. These study results highlight that receiving 
the HPV vaccine does not lead to increases in sexual risk taking, and thus researchers in 
this area can feel confident that recommending the HPV vaccine is not detrimental to 
women’s health. However, the research does reveal that all women require more 
education about the HPV vaccine and health protective behaviours that must continue 
after vaccination.  
The STI status of HPV and the current study. As previously demonstrated, the 
HPV vaccine is likely perceived as more than just a regular vaccine. The sexually 
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transmitted nature of the HPV virus is likely to have an impact on vaccine acceptance and 
uptake. This study examined these factors. Specifically, this study investigated 
participants’ perceptions of STIs (i.e., as shameful and stigmatizing), their level of 
comfort with sexuality (i.e., sexual permissiveness), and their comfort asking a doctor for 
the HPV vaccine.  
While this study was among the first to examine how the STI status of HPV and 
distrust in the medical establishment influences HPV vaccinations, there are various other 
psychological, social, and practical factors that have been found to influence actual or 
intended vaccinations. In order to develop a clear understanding of the various factors 
that influence vaccinations, these additional factors were also organized and assessed in 
this study. The theoretical framework that was used to organize this study is described 
next.  
Theoretical Framework 
Research in the area of HPV vaccination decisions has often utilized variables 
drawn from various health behaviour change theories. Concepts from theories such as the 
Theory of Planned Behaviour (TPB), Social Cognitive Theory, and the Health Belief 
Model (HBM) have frequently been applied to research on HPV vaccination intentions or 
behaviours, although often the theoretical origins of the concepts are not discussed, and 
theoretical models are not tested. Buchanan (2008) has been one of the few researchers in 
this area to specifically set out to test models of HPV vaccination decisions. In her 
dissertation research, she found that an integrated model that incorporated three 
components of the Health Belief Model (susceptibility, benefits, and self-efficacy) and 
the subjective norms component of the Theory of Planned Behaviour was more predictive 
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of university women’s intentions to obtain the HPV vaccine than either model alone. 
More specifically, she found that the HBM alone accounted for 43% of variance in 
intentions, the TPB accounted for 39% of variance, and the integrated model accounted 
for 51% of the variance in intentions. In her studies, she examined the direct relationships 
between the variables assessing each component of the models being tested, and the 
outcome vaccination intentions. In light of her research findings, and after an 
examination of both the HBM and the TPB, as well as past research in the area of HPV 
vaccination, it was decided that all components of the Health Belief Model would be 
measured in the current study, and that the concept of subjective norms from the Theory 
of Planned Behaviour would also be assessed. Based on Buchanan’s findings, the 
remaining components of the TPB were not assessed. The history of these theories is 
briefly discussed next.  
Background: Health behaviour theories. Health behaviour theories are ways to 
examine the factors that influence whether people will perform certain health behaviours 
(Conner & Norman, 1995). Ultimately, the practical application of using these theories is 
to gain an understanding of how health behaviours can be modified so that negative 
behaviours can be discouraged, and positive behaviours encouraged. Some of the most 
popular health behaviour theories are the Health Belief Model (HBM) (Becker, Haefner 
& Mainman 1977), the Theory of Planned Behaviour (TPB) (Ajzen, 1991),  and the 
Transtheoretical Model of Behaviour Change (Prochaska & DiClemente, 1983), which is 
often called the “Stages of Change” model. Research into various types of health 
behaviours has been conducted using these theories, with some theories being more 
predictive of certain behaviours than others. The Health Belief Model, for instance, has 
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historically been good at predicting vaccine intentions or acceptance (e.g., for the 
influenza vaccine), but for other issues such as smoking cessation or weight loss, the 
Transtheoretical model has gained popularity.  
The Health Belief Model. The Health Belief Model (Becker, Haefner & 
Mainman 1977) is one of the oldest health behaviour theories (Sheeran & Abraham, 
1995). In the 1950s, health professionals recognized the need to develop a framework to 
identify modifiable psychological variables that influence health behaviour (Sheeran & 
Abraham, 1995). Kurt Lewin is credited as a primary influence on the group of 
individuals who began the early research and theory building that would lead to the 
Health Belief Model. Lewin’s idea that an individual’s behaviour is influenced by their 
perception of situations or environments was embraced by these early researchers and is 
reflected in the assumptions of the model (Rosenstock, 1974). Initial tenets of the model 
stated that in order to propel an individual to participate in health behaviours, a person 
needs to believe: (1) that they are susceptible to the disease or illness, (2) that the impact 
of the disease would be at least moderately severe, (3) that taking a prescribed action 
would be beneficial in that it would prevent the disease or that it would lessen its negative 
impact on the individual, and (4) that engaging in the health behaviour would not mean 
that an individual had to overcome strong psychological barriers (Rosenstock, 1974). 
Thus, the initial four core components of the HBM are: perceived susceptibility, 
perceived severity, perceived benefits, and perceived barriers. Additional research on the 
development of the HBM eventually lead to the addition of the components of cues to 
action, self-efficacy, and knowledge. A description of each of these components is 
presented later in this document.  
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The Theory of Planned Behaviour. The Theory of Planned Behaviour assumes 
that individuals undertake a rational decision-making approach when considering health 
behaviours (Edberg, 2007). It is assumed that people’s behaviours are influenced by their 
(1) attitudes toward the behaviour, (2) what they believe other peoples’ perceptions of the 
behaviour are (these perceptions are termed subjective norms in the TPB), and (3) their 
level of perceived control for engaging in the behaviour (Edberg, 2007).  
Definitions of the Model Components Measured in This Study 
HBM: Perceived susceptibility. Perceived Susceptibility is an individual’s belief 
in how susceptible one is to a disease, health problem, or condition. Rosenstock (1974) 
described the various levels of perceived susceptibility that an individual may experience. 
They range from an individual not believing they are at risk at all, to those who admit 
there is a statistical probability of developing an illness but do not believe they are 
personally at risk, to individuals who believe they are definitely at risk. In a meta-analysis 
conducted by Janz and Becker (1984) perceived susceptibility was found to be a 
significant predictor in 77% of examined studies, making it the third most predictive 
component of the four core components of the HBM.  
 HBM: Perceived severity: Perceived severity is the component of the HBM that 
assesses individuals’ perceptions of the severity of an illness, condition, or injury 
(Maiman & Becker, 1974). When discussing the physical severity of an illness or injury, 
effects can include things such as the impact of disease on the body, pain, health 
complications, etc. (Edberg, 2007; Sheeran & Abraham, 1995). In addition to these 
physical perceptions, perceived severity can also include perceptions of how severe an 
impact an illness or injury can have on the practical, day to day aspects of one’s life (e.g., 
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not being able to drive a car as a result of breaking a leg) (Edberg, 2007; Rosenstock, 
1974), as well as the severity of possible psychosocial effects and impacts on social roles 
(e.g., feeling uncomfortable dating someone new as a result of having an STI) (Sheeran & 
Abraham, 1995). Janz and Becker (1984) found that perceived severity was the least 
predictive of the four core components, although it was still a significant predictor in 59% 
of the studies they examined.   
HBM: Perceived benefits. Perceived benefits are the benefits an individual 
perceives will arise from engaging in a specific health promoting activity (Edberg, 2007; 
Sheeran & Abraham, 1995). For example, in the context of HPV vaccination, an 
individual might perceive that being vaccinated against HPV would result in the benefit 
of immunity to the virus. In the meta-analysis conducted by Janz and Becker (1984), 
perceived benefits were significant predictors in 81% of studies, making it the second 
most predictive component of the four core components. Rosenstock (1974), in a 
discussion of this component, proposed that individuals assess the benefits that multiple 
courses of action have for themselves in relation to certain aspects of their health. An 
individual’s health related behaviour will then be influenced not only by their opinion of 
how beneficial one proposed course of action would be, but also in comparison to how 
beneficial other courses of action would be as well. For instance, if an individual was 
considering the HPV vaccine as a method to protect themselves from HPV infection, they 
may also consider the benefits of condom use or abstinence in relation to the benefits of 
the vaccine.  
HBM: Perceived barriers. Perceived barriers are the obstacles an individual 
believes stand between themselves and a desired health related activity (Sheeran & 
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Abraham, 1995), or the negatives that may arise if any individual engages in certain 
health behaviours (Edberg, 2007). Barriers can include practical barriers (e.g., time, cost) 
as well as psychological barriers. These psychological barriers can include things such as 
feelings and emotions (e.g., embarrassment, fear of stigma if asking for the HPV 
vaccine), and psychologically related skills (e.g., lack of social skills, lack of self-
efficacy) (Sheeran & Abraham, 1995). As Sheeran and Abraham point out, given this 
broad definition, there is an abundance of possible barriers that can influence whether 
individuals engage in health protective behaviours. In the study by Janz and Backer 
(2008), perceived barriers was found to be the most predictive component of the model. 
In 91% of the studies they examined, the barriers component of the HBM was a 
significant predictor.  
HBM: Cues to action. According to Edberg (2007), cues to action are external 
events that motivate a person to act. Without these cues, health behaviour change might 
not occur. Cues can be represented by a large range of things, such as mass media 
campaigns, reading a story in a magazine, educational leaflets, conversations with 
friends, and urgings of medical professionals, to name a few (Sheeran & Abraham, 1995). 
In Maiman and Becker’s (1974) chapter on the HBM and its origins and correlates in 
psychological theory, they discussed how cues to action make an individual aware of 
their feelings on a certain topic, and allow them to make decisions about how they want 
to act (e.g., should they engage in the behaviour or not?). To use cues to action 
effectively in research with the HBM, Sheeran and Abraham (1995) argue that cues to 
action should be operationalized by asking respondents if they received cues, and if so, 
how much the cue influenced their decision to engage in the target behaviour. They also 
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note that a crucial aspect of using Cues to Action in research is to ensure that the range of 
relevant cues is assessed.   
HBM: Self-efficacy. Self-efficacy is a construct originally derived from Social 
Learning Theory (Bandura, 1977). It is a person’s belief in his or her ability to take an 
action (Edberg, 2007; Leonard, Hotz, Hansen & Plotnikoff, 1999). When used in the 
Health Belief Model, it measures a person’s self-efficacy in carrying out a health 
behaviour (in the current study, getting the HPV vaccine). Self-efficacy has been found to 
be predictive of health behaviours across many studies (Wallston, 2001).  
HBM: Knowledge. The component of knowledge is rather self-explanatory; an 
individual’s knowledge of a health issue is believed to have an impact on their desire to 
engage in specific health protective behaviours. For instance, if an individual is not aware 
of a particular health threat or protective behaviour, they cannot be expected to act on this 
information. Thus, the amount of knowledge that an individual has about HPV or the 
HPV vaccine may have an impact on their desire to receive the immunization. 
TPB: Subjective norms. Broadly, subjective norms are “the customary codes of 
behaviour in a group or culture, together with the beliefs about what those codes mean” 
(Edberg, 2007, p. 39). The Theory of Planned Behaviour states that one of the 
determinants of an individual’s intention to engage in a certain behaviour, is the 
subjective norms that surround that behaviour. These norms are the beliefs that a person 
has about significant others’ opinion of them engaging in the behaviour (Conner & 
Sparks, 1995). Only the norms of individuals or groups (called “referents” in the TPB) 
whom the person believes are significant are assumed to influence behaviour. In the 
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current study, possible referents were parents, friends, and romantic partners, as well as 
doctors or other health professionals, and media sources.  
Interestingly, the impact that peers and social groups have on behaviour was noted 
in early writings describing the HBM. For instance, Rosenstock (1974) states that beliefs 
“are undoubtedly influenced by the norms and pressures of…social groups” (p.4). Thus, 
by adding a social norms component to the planned adapted HBM, I am not only acting 
in accordance with previous research findings in the area of HPV vaccination, but the 
addition also falls in line with earlier conceptualizations of the HBM and related 
concepts. A study that utilized the Theory of Planned Behaviour to assess mothers’ 
intentions to vaccinate their daughters for HPV also found that subjective norms were 
associated with vaccine intentions (Askelson et al., 2010). Thus, the current study also 
assessed participants’ subjective norms. 
The Model Tested In The Current Study 
When working with the Health Belief Model, one quickly realizes that there are 
limitations to overcome when trying to develop a model to test the components described 
in this theory. As Sheeran and Abraham (1995) discuss, no formal definitions of the 
model components have been developed. Thus, definitions have been left open to the 
interpretation of individual researchers. In addition, no clear paths between variables have 
been established. For example, a formula was never developed to weigh perceived 
benefits against perceived barriers, although the constructs are at times described as 
mathematically related, with benefits needing to be subtracted from barriers (Sheeran & 
Abraham, 1995). The result of the flexible operationalization of the constructs of the 
HBM, and the lack of established hypotheses about how the components may impact one 
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another, has meant that researchers develop their own measurements and models based 
on their areas of research. 
The goal of this study was to develop a comprehensive structural equation model 
of vaccination decisions, which included an investigation into the interrelationships 
between the model components. Because little model testing has been conducted in this 
area, a model of vaccination decisions had to be developed from the ground up. 
Hypotheses about the possible paths between components, and how the components and 
variables may impact each other were developed after carefully considering the research 
in this area. The initial model of HPV vaccine intentions that was developed and tested 
for this study can be seen in Figure 1. Knowledge and Cues to Action are the first 
variables to be considered in the model. It is proposed that the level of Knowledge an 
individual has about HPV, and the Cues that they receive from others to obtain it, are the 
primary variables that influence how the decision making process begins. Level of 
Knowledge and Cues are then hypothesized to impact individuals’ perceptions of the 
Severity of HPV, perceptions of Susceptibility to the virus, and views of the Subjective 
Norms surrounding vaccination. Once these constructs have been processed by the 
individuals, Benefits and Barriers associated with vaccinations are considered. Barriers 
are also then influenced by perceptions of self-efficacy, as high or low levels of efficacy 
may influence how able or unable an individual feels they are to overcoming barriers. 
Finally, after an assessment of the Barriers and Benefits individuals believe surround 
vaccination, vaccination intentions are formed.  
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Figure 1 
Proposed Model of HPV Vaccination Intentions 
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Past HPV and HPV Vaccine Research Related to the Model Components Being 
Tested 
There have been multiple studies investigating factors that are associated with 
anticipated or actual HPV vaccine acceptance. While the current study sought to 
understand how some novel variables influence vaccination decisions, in order to develop 
a comprehensive understanding of HPV vaccine decisions, various other factors that past 
research had found to be predictive of immunizations were also investigated. Because this 
study used a modified Health Belief Model as its theoretical framework, the results of 
previous studies are organized and described below as they relate to applicable HBM and 
TPB categories. 
Susceptibility. The degree to which a woman or girl feels susceptible to HPV 
infection has been found to influence vaccine acceptance. While a few studies have 
specifically asked participants if they felt susceptible or at risk of acquiring HPV, more 
studies have investigated factors that can presumably be thought to influence perceptions 
of susceptibility (e.g., whether one is sexually active or not, whether one has ever had an 
abnormal Pap test, whether one is married, etc.). One study that investigated perceived 
susceptibility specifically was done by Kuitto, Pickel, Neumann, Jahn and Metelmann 
(2010). They conducted a questionnaire study of 760 German women to investigate 
factors associated with actual HPV vaccine receipt and found that high perceived risk of 
HPV infection was indeed predictive of vaccination.  
Current sexual activity and relationship status have been found to influence HPV 
vaccination intentions or behaviours. For example, Marshall, Ryan, Roberton, and 
Baghurst (2007) found that married individuals were unlikely to want the HPV vaccine in 
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comparison to those who were unmarried. In addition, as individuals aged, they were less 
likely to want to be vaccinated (one may assume because they felt less susceptible to 
infection). In the same study, it was also found that those who were in a monogamous 
relationship and those who were not currently sexually active reported that they would be 
concerned about getting a vaccine that did not relate to their current life situation (i.e., 
they did not believe themselves to be at risk of infection).  Caskey, Lindau and Alexander 
(2009) found similar results in their study of 1011 females aged 13-26 years. When they 
assessed barriers to HPV vaccine adoption, 13% of 13-17 year olds, and 23% of 18-26 
years olds reported “other” reasons for not wanting the vaccine. These included being 
married or already having HPV (and thus believing one is not susceptible). When sexual 
activity was examined as a barrier, 47% of 13-17 years olds noted that not being sexually 
active was an obstacle to receiving the vaccine, while 19% of 18-26 years olds reported 
the same. Interestingly, the same study also found that 78-80% of participants reported 
that they would want the vaccine if they had an abnormal Pap test in the past, indicating 
again, that factors related to susceptibility influence desires to be vaccinated.   
Having multiple sex partners or ever having had an STI has been found to be 
predictive of vaccine acceptance in some studies. Jones and Cook (2008) conducted a 
study examining intent to receive the HPV vaccine among 340 college students. Ever 
having had an STI, or having a close friend or relative who had HPV was related to 
greater intent to receive the HPV vaccine. Compared to individuals who had never had 
sex, those who have had sex were more likely to intend to receive the vaccine. When 
number of sexual partners was examined, individuals with more than 5 sexual partners 
were more likely to want the HPV vaccine than were people with 1 to 5 partners.   
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The influence of having an abnormal Pap test, and thus feeling more at-risk, and 
its possible link to HPV vaccine acceptance were also found in other studies (Eaton et al., 
2008; Ferris, Waller, Owen & Smith, 2008; Short et al., 2010). A study of mid-adult 
women who had experienced an abnormal Pap test found that these women were more 
likely to report that they would want the HPV vaccine after receiving an educational 
intervention, than women who had not had a history of abnormal tests (Ferris, Waller, 
Owen & Smith, 2008). The authors of the same study also found that knowledge of the 
link between HPV and cervical cancer, as well as beliefs about their own risk of acquiring 
HPV, positively influenced women’s desires to be vaccinated. In a study that examined 
perceived prevalence and risk of acquiring HPV in women who have sex with women (N 
= 275), participants were also more likely to perceive that they were at risk for HPV 
infection if they had ever had an abnormal Pap test (Eaton et al., 2008). Twenty-seven 
percent of this population reported having had abnormal Pap tests in the past, and 5% had 
been officially diagnosed with HPV. 
In light of this past research, the current study investigated participants’ 
perceptions of susceptibility in various ways. General questions inquired specifically 
about participants’ perceived susceptibility (e.g., do you feel susceptibility to HPV 
infection?) and were used to create a scale measuring perceptions of susceptibility. In 
addition, other questions about specific sexual, relationship, and gynecological 
behaviours or experiences were also asked as these variables were proposed to influence 
vaccination decisions.  
Knowledge. A large amount of research investigating HPV knowledge was 
conducted around the time of the HPV vaccine release. These early studies revealed that, 
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in general, HPV knowledge was low to moderate (Brewer & Fazekas, 2007; Zimet, 
2005). Lenehan et al. (2008) found that Canadian women had a moderate level of HPV 
knowledge, although women knew little about the HPV vaccine. Research has also been 
conducted to examine the influence that HPV knowledge has on intentions or actual 
vaccination rates. The results of these studies have been mixed (see the review of HPV 
vaccine predictors conducted by Brewer & Fazekas, 2007, for more information).  
Some studies have found that higher levels of HPV knowledge are associated with 
increased vaccination intentions or behaviours (Gerend, Weibley & Bland, 2009; 
Woodhall et al., 2007). An interesting study that investigated the effectiveness of a 
knowledge intervention on HPV vaccine acceptance, found that when comparing 
individuals who had received an online knowledge intervention with individuals who did 
not, that those who viewed the site felt increasingly susceptible to HPV infection, had 
more knowledge about HPV and its risk factors, and had improved attitudes toward the 
vaccine (Doherty & Low, 2008). Interestingly, while both men and women had more 
positive attitudes toward vaccination after viewing the site, women’s scores were 
significantly higher than men’s. It is important to note, however, that before viewing the 
website intervention the researchers found that women knew more about HPV and its risk 
factors than men, and that women felt more at risk for acquiring the virus. Another 
intervention study found similar results where after receiving an intervention intended to 
raise HPV related knowledge, participants’ acceptance of the HPV vaccine for their 
daughters increased (Chan, Cheung, Lo & Chung, 2007). 
In contrast to the research described above, some studies have not found a 
relationship between HPV knowledge and vaccinations. For example, a study that 
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compared two groups of participants, one who was given information about HPV and a 
control group who was not, found that although knowledge differed between the two 
groups at the end of the study, HPV vaccine acceptance was not significantly different 
(Dempsey, Zimet, Davis & Koutsky, 2006). Buchanan (2008) also did not find that 
knowledge predicted HPV vaccine intention in her college sample, although the internal 
reliability of her measure was low, and might have accounted for the nonsignificant 
results.  
While the impact of knowledge on HPV vaccination appears to vary, the influence 
of knowledge on other health behaviours seems likely. After all, knowing that a Pap test 
is necessary and what it is for is likely to influence whether women get the test. It may be 
that if knowledge does not have direct links to HPV vaccine acceptance, it has indirect 
links. These indirect relationships may arise through the influence of knowledge on 
factors such as perceptions of susceptibility, severity and social norms. This study 
investigated whether knowledge has a direct impact on vaccination decisions, as well as 
whether it had an impact indirectly, through variables such as perceived severity and 
susceptibility. This was done through structural equation modeling.  
Severity. How severe an individual believes HPV infection to be is theorized to 
influence their HPV vaccination behaviours. While individuals generally perceive HPV 
infection or its outcomes to be severe (Cates, Brewer, Fazekas, Mitchell & Smith, 2009), 
the predictive ability of this construct as it relates to HPV vaccination is still debateable 
(Brewer & Fazekas, 2007). Some studies have found a relationship between severity and 
HPV vaccine behaviours. Zimet et al. (2005) found that parents who would accept the 
HPV vaccine for their daughters were more likely to perceive an STI diagnosis as 
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physically and emotionally severe. Other studies have not found such a relationship, 
however. In her dissertation, Buchanan (2008) did not find that perceived severity was 
predictive of HPV vaccine intentions, and neither did Jones and Cook (2008), who did not 
find a relationship between perceived severity of HPV and intent to get the vaccine in 
their study of male and female college students. Dempsey, Zimet, Davis and Koutsky 
(2006), also did not find that severity was predictive of vaccine intentions.  
In addition to investigating how severity is related to HPV vaccinations, research 
has also reported on individuals’ perceptions of the severity of HPV or its outcomes. A 
study that investigated racial differences in HPV knowledge and vaccine acceptability, 
found that 71% of black women and 91% of white women believed that HPV would be a 
serious threat to health (Cates, Brewer, Fazekas, Mitchell & Smith, 2009). Because of its 
link to cancer, it is also important to understand if women associate HPV with cancer, and 
whether they believe that this risk is severe. This study did this by investigating fear of 
cervical cancer. Studies have shown that a fear of developing cancer is a common 
reaction after a woman has an abnormal Pap test or is told she has HPV (Gath et al., 1995; 
Juraskova et al., 2007; Karasz, McKee & Roybal, 2003; Maissi, Marteau, Hankins, Moss, 
Legood & Gray, 2004). A Canadian study by Sauvageau, Duval, Cilca, Lavoie and 
Ouakki (2007) found that 57% of their adult, female participants feared developing 
cervical cancer, and that this anxiety about cervical cancer was consistent across all age 
groups. The same study found that 93% of participants believed that cervical cancer is 
serious. Similar findings were also found by Kahn, Rosenthal, Hamann and Bernstein 
(2003), with 94% of their female sample reporting that they believed that cervical cancer 
would be a moderate to severe health problem. Interestingly, a German study found that a 
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fear of cancer predicted HPV immunizations (Kuitto, Pickel, Neumann, Jahn & 
Metelmann, 2010). 
While the research described above appears to indicate that perceived severity 
does not influence HPV vaccine behaviour, a systematic review of HPV vaccination 
predictors found mixed results about the impact that perceived severity has on vaccine 
acceptance (Brewer and Kazekas, 2007). In light of this debate, and with the 
understanding that individuals do believe that HPV is severe, the current study 
investigated whether a relationship between these variables does exist. Indirect 
relationships between the variables were also assessed during the testing of the proposed 
model of HPV vaccination decisions.  
 Barriers. As discussed in the theory section of this document, the barriers that can 
impede a person from engaging in a health behaviour can be both practical/physical as 
well as psychological. Earlier in this paper some potential psychological barriers were 
discussed, such as vaccine safety fears, medical distrust, and factors related to the STI 
status of HPV. This study investigated whether these were indeed barriers to HPV 
vaccination. Other barriers were also investigated. For instance, past research has 
consistently found that cost is a major barrier to HPV vaccination, as is access to a health 
care professional, and time. Types of barriers investigated by past research are discussed 
now.  
 The cost of the HPV vaccine has been one of the most researched potential 
barriers, and studies have found that cost does influences intentions to vaccinate. In their 
study examining barriers to HPV vaccine adoption, Caskey, Lindau and Alexander (2009) 
reported that 27% of women between 18 and 26 reported that the cost of the vaccine is 
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too high. Kahn et al. (2008) also found that cost was a concern, where only 42% of girls 
and women aged 13 to 26 from their study felt that they could afford to get vaccinated. 
Not surprisingly then, a Canadian study found that 91% of male and female adults living 
in Quebec would agree to the HPV vaccine if it was funded; however, this rate dropped to 
72% if individuals had to pay $100 per dose (Sauvageau, Duval, Cilca, Lavoie & Ouakki, 
2007). More worrisome, the proportion of individuals aged 18 to 25 (one of the most 
important target groups for the vaccine) changed their perceptions of the vaccine once 
cost was added as a factor, with the rate of people who would strongly agree that they 
would get the vaccine falling from 56% to 28% if individuals had to pay. This change 
was not as drastic for individuals aged 26 to 30. One can presume this is due to the 
increased financial resources of this group. Rosenthal et al. (2008) found that 9% of their 
parent sample thought that the HPV vaccine was too expensive, 47% were unsure, with 
only 44% believing that the cost would not be prohibitive. In addition, the study by Kahn, 
Rosenthal, Hamann and Bernstein (2003) also found that some participants reported cost 
as a concern when contemplating HPV vaccination.  
Cost is not the only practical barrier to vaccination, however. A fear of needles or 
the pain of the injection has also been cited as a barrier in some studies (Burke, Vail-
Smith, White, Baker & Mitchell, 2010; Kahn et al., 2003). Gottvall, Larsson, Hoglund 
and Tyden (2009) found that 19% of their Swedish student sample reported that a fear of 
needles would be a barrier. A qualitative research study by Short et al. (2010) found that 
the vast majority of their adult sample (aged 27-55) believed that there were barriers to 
HPV vaccine uptake and these included cost, a fear of side effects, and hassles. Burke, 
Vail-Smith, White, Baker and Mitchell (2010), also found that a fear of side effects would 
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act as a barrier. This was reported as a concern by 42.9% of their sample. Caskey, Lindau 
and Alexander (2009) found that not having a regular healthcare provider is a barrier to 
adoption as well, while the hassle of having to go to a doctor to get the vaccine was cited 
as a barrier in another study (Burke et al., 2010).   
As the above research demonstrates, a variety of psychological and practical 
considerations can impact HPV vaccine intentions and actual uptake. The current study  
investigated some of these practical and psychological barriers. These included fear of 
stigma if asking a doctor for the vaccine, physician trust, pharmaceutical company trust, 
STI stigma and shame, sexual permissiveness, and cost.  
 Benefits. In order for a person to be motivated to engage in a health promoting 
behaviour, the HBM would propose that they recognize that the behaviour will be 
beneficial. In her examination of the utility of the HBM for predicting HPV vaccination 
intentions, Buchanan (2008) found that perceived benefits were predictive of intentions. 
In Canada, Ogilvie et al. (2007) found that perceptions of the vaccine was the strongest 
predictor of mother’s intentions to vaccinate their daughters against HPV. Items that 
assessed these perceptions included items that inquired about HPV vaccine safety, 
effectiveness, whether vaccine are beneficial in general, and whether the HPV vaccine is 
beneficial for boys and girls, specifically. 
Researchers have investigated whether participants believe that the HPV vaccine 
will be/is effective. For instance, Rosenthal et al. (2008) found that 75% of their study’s 
parent sample believed that the HPV vaccine would protect their children from cervical 
cancer and genital warts, indicating that beliefs in the benefit of the vaccine vary (25% of 
the sample did not believe it would be protective). Basu, Chapman and Galvani (2008) 
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conducted a study that revealed that participants believed that being vaccinated against 
HPV would significantly lower their risk of cervical cancer and genital warts. Of course, 
belief in the effectiveness of the vaccine is a perceived benefit. If an individual believes 
the vaccine will work to protect them from infection, then they will likely believe that the 
vaccine is beneficial. Caskey, Lindau, and Alexander (2009) investigated the concept of 
perceived effectiveness and vaccine uptake. They found that 16% of their female 
participants, aged 13-26, reported that they were unsure if the HPV vaccine would work. 
In their study, however, beliefs about the effectiveness of the vaccine were not predictive 
of HPV vaccinations.  
Dempsey, Zimet, Davis and Koutsky (2006) also investigated perceived benefits 
of HPV vaccination. They found that parental beliefs about the benefit of the vaccine for 
children or for society were significantly associated with vaccine acceptance. Relatedly, 
an Icelandic study of willingness to participate in an HPV vaccine trial found that the 
main reason individuals would want to participate in a trial was for their own or 
community benefits (Gudmundsdottir et al, 2003). These studies revealed that not only 
are individual benefits a motivating factor to encourage vaccinations, but that beliefs in 
the benefit of vaccinations for society at large may also be predictive of vaccination 
decisions (in the current study these beliefs are referred to as vaccine positive beliefs). 
In light of the research summarized above, this study investigated the impact that 
perceived benefits of HPV vaccination had on vaccination decisions. The variables that 
assessed the construct of benefits in this study measured beliefs in the effectiveness of the 
HPV vaccine, as well as beliefs that vaccines are beneficial for the self or society (vaccine 
positive beliefs).   
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 Self-efficacy. Deciding to obtain a vaccine or to engage in any health promoting 
activity will be influenced by how much self-efficacy a person has for engaging in the 
behaviour. While self-efficacy beliefs for a variety of behaviours may be complex and 
require concerted effort to develop (for example self-efficacy to quit smoking or to begin 
a physical activity regime), the type of self-efficacy required to obtain a vaccine is likely 
to be more focused on feeling efficacy to overcome barriers to adoption, for instance, 
feeling efficacy in one’s ability to get to a doctor for three shots, or for saving the money 
needed to purchase the shots. A link between self-efficacy and intentions to get the HPV 
vaccine has been found in at least two studies (Buchanan, 2008; Kahn et al., 2008). Kahn 
et al. (2008) found that intentions to get vaccinated were related to individuals’ beliefs in 
their ability to get the vaccine, although the authors mention that this relationship was not 
as strong as they had originally anticipated. Buchanan was also one of the first to examine 
this construct and found it to be predictive of intentions as well. Due to its inclusion in 
new versions of the HBM, and due to the promising results that other studies have found 
when investigating this variable, this current study investigated how self-efficacy 
influences HPV vaccination. After all, while individuals may recognize that there are 
barriers to obtaining the HPV vaccine, they may have varying levels of self-efficacy for 
overcoming such barriers.  
Cues to action. Cues to action are the external events that occur that motivate a 
person to act in a certain way. In terms of cues for HPV vaccination, these may be cues 
from friends, family or media, although the most researched types of cue are those that 
come from physicians or other health professionals. As discussed elsewhere in this 
document, Caskey, Lindau and Alexander (2009) investigated factors that influence HPV 
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vaccination in girls and women. They found that for both age groups investigated (those 
13-17 and those 18-26) speaking with a healthcare provider was associated with 
vaccination. For those aged 18-26, speaking with a  family member was also predictive. 
In their large study of parental attitudes toward the HPV vaccine, Dempsey, Zimet, Davis 
and Koutsky (2006) found that physician recommendations were related to vaccine 
acceptance. In a Canadian study, Lenehan et al. (2008) found that physician 
recommendations would influence women’s willingness to obtain the vaccine. As these 
results indicate, doctors who discuss the vaccine with their patients are likely to influence 
uptake, indicating that cues to action are likely associated with HPV vaccinations. While 
the majority of HPV vaccine research has investigated physicians’ cues to action, the 
current study will also investigate cues from other sources as well. 
Subjective norms. The final type of research that will be reviewed in this section 
on past predictors of HPV vaccinations are studies that have investigated the impact of 
subjective norms on HPV vaccination rates or intentions. Buchanan (2008) found that the 
subjective norms component of the Theory of Planned Behaviour was the only 
component from this model that was predictive of intentions to receive the vaccine in her 
study comparing the HBM and the TPB. Limited other studies have also investigated 
norms. Kahn et al. (2003) investigated 52 young women’s attitudes toward the HPV 
vaccine, as well as their intentions to receive it. They found that various factors were 
associated with intentions, one of which were women’s beliefs that others would approve 
of the vaccine. These significant others included parents and romantic partners. Dempsey 
et al. (2006) also investigated parental attitudes toward the HPV vaccine. Along with 
other factors, including cues to action as noted above, they found that peers influenced 
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decisions to obtain the vaccine. Finally, a Canadian study found that subjective norms 
were predictive of mother’s intentions to vaccinate their daughters, with physician’s 
recommendations being particularly influential (Ogilvie et al., 2007). In light of this 
research, the current study examined participants’ beliefs about the subjective norms of 
others.  
The Current Study 
  This study was a theoretically guided investigation into factors that are related to 
actual or intended HPV vaccinations in a sample of women who reside in Canada aged 18 
to 30. A modified version of the Health Belief Model was used as the theoretical 
framework for this study. All components of the HBM were utilized in the study model, 
with the addition of the construct of subjective norms from the Theory of Planned 
Behaviour. Direct relationships between the variables used to assesses the theory 
components and the study outcomes were investigated. In addition, a proposed model of 
HPV vaccination intentions was designed and tested. 
While past studies have examined the impact of multiple variables on HPV 
vaccinations, the current study investigated the impact of a number of novel variables. 
The new variables that were assessed in this study were: distrust in physicians and 
pharmaceutical companies, sexual attitudes, STI stigma and shame, and comfort asking a 
physician for the vaccine due to fear of stigma. All of these variables were assessed under 
the barriers component of the HBM. In addition to these novel variables, past research 
has investigated various other factors and their relationship to HPV vaccination decisions. 
These variables were organized using the theoretical framework from this study, and their 
relationship with the study outcomes was also assessed. A brief discussion of the study 
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variables that were assessed in this study follows. A summary of this description can also 
be found in Table 1. For organizational purposes, each component of the model is listed 
here along with the variables that will be used to assess it (1) To investigate the impact of 
perceived susceptibility on HPV vaccination intentions or actual uptake, questions 
inquiring about perceptions of susceptibility were asked and compiled into a scale. In 
addition, questions inquiring about relationship history and sexual history were asked. 
These questions may influence an individual’s perception of their susceptibility. Sexual 
history questions included past and current condom use, number of sexual partners, 
sexual experiences (e.g., ever having intercourse) and ever having been diagnosed with an 
STI. (2) To investigate the perceived severity of HPV infection, questions assessing the 
perceived severity of the virus on the body were asked, as were questions on the 
perceived severity of treatment, fears of cervical cancer, and the social impact of 
infection.  (3) Perceived benefits of vaccination were assessed by asking participants 
whether they believed that getting the HPV vaccine would be beneficial (i.e., it would 
prevent HPV infection), and whether they valued vaccinations (vaccine positive beliefs). 
(4) Two types of perceived barriers were investigated in this study: psychological 
barriers and practical barriers. The psychological barriers included physician and 
pharmaceutical company distrust, perceptions of STIs and related stigma and shame, fear 
of stigma if asking a doctor for the vaccine, attitudes toward sex, and vaccine safety fears. 
Practical barriers that were assessed included things such as cost and access to a doctor 
one feels comfortable speaking with. (5) Knowledge of HPV was investigated through an 
HPV knowledge questionnaire.  Knowledge of the HPV vaccine was also assessed with 
its own questionnaire. (6) Various cues to action were investigated by asking participants
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Table 1 
Variables Used In the Current Study 
 Health Belief Model  TPB 
Variable/Scale Perceived 
Susceptibility 
Perceived 
Severity 
Perceived 
Benefits 
Perceived 
Barriers 
Know-
ledge 
Cues to 
Action 
Self 
Efficacy 
Subjective 
Norms 
Susceptibility scale questions  X        
Relationship status info. X        
Sexual experience info. X        
Gynaecological health history X        
Severity of virus on body  X       
Severity of treatment  X       
Fears of cervical cancer  X       
Severity of social impact  X       
Vaccine efficacy   X      
Vaccine positive beliefs   X      
Pharmaceutical company trust    X     
Physician trust    X     
STI stigma and shame scale    X     
Fear doctor stigma     X     
Access to trusted medical care    X     
Sexual attitudes (SAS)    X     
General vaccine safety fears    X     
HPV vaccine safety fears    X     
Cost    X     
HPV knowledge questions     X    
HPV vaccine knowledge questions     X    
Cues to action questions      X   
Obtaining vaccine self-efficacy       X  
Subjective norms         X 
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if they have heard about the HPV vaccine from various sources (e.g., friends, the media, 
romantic partners, parents). (7) Feelings of self-efficacy were investigated by asking 
various questions about participants’ level of belief that they could obtain the vaccine in 
order to create a scale score. Finally, (8) The influence of subjective norms on vaccination 
intentions or actual uptake was also assessed. Participants’ beliefs of the opinions of 
significant others on the topic of HPV vaccination were assessed (e.g., would this person 
or group support you getting the vaccine?). 
While many predictor variables have been described, it is also important to 
understand how outcome variables were assessed in the current study. Actual vaccination 
status was one of these outcomes. Whether female participants had received the HPV 
vaccine or not was assessed, and participants were classified as either vaccinated or not 
vaccinated. Thus, having obtained the HPV vaccine or not was one dichotomous outcome 
variable used in this study. Individuals who had obtained the vaccine did not complete 
any additional outcome items. The remaining outcome items assessed the intentions of 
those who had not yet been vaccinated. Participants who had not received the vaccine 
were asked about their intentions to receive it. More specifically, these individuals were 
asked two questions (1) if they would like to get the vaccine, and (2) whether they think 
they will actually get it, regardless of whether they want it or not. It was hypothesized that 
the two outcome items, while similar, would assess two distinct aspects of vaccination 
intentions. The first, desire to get vaccinated, assessed whether individuals want the 
vaccine. The second item, thoughts about whether one would actually get it, assessed the 
more complex idea that although individuals have a certain level of desire for the vaccine, 
this level of desire may not correspond to whether an individual actually thinks they 
Factors that influence HPV vaccinations  62 
 
would ultimately engage in the behaviour. Much like a cigarette smoker may desire to 
quit smoking, they may or may not think that they actually would quit. Social psychology 
has shown that attitudes are often not predictive of behaviours (Myers & Spencer, 2001). 
However, attitudes are more predictive when the measured attitude is specific to the 
situation under investigation (Myers & Spencer, 2001). Thus, the current research aimed 
to investigate both desires, and actual thoughts that one would engage in the behaviour. 
In summary than, the current study had three main outcome variables that were 
assessed: The relationship between the model variables and (1) whether individuals 
obtained the vaccine or not (yes or no), (2) non-vaccinated women’s desire to get the 
vaccine (one item rated on a 5 point scale), and (3) whether non-vaccinated women 
thought they would actually get it (one item rated on a 5 point scale). Thus, the current 
study investigated both actual uptake behaviours, as well as intentions. While all three 
outcomes were used when testing the direct effects of the predictor variables on 
outcomes, only HPV vaccine desires were used as the outcome when testing the proposed 
model of HPV vaccination intentions.  
Hypotheses 
The overall research question this study attempted to answer was: “What factors 
influence actual or anticipated HPV vaccinations in a sample of Canadian women aged 
18-30?” The following set of hypotheses was developed to investigate the direct 
relationships between the predictor variables used in this study, and the outcome 
variables. All hypotheses, except for one, predicted positive relationships between the 
components and the outcomes (e.g., higher perceived severity, more positive subjective 
norms, or more cues to action would lead to more vaccinations or higher intentions to 
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vaccinate). One hypothesis, which described  perceived barriers, anticipated a negative 
relationship, so that as perceived barriers increase, actual vaccinations or intentions to 
vaccinate decrease. The study hypotheses were: 
1. Perceived susceptibility to HPV infection will predict HPV vaccination, with 
higher levels of susceptibility being positively associated with actual or intended 
vaccinations.  
2. Perceived severity of HPV infection will predict HPV vaccination, with higher 
levels of perceived severity being positively associated with actual or intended 
vaccinations. 
3. Perceived benefits of receiving the vaccine will predict HPV vaccination, with 
higher levels of benefits being positively associated with actual or intended 
vaccinations. 
4. Perceived barriers to receiving the vaccine will predict HPV vaccination, with 
higher levels of perceived barriers being negatively associated with actual or 
intended vaccinations.     
5. Knowledge of HPV will predict HPV vaccination, with higher levels of 
knowledge being positively associated with actual or intended vaccinations. 
6. Self-efficacy for receiving the HPV vaccine will predict HPV vaccination, with 
higher levels of efficacy being positively associated with actual or intended 
vaccinations.  
7. Cues to Action will predict HPV vaccination, with more cues being positively 
associated with actual or intended vaccinations. 
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8. Subjective norms will predict HPV vaccination, with positive norm beliefs 
being positively associated with actual or intended vaccinations.  
 
In addition to these hypotheses, it was also predicted that the proposed model of 
HPV vaccination intentions developed for this study would be a valid model, in terms of 
showing good fit with the study data.  Please see Figure 1 to review the model that will be 
tested. It was anticipated that knowledge and cues to action would influence perceived 
severity, perceived susceptibility, and subjective norms, which in turn would influence 
perceived barriers and benefits. Barriers were also anticipated to be impacted by self-
efficacy. And finally, barriers and benefits were expected to impact vaccination decisions.   
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Chapter II 
Method 
Participants   
Participants were 374 women, aged 18 to 30, residing in Canada. Participant ages 
ranged from 18 to 30 with an average age of 22.05 years (SD = 3.54). It should be noted 
that due to their ages, all individuals who participated in this study were most likely not 
involved in the grade eight school-based vaccination programs that began in 2006 or 
2007. Thirty-six people who participated in this study were 18 years old at the time of 
data collection, and thus may have been in grade 8 the first year the vaccine was offered 
in schools. However, when asked why they obtained the vaccine, no participants reported 
that it was offered to them at school for free. Three people did report that they were able 
to obtain the vaccine at their school because they had medical insurance, but the type of 
school and the age when the vaccine was offered were not reported. The majority of 
participants, 90.4%, came from the province of Ontario, although women from five other 
provinces also took part in this study. These provinces were Alberta, British Columbia, 
Manitoba, New Brunswick, and Nova Scotia. The number of individuals from each of 
these other provinces ranged from two to 16. The majority of participants, 95.4%, had 
completed at least some university or college. When ethnic background was inquired 
about, the majority of participants, 79.7% of the sample, reported that they were 
White/Caucasian, 6.1% reported they were Middle Eastern/West Asian, 3.5% reported 
they were Chinese/Japanese/South-East Asian, 3.2% reported they were Black/African 
Canadian or American, 2.7% reported they were South Asian, 1.6% reported they were 
Aboriginal, 0.8% reported they were Latin American/Mexican, 1.9% reported they were 
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biracial, and 2.1% indicated they had an “other” background. Individuals could check 
more than one option, and thus, percentages exceed 100.  
Measures 
 Measures presented to vaccinated and unvaccinated participants were mostly 
identical with the exception of some outcome measures. Where differences existed, they 
have been noted below. Many of the measures described were adapted from previous 
studies conducted by other researchers, or were created entirely by this author. Below, 
credit is given to scale items created and used in previous research. If a source is not 
mentioned, items were created by this author. Please see the Appendix to view 
questionnaires developed for this study. Questionnaires developed by other researchers 
are not included in this appendix. Before beginning this dissertation work, this author 
conducted a study investigating male HPV vaccination intentions that utilized earlier 
versions of some of the scales described below. While some of these adapted/created 
scales were changed significantly before the current study was conducted (e.g., scales 
assessing severity and susceptibility variables), some scales remained relatively 
unchanged. These scales and their Cronbach’s alpha values are reported below where 
applicable.  
Demographic Variables  
Demographic questions inquired about participant age, education level, ethnicity, 
sexual orientation, household income, and province of residence. 
Knowledge Variables 
HPV knowledge. An HPV knowledge questionnaire, based largely on one 
developed by Daley et al. (2008), was used to assess HPV knowledge. Daley’s scale 
Factors that influence HPV vaccinations  67 
 
contains 22 items and was found to have a Cronbach’s alpha of .81. Because recent 
research and media stories have discussed the link between HPV and head and neck 
cancers, two additional questions related to oral transmission were added to the scale for 
this study. The Cronbach’s alpha for this scale in this study was found to be .84. In order 
to determine if the items added to this scale improved the Cronbach’s alpha value, the 
score for the original 22 items was calculated, and was found to be .81, indicating the 
addition of the two items for this study improved the scale. Participants could respond to 
each question by indicating true, false or unsure. Scores were computed by summing the 
number of correct responses to each question. 
HPV vaccine knowledge. To assess HPV vaccine knowledge, a seven item scale 
was used. Six of the scale items were used by Caskey et al. (2009) in a study where the 
questionnaire was administered to over 1000 female participants. Unfortunately, internal 
reliability statistics for these six items were not reported, although the results of their 
study did find that HPV vaccine knowledge varied.  In addition to these six items, an 
additional question was added by the present author to inquire about participants’ 
knowledge that the vaccine protects against genital warts. This was done to ensure that 
the scale items inquired about both cervical cancer and genital wart protection. The 
original six items made no mention of genital warts. Similar to General HPV knowledge, 
response options were true, false or unsure, and scale scores were computed by summing 
the number of correct responses. The Cronbach’s alpha for the seven item scale was 
found to be .66. The alpha for the scale with just the original 6 items was .65, indicating 
that the addition of the seventh item did not decrease the Cronbach’s alpha value. 
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Perceived Susceptibility Variables 
 Sexual history questions. The study questionnaire contained 8 questions 
inquiring about participants’ past sexual experiences. These questions investigated: sexual 
orientation, if a participant ever engaged in sexual activity, how many sexual partners one 
has had, sex of most recent sexual partner, how many individuals a participant has had 
vaginal and anal intercourse with, age at first vaginal and anal intercourse, and how often 
condoms were used with male sexual partners currently and in the past.   
 Relationship status. Three items assessed participants’ romantic relationship 
status. The items inquired about current relationship status, relationship status over the 
past two years (assessed with a five-point scale), and current relationship length.   
Gynaecological health history. Information on participants’ gynaecological 
history was gathered with five items which asked about Pap test history (if a test had ever 
been done, if it was abnormal, and if abnormal, the medical follow-up that was done), and 
STI and HPV infection experience.  
Perceived susceptibility. To assess participants’ feelings of susceptibility to HPV 
infection, four likert-scale questions were developed for this study. Questions asked 
participants if they felt at risk of experiencing: HPV, cervical cancer, genital warts, and 
having an abnormal Pap test. Response options ranged from 1 (very unlikely) to 5 (very 
likely). The Cronbach’s alpha for the scale was found to be .88. 
Perceived Severity Variables  
Perceived severity of HPV infection. Perceived Severity of HPV Infection  was 
measured with five items that assessed participants’ emotional upset if they were to 
become infected with HPV, or if they were to develop a symptom such as genital warts, 
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or abnormal cervical cells. Upset at HPVs potential impact on the body and future fertility 
was also assessed. Responses were recorded on a scale ranging from 1 (not at all) to 5 
(very much). Then Cronbach’s alpha for this scale was .73. 
 Perceived severity of HPV treatment. Participants’ upset at the impact or pain 
of treatment associated with HPV related illnesses such as genital warts or abnormal 
cervical cells, was assessed with five likert-scale questions. Response options ranged 
from 1 (not at all) to 5 (very much). The Cronbach’s alpha for this scale was .80. 
 Perceived severity of the social impact of HPV infection. Similar to the 
previous two severity scales, perceived severity of the social impact of having HPV was 
assessed with six likert-scale items. Questions inquired about participants’ upset if 
various significant others (doctors, friends, romantic partners) found out the participant 
had HPV, as well as the level of upset the participant would feel/did feel if they had to tell 
future romantic or sexual partners that they were infected. Again, response options ranged 
from 1 (not at all) to 5 (very much). The Cronbach’s alpha for this scale was .88. 
Fear of cervical cancer. Past research has consistently found that women who are 
told they have HPV or abnormal Pap tests, fear cancer. Because of this, the current study 
investigated whether women’s fears of cervical cancer had an impact on vaccination 
decisions. Fear of cervical cancer was assessed by adapting the items of the Fear of Breast 
Cancer scale (Champion et al., 2004), to instead reflect fear of cervical cancer. The items 
developed by Champion et al. were used, except where the word breast appeared, it was 
replaced with the word cervical. Thus, the item that originally read “When I think about 
breast cancer, I get nervous”, was changed to read “When I think about cervical cancer, I 
get nervous”. Items were rated on a 5-point Likert scale ranging from 1 (strongly 
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disagree) to 5 (strongly agree). The Cronbach’s alpha was .91 for the original Fear of 
Breast Cancer Scale, and the construct validity of the original scale was supported by its 
ability to predict mammography, as well as by relationships between the scale scores and 
perceptions of threat and self-efficacy. The Cronbach’s alpha for the fear of cervical 
cancer scale used in the present study was .94. 
Perceived Benefit Variables 
 HPV vaccine effectiveness. Participants’ perception of the effectiveness of the 
HPV vaccine was measured with eight likert-scale questions. Questions  inquired about 
participants’ beliefs about the protective benefits of the vaccine as they relate to HPV 
infection, genital wart infection, abnormal cervical cells, future fertility, cancer, and 
romantic and sexual relationships. Responses options ranged from 1 (not at all) to 5 (very 
much). The Cronbach’s alpha for this scale was .94. 
 Vaccine positive beliefs. Past research has shown that some individuals support 
HPV vaccination because it is beneficial to society. To tap into this construct, a 5-item 
scale used by Marlow, Waller and Wardle (2007) to assess parents’ perceptions of the 
importance of children’s vaccines was adapted for use in this study. Items were reworded 
to assess participants’ beliefs in the positive impact of their own vaccinations, versus the 
original scale that assessed parents’ perceptions of the importance of vaccinating their 
children. Items asked participants about their level of belief that vaccinations protect 
against outbreaks, and protect others. Items also assessed beliefs that vaccines contribute 
to health, and that failing to get vaccinated puts others at risk. Responses were scored on a 
5-point Likert scale that ranged from 1 (strongly disagree) to 5 (strongly agree). The 
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Cronbach’s alpha for the scale used by Marlow and colleagues was .76. In the present 
study the Cronbach’s alpha for the adapted scale was .90. 
Perceived Barrier Variables 
Vaccine safety fears. Vaccine safety fears were measured with six items that 
inquired about participants’ concerns about vaccines in general, as well as about the HPV 
vaccine specifically. These items were originally meant to assess two types of safety 
concerns, those of vaccines in general, and those of the HPV vaccine. However, the items 
were combined to create one scale due to a high correlation between the two scale scores. 
Questions asked if participants thought vaccines were safe, and if they worried about side 
effects. Participants could respond on a scale ranging from 1 (strongly disagree) to 5 
(strongly agree). The Cronbach’s alpha for this scale was .91. A pilot study that was 
conducted prior to this research utilized the two safety fear scales. The Cronbach’s alpha 
values for these scales in the pilot study were .76 for the general vaccine safety concern 
scale, and .81 for the HPV vaccine safety concern scale. 
 Fear of stigmatization if asking for the vaccine (Fear of Doctor Stigma). Due 
to the sexually transmitted nature of the HPV virus, it was hypothesized that participants 
may feel at risk of being stigmatized if they ask a health care provider for the HPV 
vaccine. To assess these feelings, a ten item likert-type scale was used. Response options 
ranged from 1 (strongly disagree) to 5 (strongly agree). Items asked participants if they 
worry their doctor would think they sleep around, have poor morals, would cheat on their 
romantic partner, are protecting themselves, etc., if they asked for the HPV vaccine. The 
Cronbach’s alpha value for the scale was .92. An earlier version of this scale was used in 
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the pilot study conducted by this author and yielded a Cronbach’s alpha value of .72 in 
that study.  
Brief Sexual Attitudes Scale (SAS).  The Brief Sexual Attitudes Scale 
(Hendrick, Hendrick and Reich, 2006) is a shortened (25 item) version of the original 
SAS developed by Hendrick and Hendrick (1987). It was used to measure participants’ 
attitudes toward sex. The scale is comprised of  four subscales assessing Permissiveness 
(perceptions of casual sexuality), Birth Control (perceptions of responsible sexuality), 
Communion (perceptions of idealistic sexuality), and Instrumentality (perceptions of 
biological/utilitarian sexuality). Responses were recorded on a 5-point Likert scale that 
ranged from 1 (strongly disagree) to 5 (strongly agree). When Hendrick et al. (2006) 
assessed the internal reliability of the subscales, they found Cronbach’s alpha coefficients 
for the permissiveness subscale to be .95, for birth control to be .87, for communion to be 
.79, and for instrumentality to be .80. A total scale score is not computed. The main 
subscale of interest in the current study was the Permissiveness subscale, where it was 
found to have a Cronbach’s alpha of .92.  
 STI Stigma and Shame Scale. To measure the level of stigma and shame 
participants associate with STIs, the STI Stigma and Shame Scales, developed by 
Fortenberry et al. (2002) were used. These scales are made up of 6 items assessing 
feelings of shame (original Cronbach’s alpha = .80) and five items assessing fears of 
stigma (original Cronbach’s alpha = .77) in situations related to doctor visits for STI 
related treatment and examination. In this study, responses were recorded on a 5-point 
Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). The items were 
combined to create one scale score (confirmed as methodologically sound by principal 
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component factor analysis). The Cronbach’s alpha value for the scale in the current study 
was .92.  
Physician Trust Scale. The Wake-Forrest Physician Trust Scale (Hall et al., 
2002) was used to measure participants’ trust in physicians. The scale is comprised of 10 
items assessing various constructs related to physician trust, such as their competency, 
thoughtfulness, and honesty. This scale has been shown to have comparable internal 
consistency, reliability, and ranges as other similar measures (Hall et al., 2002). However, 
the creators of this scale note that their measure also has the benefit of having a lower 
mean score, a more normal distribution, and better discriminatory power (Hall et al., 
2002). Internal reliability was reported as .93 in the original study conducted by the scale 
authors. Response options ranged from 1 (strongly disagree) to 5 (strongly agree).  The 
Cronbach’s alpha value for the scale in the current study was .94. 
 Pharmaceutical company trust. A 10 item measure to assess participants’ trust 
in pharmaceutical companies was used in this study. It was previously developed for 
another study conducted by this author. Questions inquired about issues such as trust, 
employee honesty, profit motivation, and advertising claims. Items were scored on a 5-
point Likert scale that ranged from 1 (strongly disagree) to 5 (strongly agree). The 
Cronbach’s alpha value for the scale in the current study was .85. In a pilot study 
conducted by this author, this scale also had a Cronbach’s alpha value of .85. 
Access to medical care. Six questions were used to assess participants’ access to 
medical care, and to gather details about their health care provider. Participants were 
asked if they have a regular family doctor, and if so, what the gender and age of their 
doctor was. Participants were also asked how comfortable they feel speaking to their 
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doctor about any health concern (measured on a 5-point Likert scale). If participants did 
not have a regular doctor, they were asked if they have access to regular medical care, and 
how comfortable they felt speaking to the doctor(s) that they do come into contact with.    
 Cost. Four questions to assess how the cost of the HPV vaccine might influence 
participants’ desire to get the vaccine were asked. Response options ranged from 1 (not at 
all) to 5 (very much). These four items were used to create a scale score, which was found 
to have a Cronbach’s alpha of .80.    
Insurance. Participants were asked two questions to determine if they had 
insurance coverage that would have paid for the HPV vaccine. They were asked if they 
have an insurance plan, and if so, if they knew if it covered the vaccine at the time they 
considered and made their decision to get vaccinated or not.  
Self-Efficacy Variable 
Self-efficacy for obtaining the HPV vaccine. A four item scale was used to 
assess unvaccinated participants’ level of self-efficacy for obtaining the HPV vaccine. 
Three of the scale items were taken from a study conducted by Kahn et al. (2008). These 
items inquired about participants’ belief that they could get all three vaccines, that they 
would have time to get the vaccine, and that they would be able to afford it. Kahn et al. 
found a Cronbach’s alpha of .82 for the scale comprised of these three items. An 
additional fourth item was added to this scale for this study, in order to strengthen its 
ability to assess self-efficacy for overcoming barriers to HPV vaccination. The item asked 
participants if they felt they could “overcome barriers to getting the HPV vaccines”. 
Responses to all items were measured on a 5-point Likert scale ranging from 1 (very 
unlikely) to 5 (very likely). The Cronbach’s alpha value for the scale was .81. If the item 
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that was added for this study was removed from the scale, the Cronbach’s alpha of the 
original three items was .72, indicating the addition of this item strengthened the scale.  
Cues to Action Variable 
Cues to action. Inspired by other HPV vaccine studies, a 10 item scale was 
created and used to assess cues that are believed to prompt participants to obtain, or want 
to obtain, the HPV vaccine. The 10 items each began with a yes/no statement asking if 
participants had experienced a prompt from the subject of the item (e.g., a friend, 
romantic partner, school, commercial, news story). If participants indicated that they had, 
they were then asked to rate, on a 5-point scale ranging from 1 (made me definitely not 
want to get the vaccine) to 5 (made me definitely want the vaccine), how much influence 
this prompt had on their desire to want the HPV vaccine. For this study, scores were 
computed by assessing how many positive cues to action (cues that encouraged the 
individual to get the vaccine) an individual had received. If a cue encouraged an 
individual to maybe want the vaccine, one point was awarded. If a cue encouraged an 
individual to definitely want the vaccine, two points were awarded. Thus, scale scores 
could range from 0 (no positive cues) to 20 (all 10 cues made the individual definitely 
want the vaccine).  
Subjective Norm Variables 
Subjective norms about HPV vaccination. An eight item measure was used to 
assess participants’ beliefs in the social norms surrounding HPV vaccination. The 
measure was inspired by one developed and used by Buchanan (2008). It was comprised 
of eight items listing eight different significant others or groups, and asked participants to 
indicate whether they believed the significant other or group would endorse HPV 
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vaccination or not. Responses were recorded on a five-point likert scale ranging from 1 (I 
definitely should not get the HPV vaccine) to 5 (I definitely should get the HPV vaccine). 
The Cronbach’s alpha value for the scale was .89. 
Open-Ended Question 
An open ended question was placed at the end of the study questionnaire in order 
to provide participants with an opportunity to provide additional information about 
reasons why they have or have not gotten the HPV vaccine. Participants were asked to: 
“Please describe all of the reasons why you have or have not gotten the HPV vaccine.”  
Outcome Measures 
 Actual vaccine obtainment. To determine if participants had received the HPV 
vaccine or not, they were asked if they had obtained any of the HPV vaccine shots. 
Individuals could indicate if they had or not, and if so, they were asked to indicate how 
many of the shots they had received. Individuals were considered to have been vaccinated 
if they received at least one shot. 
Desire to get the HPV vaccine. Non-vaccinated participants were asked to 
indicate on a five-point scale ranging from 1 (definitely not like to) to 5 (definitely would 
like to), how much they would like to get the HPV vaccine, regardless of whether they 
think they actually will.  
Actually think will get the vaccine. Non-vaccinated participants were also asked 
how likely they are to actually get the HPV vaccine. Responses were recorded on a five-
point likert scale ranging from 1 (very unlikely) to 5 (very likely).  
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Procedure  
This study was approved by the Research Ethics Board at the University of 
Windsor. Data were collected in the Fall of 2011. Participants were recruited for this web-
based study in three ways: (1) The University of Windsor psychology participant pool 
website, (2) Email snowball sampling, and (3) The social networking site Facebook. 
Individuals who were recruited through the psychology participant pool were able to view 
a description of the study online through the participant pool system, and were able to 
choose to sign up to participate. If individuals signed up for this study, they were given 
access to the study website where they could complete the study at any time within a one 
week time frame. Individuals who were recruited through email snowball sampling 
received an email which contained a description of the study and a link to the study 
website. The author sent out the original email message to family and friends with the 
request that the email be forwarded on. The third method used to recruit participants was 
through Facebook. A Facebook “page”, describing the study and providing potential 
participants with the web link to the study, was developed. Facebook users could have 
found this page through a variety of methods. For instance, individuals conducting key 
word searches could have located the page and viewed it (e.g., HPV Vaccine, HPV 
Canada), but probably the most effective method of Facebook recruitment was through 
requests to participate in the study that were sent out by this author, to Facebook Friends, 
which included a request to forward the study page information on to eligible women. 
 Incentives for participation varied depending upon how participants learned of the 
study. Women who were registered in the psychology participant pool received one bonus 
point in an eligible psychology class in exchange for their participation. Women who 
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learned of the study through any of the other methods were offered the chance to enter a 
random draw for two $250 Amazon.ca gift cards. The gift cards were sent electronically 
to the winners’ email addresses.  
This study was hosted on-line through the web survey provider FluidSurveys. 
FluidSurveys stores collected data within Canada, ensuring that data is stored securely 
and can be accessed only by survey creators. The first web page  participants encountered 
when they clicked on the study web link was the “Letter of Information to Participate in 
Research” page. Participants were required to indicate that they had read the letter before 
they could continue to the next study page, complete screening questions, and if eligible 
to participate, begin the questionnaire. 
Once participants had completed the study questionnaire they were asked if they 
would like to provide their information to receive the type of compensation advertised 
to them in the study recruitment materials (bonus point or draw entry). If participants 
chose to provide their personal information, they were routed to a new FluidSurvey 
that collected their information and stored it in a new, separate database from their 
questionnaire data. This was done to ensure that survey data could not be linked to 
participants’ names or email addresses.  
Data Analysis 
The data analytic strategy for this study included logistic regression and multiple 
regression analyses, as well as testing the proposed modified Health Belief Model 
presented earlier in this paper through Structural Equation Modeling (SEM). To begin, 
logistic regression analyses were conducted to investigate the relationships between the 
variables assessing each of the study’s model components (e.g., Perceived Severity, 
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Perceived Benefits), and a dichotomous outcome variable: vaccination status (have 
received the HPV vaccine or have not received the HPV vaccine). Following these 
logistic regressions, the rest of the analyses conducted used only the data from women 
who had never been vaccinated.  
Two sets of multiple regression analyses were conducted next. The intent was to 
examine factors that predict intentions to receive the HPV vaccine. The first group of 
multiple regressions investigated the relationships between the variables assessing the 
model components, and an outcome variable that asked participants if they would like to 
get the HPV vaccine, with possible responses ranging from one to five. The second group 
of multiple regressions investigated the relationships between the component variables 
and an outcome that asked participants if they actually thought they would get the 
vaccine, regardless of whether they wanted it or not. This outcome variable was also 
measured on a five-point scale. 
Following the examination of direct relationships between the proposed predictor 
variables and the various outcomes, structural equation modeling was used to test the 
modified Health Belief model of HPV vaccination intentions that was proposed in this 
study. See Figure 1 to review this model.  
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Chapter III 
Results 
Data Screening 
In order to participate in this study, individuals had to meet specific criteria. A 
participant had to be a woman, living in Canada, aged 18 to 30. The first page of the 
study website, which described the purpose of the study and the participation criteria, was 
visited by 458 individuals. Of these visitors, 394 people met the participation criteria and 
began the survey. Not all individuals who began the survey completed it. In total, 374 
women, or 94.9% of those who began it, completed the survey.  
Data was screened for outliers by examining boxplots and comparing means of the 
total sample to means of a 5% trimmed sample (removing individuals with the top 2.5% 
and the bottom 2.5% of values). Boxplots revealed that while a few individuals (e.g., 2-10 
people) had outlying scores on some variables, that no one individual was responsible for 
many outlying scores. When total sample means and 5% trimmed means were examined, 
it was found that mean scores either did not change, or changed very little. Thus, it was 
decided that no participants would be removed due to outlying responses. Missing data 
was also not a problem for the 374 women who completed the survey. While some 
questions could only be answered by a portion of the sample based on their answers to 
previous survey questions  (e.g., questions about Pap testing could only be answered by 
individuals who had ever had a Pap test), for questions in which all individuals could 
provide responses, very little missing data was detected. Thus, again, no individuals had 
to be removed from the final dataset. Graham (2009) states that if 5% or less of data is 
missing, that listwise deletion is an acceptable approach to dealing with missing data. As 
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this was the case with this dataset, listwise deletion was used when conducting descriptive 
and regression analyses in SPSS. Because SEM modeling requires complete data, for any 
missing cases (which were minimal) mean substitutions were used.  
Tests of scale score normality (kurtosis) were also conducted. Byrne (2010) states 
that for the purposes of SEM that a kurtosis score greater than 5.0 should be considered 
non-normal. Based on this this rule, no scales were found to have non-normal 
distributions.   
Factor Analysis and Reliability of Study Measures 
 Due to the lack of validated scales to measure the various constructs under 
investigation, many of the measures used in this study had to be adapted from previous 
research or were designed specifically for this project. Because of this, it was important to 
ensure that these created scales were factor analysed. All created scales were analysed 
using principal components factor analysis without rotation, and it was found that with 
the exception of the scales assessing (1) participant concern about experiencing stigma if 
asking a doctor for the HPV vaccine (Fear of Doctor Stigma), and (2) subjective norms 
assessing how much others influence the participants’ behaviours (HPV Subjective 
Norms), that all of the scales proved to be unidimensional measures of the constructs they 
were intended to assess. Specifically, all scales had items that loaded on Factor 1 with 
values of at least .35 and no strong loadings on another factor. After examining the factor 
structure of the Fear of Doctor Stigma scale, it was decided that the two items that did not 
load onto the primary factor be removed, reducing the scale from 12 items to 10. The Fear 
of Doctor Stigma Scale asks participants “If I asked my doctor for the HPV vaccine, the 
doctor would think…”. The two items that were removed were “nothing of it” and “that I 
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want to protect my sexual partners”. The HPV Subjective Norm scale was also 
strengthened by removing the one item that did not load adequately, reducing this scale 
from eight to seven items. The item that was removed inquired about the opinions of 
religious organization members in the participants’ life. After these changes were made, 
the scale items for each of the two measures were factor analysed again. The results 
revealed that for each measure, all items now loaded well onto one factor.  
Cronbach’s alpha reliability coefficients were computed for all scales. Please see 
Table 2 to view Cronbach’s alpha values for each scale, the scale possible range and 
actual range, and the scale mean and standard deviation. All values were acceptable 
(Cronbach’s alpha > .70), except for the value for the HPV vaccine knowledge scale, 
which had a Cronbach’s alpha value of .66. Due to its lower value, and because research 
has found mixed results when investigating the relationship between knowledge variables 
and HPV outcomes variables, the decision was made to exclude this scale from analysis. 
Because there were two knowledge scales used in this study, HPV knowledge and HPV 
vaccine knowledge, one scale was still available to represent the knowledge component 
of the theoretical model, and thus the exclusion of the vaccine knowledge scale did not 
hinder the ability to test the proposed theoretical model.  
In order to ensure that scale intercorrelations were not too high, leading to 
multicollinearity, correlations were computed between all continuous variables (see Table 
3). Only two scales were found to be highly correlated. These scales were the scale 
assessing general vaccine safety fears and the scale assessing HPV vaccine safety fears (r 
= .69). As mentioned in the Measures section, due to this high correlation, and because of 
the conceptual similarity between the two scales, the items that comprised them
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Table 2  
 
Cronbach’s Alpha Values, Scale Ranges, and Scale Means and Standard Deviations for 
Scales used in Analyses 
 
 
Measure  
 
Cronbach 
Alpha 
Possible 
range 
Actual 
range 
Mean 
Standard 
deviation 
 
HPV Knowledge 
 
.84 0-24 0-24 14.47 4.49 
HPV Vaccine Knowledge 
 
.66 0-7 0-7 5.01 1.47 
Susceptibility .88 1-5 1-5 1.89 0.88 
 
General Severity 
.73 1-5 2.8-5 4.48 0.56 
 
Treatment Severity 
.80 1-5 1.2-5 4.28 0.66 
 
Social Severity 
.88 1-5 1-5 4.05 0.94 
 
HPV Vaccine Effectiveness 
.94 1-5 1-5 3.36 1.04 
 
Vaccines Positive Beliefs   
.90 1-5 1-5 3.71 0.88 
 
Fear Cervical Cancer 
.94 1-5 1.25-5 3.51 0.94 
 
Safety Concerns 
.91 1-5 1-5 3.37 0.90 
 
Asking Dr. Stigma  
.92 1-5 1-4.3 1.82 0.66 
 
SAS Permissiveness Subscale 
.92 1-5 1-4.4 2.02 0.81 
 
STI Sigma and Shame  
.92 1-5 1-4.91 2.41 0.82 
 
Physician Trust  
.94 1-5 1-5 3.55 0.85 
 
Pharmaceutical Company  
Trust 
.85 1-5 1-4.6 2.85 0.58 
 
HPV Vaccine Cost .80 1-5 1-5 2.12 
 
1.21 
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Measure  
 
Cronbach 
Alpha 
Possible 
Range 
Actual 
Range 
Mean 
Standard 
Deviation 
 
Vaccination Self Efficacy 
 
.81 1-5 1-5 3.54 0.90 
HPV Vaccine Subjective 
Norms 
.89 1-5 1-5 3.26 0.65 
 
Positive Cues to Action 
- 0-20 0-14 2.34 2.78 
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Table 3 
 
Correlations Between Continuous Study Variables 
 
 1 2 3 4 5 6 7 8 9 10 11 12 13 
1 Desire Vac 1             
2 Actually Think Vac .78** 1            
3 HPV Knowledge -.08 -.10 1           
4 Susceptibility Scale .16* .03 .29** 1          
5 General Severity .01 .11 -.20** -.14* 1         
6 Treatment Severity -.05 -.01 -.19** -.07 .58** 1        
7 Social Severity -.02 .05 -.18** -.10 .47** .52** 1       
8 Fear Cerv Cancer -.08 .02 -.10 .10 .32** .31** .26** 1      
9 Vac Effectiveness .67** .61** -.13* .06 .14* .12 .12 .05 1     
10 Vac Pos Beliefs .54** .42** -.12 .05 .12 .09 .08 .06 .50** 1    
11 Safety Concerns -.42** -.25** -.09 -.05 .22** .27* .20** .31** -.24** -.43** 1   
12 SAS Perm .13 .03 .33** .31** -.30** -.20** -.27** -.20** .06 .02 -.18** 1  
13 Stigma And Shame -.05 .02 -.36** -.17* .22** .28** .44** .27** -.02 .13 .14* -.30** 1 
14 Physician Trust .15* .25** -.08 -.15* .12 .03 .13 -.04 .22** .18** -.11 -.15* -.04 
15 Pharm Trust .34** .23** -.15* -.12 .11 .04 .08 -.03 .29** .32** -.34** -.09 .00 
16 Vac Cost  .17* .02 -.10 .10 -.01 .00 .08 .02 .21** .14* -.07 .07 .01 
17 Fear Dr. Stigma -.15* -.14* -.11 -.02 .07 .05 .12 .09 -.18** .00 .05 -.04 .36** 
18 Pos Cues Action .63** .58** -.03 .15* .07 -.01 .05 .06 .50** .37** -.20** .06 -.04 
19 Self-Efficacy .39** .39** .05 .03 -.03 -.05 -.05 -.17** .39** .26** -.24** .18** -.11 
20 Subjective Norms .54** .52** .02 .10 .00 -.05 .05 -.05 .45** .29** -.29** .09 -.08 
Note. *p < .05, ** p < .01. 
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 14 15 16 17 18 19 20 
1 Desire Vac        
2 Actually Think Vac        
3 HPV Knowledge        
4 Susceptibility Scale        
5 General Severity        
6 Treatment Severity        
7 Social Severity        
8 Fear Cerv Cancer        
9 Vac Effectiveness        
10 Vac Pos Beliefs        
11 Safety Concerns        
12 SAS Perm        
13 Stigma And Shame        
14 Physician Trust 1       
15 Pharm Trust .28** 1      
16 Vac Cost  -.03 .06 1     
17 Fear Dr. Stigma -.16 -.07 .10 1    
18 Pos Cues Action .22** .26** .05 -.18** 1   
19 Self-Efficacy .10 .27** -.26** -.17* .34** 1  
20 Subjective Norms .16* .27** .11 -.26** .47** .40 1 
Note. *p < .05, ** p < .01. 
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were combined in order to create one scale score to assess vaccine safety fears (this 
combined scale score represents the variable called Vaccine Safety Concern within this 
document). No correlations between any of the other scale predictor variables were found 
to be high.  
Sample Characteristics 
 Recruitment source. Participants were asked how they found out about this 
study. Of those who answered this question, 298 found out about it through the university 
psychology participant pool (79.7% of the sample), and 73 found out about it online 
through Facebook or email (19.5% of the sample). Three people did not answer this 
question.  
Romantic relationships and sexual history. The majority of participants, 94.4% 
of the sample, reported that they were heterosexual, 3.7% were bisexual, 0.3% were 
lesbian, and 1.1% reported their sexual orientation as “other”. For those individuals who 
reported that they were bisexual, 12 out of the 14 women had had a male sexual partner as 
their most recent partner. The majority of study participants were either single and not 
dating (27.5%), or in a committed dating relationship but not living together (38.8%). A 
fairly equal proportion of the remaining participants were either single and dating 
(14.4%), cohabitating with a partner but not married (8.8%), or married (10.4%). The 
average reported relationship length was 3.59 years (SD = 2.87). When asked if they had 
ever engaged in any type of sexual activity (touching, intercourse, other activities), 84% 
of participants indicated that they had. The number of reported sexual partners an 
individual had ever had any type of sexual contact with ranged from 1 to 45, with a mean 
of 5.12 (SD = 5.66). When vaginal intercourse was inquired about specifically, 72.7% of 
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individuals reported that they had had vaginal intercourse. The average age at which 
vaginal intercourse first took place was 17.38 (SD = 2.10), and the mean number of 
partners a woman had had was 4.23 (SD = 5.05). Participants were also asked about their 
experiences with anal intercourse, and 19.5% of the women reported that they had 
engaged in this type of sexual activity. The average age of first anal intercourse was 19.48 
(SD = 2.56), and the mean number of partners was 1.39 (SD = 0.72). Condom use with 
past and present sexual partners was also investigated. With past partners, 4.4% of 
women who had had vaginal intercourse reported that they never used condoms, 10.7% 
reported they did not use them often, 9.2%  reported they used them half of the time, 
22.1% reported they used them most of the time, and 26.5% of participants always used 
them. With current partners, 30.5% of participants did not use condoms, 10.7% did not 
often use them, 6.6% of participants reported they used them half the time, 14% reported 
they used them most of the time, and 26.5% reported they always used them. 
Sexual health. Participants were asked if they had ever had a Pap Smear test. 
Surprisingly, only 59.6% of the sample had ever had a Pap test (39.3% of individuals had 
never had one, and 0.2% of the women were unsure). To investigate this further, the 
proportion of women who had had vaginal intercourse and who had ever had a Pap test 
was analysed. Results revealed that 78.7% of women who had had vaginal intercouse had 
had a Pap test. When participants were asked if they had ever had an abnormal Pap test, 
47 women (12.6% of all participants) reported that they had. Women who had had an 
abnormal Pap test were asked to indicate the highest level of intervention that they had 
received as a result of their abnormal test. Twenty women reported that they had a follow-
up Pap test, 12 women had a colposcopy, and nine women had abnormal cells removed.  
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Five women reported other outcomes such as: requiring yearly biopsies, nothing being 
done, and currently awaiting follow-up appointments.  
Whether individuals had ever had an STI was also investigated. Only 4.5% of 
participants (17 women) reported that they had ever had an STI (0.8% reported they were 
unsure if they had ever had one). When asked about HPV or genital wart infection 
specifically, 3.7% of participants (14 women) reported that they had been diagnosed with 
this STI.   
HPV Vaccine Obtainment 
Participant vaccination rates. One of the main objectives of this study was to 
investigate factors that predict HPV vaccine obtainment. For the purposes of the 
following analyses, obtainment was defined as a participant having obtained at least one 
HPV shot. The majority of study participants had not received an HPV vaccine shot. 
More specifically, 269 people had not received the vaccine (71.9% of the sample), while 
101 women had (27.0% of the sample). Of those who had received the vaccine, 75 
women (74.26% of those who received at least one shot) reported getting all three shots, 
12 reported getting two (11.88%), and 11 (10.89%) reported getting one. The majority of 
women who reported that they had received only one shot reported that they would not be 
going back for any more, while the majority of women who reported that they had 
received two shots reported that they would be finishing the series. A summary of these 
vaccination rates, as well as a summary of the reasons given for not wanting to continue 
to be vaccinated, is presented in Table 4.  
Table 5 presents a summary of key demographic and relationship and sexual 
history variables based upon HPV vaccination status. Chi square analyses and t-tests were
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Table 4 
 
Summary of Participant Vaccination Rates 
  
  
N (% of sample) 
 
 
 
Vaccine Obtained 
 
 
     No 269 (71.9)  
     Yes 101 (27.0)  
 
Number of Shots Obtained  
 
 
     One 11 (2.9)  
     Two 12 (3.2)  
     Three  75 (20.1)  
 
Reasons For Not Completing 
HPV Vaccine Series 
 
 
 
     No time 9  
      
     Decided not important 
 
4 
 
      
     Cost 
 
3 
 
      
     No consistent health care       
     provider 
 
 
3 
 
     Read a story about the    
     vaccine online 
 
2 
 
     Negative side effect 1  
      
     Afraid of needles 
 
1 
 
      
     Friend or family did not    
     want me to continue 
 
 
1 
 
Note. An individual was classified as having obtained the vaccine if they reported 
receiving any number of shots.  
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used to test for possible group differences based on the key demographic variables. Please 
see Table 5 to review the results of these tests. 
HPV vaccine obtainment:  Logistic regression analyses. In order to examine 
the impact that the study variables have on actual vaccination behaviours, logistic 
regression analyses investigating the predictive ability of the variables representing each 
model component except for self-efficacy which was not assessed in participants who had 
received the vaccine, were conducted. Thus, seven logistic regressions, one for each 
model component (Knowledge, Susceptibility, Severity, Benefits, Barriers, Cues to 
Action, and Subjective Norms) were conducted, with actual vaccination status (whether 
one obtained at least one shot of the vaccine or not) as the dichotomous outcome variable.  
 Knowledge. A logistic regression was run to examine whether HPV knowledge 
predicted HPV vaccination behaviour. The logistic regression revealed that HPV 
knowledge scores did not predict whether women received the HPV vaccine or not, 
model χ2 (1, N = 370) = 1.50, p >.05. 
Perceived Susceptibility. It was predicted that a number of relationship variables 
(relationship status and relationship length), a gynecological variable (ever having had an 
abnormal Pap test), and sexual history experiences (ever having engaged in vaginal or 
anal intercourse, number of vaginal or anal sexual partners), as well as scores on the HPV 
Susceptibility Scale would be related to HPV vaccine obtainment. Because some 
relationship, sexual, and gynecological health history questions were not applicable to all 
individuals (e.g., those who had never had sex were unable to indicate a number of 
individuals that they had intercourse with), multiple logistic regressions were conducted 
to test this model component, rather than just one. This was done in order to ensure a
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Table 5 
 
Demographic, Relationship, and Sexual History Information by HPV Vaccination Status 
 
 
Vaccine Obtained 
N = 101 
Vaccine Not 
Obtained 
N = 269 
 
 N (% of sample) N (% of sample) χ2 
 
Relationship status 
  
1.27 
     Single 24 (23.8) 78 (29.0)  
     Dating  17 (16.8) 37 (13.8)  
     Committed    
     Relationship 
 
60 (59.4) 154 (57.2) 
 
Yes, have engaged in 
sexual activity 
 
89 (88.1) 222 (82.5) 
 
1.23 
Yes, have had a Pap 
Test 
 
72 (71.3) 149 (55.4) 
 
6.93* 
Have had an abnormal 
Pap 
 
18 (17.8) 28 (10.4) 
 
1.26 
Told have HPV 4 (4.0) 9 (3.3) n/a 
  
 
Mean (SD) 
 
 
Mean (SD) 
 
 
t 
 
Age 
 
21.2 (2.84) 
 
22.37 (3.71) 
 
3.23* 
 
Relationship length in 
years 
 
2.72 (2.12) 3.92 (3.07) 
 
3.06* 
Age first vaginal 
intercourse 
 
16.84 (1.57) 17.59 (2.22) 
 
3.15* 
Number of vaginal 
intercourse partners 
 
4.42 (4.19) 3.72 (5.30) 
 
1.09 
Note. An individual was classified as having obtained the vaccine if they reported 
receiving any number of shots. * p < .01. 
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large enough sample size for the analyses.  Only two susceptibility variables were found 
to individually predict HPV vaccine obtainment: relationship length, and whether an 
individual had ever had vaginal intercourse. These two variables were then entered into a 
logistic regression together in order to determine whether both still predicted vaccine 
obtainment. The tested model was significant. Model χ2 (2, N = 222) = 9.84, p < .01, 
Hosmer & Lemeshow R2 = 8.74, p > .05, .04 (Cox & Snell), .06 (Nagelkerke). 
Relationship length negatively predicted HPV vaccination behaviours (B = -0.01, p < 
.05), and vaginal intercourse status positively predicted HPV vaccination status (B = 1.12, 
p = .05). Individuals who had had vaginal intercourse were three times more likely to 
receive the HPV vaccine than those who had never had vaginal intercourse, odds ratio = 
3.08, 95% CI [0.99, 61.42]. Meanwhile, as relationship length increased, the odds of 
having the HPV vaccine diminished slightly, odds ratio = 0.99, 95% CI [0.98, 1.00]. 
Predictive success of the model was 72.1%. 
Perceived Severity. A logistic regression was run to determine if scales assessing 
participants’ perceptions of the severity of HPV in general, HPV treatment, and HPV’s 
social impact, as well as fears of cervical cancer, were predictive of vaccine obtainment. 
The model investigating these severity measures was not significant, χ2 (4, N = 367) = 
6.78, p >.05. An examination of the predictive ability of each of the individual measures 
was conducted and it was found that perceptions of the severity of HPV vaccine treatment 
did significantly impact HPV vaccination decisions (B = 0.51, p < .05). For every point 
increase in perceptions of the severity of HPV treatment, the likelihood that an individual 
would get vaccinated increased approximately one and half times, odds ratio = 1.68, 95% 
CI [1.05, 2.67].  
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Perceived Benefits. The impact that beliefs about the effectiveness of the HPV 
vaccine (Vaccine Effectiveness), and beliefs about the benefits of vaccination (Vaccine 
Positive Beliefs), have on actual HPV vaccination behaviours was investigated next. It 
was found that the model that included both of these variables significantly predicted 
HPV vaccination behaviours, Model χ2 (2, N = 368) = 77.41, p < .01, Hosmer & 
Lemeshow R2 = 12.44, p > .05, .19 (Cox & Snell), .27 (Nagelkerke). Predictive success of 
the model was 75.0%. Both scales assessing benefits were found to be positively 
predictive. As participants’ beliefs that the HPV vaccine would effectively reduce HPV 
infection increased (B = 0.92, p < .01), and as beliefs that vaccinations are beneficial to 
society increased (B = 0.45, p < .05), the likelihood that an individual would get 
vaccinated increased. For each scale point that beliefs about the effectiveness of the HPV 
vaccine increased, the likelihood that an individual would get the HPV vaccine increased 
2.52 times, 95% CI [1.78, 3.56]. For each scale point that beliefs that vaccines are 
beneficial for society increased, the likelihood that an individual would get the vaccine 
increased 1.57 times, 95% CI [1.07, 2.30]. 
 Perceived Barriers. There were many barriers to HPV vaccination that were 
predicted to influence inoculation behaviours. The following variables were entered into a 
logistic regression model as possible predictors: Pharmaceutical Company Trust, 
Physician Trust, STI Stigma and Shame, Fear of Doctor Stigma, access to a health care 
professional, the Permissiveness subscale of the Sexual Attitudes Scale, HPV Vaccine 
Safety Fears, Vaccine Cost, and having insurance that would pay for the vaccine. It was 
found that the model was predictive of HPV vaccination behaviours, Model χ2 (9, N = 
336) = 159.25, p < .01, Hosmer & Lemeshow R2 = 11.00, p > .05, .38 (Cox & Snell), .54 
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(Nagelkerke). An examination of the possible predictors revealed that three of the 
variables significantly predicted vaccination uptake: HPV Vaccine Safety Fears (B = -
1.49, p < .01), Fear of Doctor Stigma (B = -1.07, p < .01), and whether the vaccine was 
covered by insurance (B = -2.55, p < .01). In addition, one variable approached 
significance: STI Stigma and Shame (B = 0.40, p = .58). Prediction success of the model 
was 84.8%. When the influence that HPV Vaccine Safety Fear has on HPV vaccination 
behaviours was examined, it was found that as concern about the safety of vaccines 
increased, the likelihood that an individual would get vaccinated decreased, odds ratio = 
0.23, 95% CI [0.15, 0.35]. Relatedly, as concern that physicians would have negative 
opinions about the participant if they asked for the HPV vaccine increased (Fear of 
Doctor Stigma), the likelihood that an individual would get the HPV vaccine decreased, 
odds ratio = 0.34, 95% CI [0.19, 0.62]. Individuals who did not have insurance that 
covered the vaccine were less likely to get vaccinated, odds ratio = 0.08, 95% CI [0.04, 
0.16]. Finally, the impact of participant’s beliefs about the stigma and shame associated 
with STIs and its impact on HPV vaccine behaviour approached significance. As 
perceptions of stigma and shame increased (become more negative), the likelihood of 
getting vaccinated decreased, odds ratio = 1.50, 95% CI [0.99, 2.27].    
 Cues to Action. A logistic regression was conducted to investigate whether 
Positive Cues to Action would predict HPV vaccination behaviour. Results indicated that 
cues to action did predict vaccination behaviours, Model χ2 (1, N = 346)= 68.11, p < .01, 
Hosmer & Lemeshow R2 = 11.97, p < .05, .18 (Cox & Snell), .26 (Nagelkerke). 
Predictive success of the model was 76.3%. Positive Cues to Action positively influenced 
vaccination behaviour (B = 0.38, p < .01). As the number of positive cues increased, there 
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was a greater likelihood that an individual would receive the HPV vaccine, odds ratio = 
1.46, 95% CI [1.32, 1.62]. 
Subjective Norms. Finally, it was predicted that Subjective Norm scores would 
predict actual HPV vaccination outcomes. The model testing this prediction was 
significant, Model χ2 (1, N = 368) = 72.38, p < .01, Hosmer & Lemeshow R2 = 30.18, p < 
.01, .18 (Cox & Snell), .26 (Nagelkerke). Predictive success of the model was 77.4%. As 
Subjective Norm scores increased (indicating more positive norms), individuals were 
more likely to get the HPV vaccine, odds ratio = 6.03, 95% CI [3.74, 9.74].  
 Final logistic regression model of all significant predictors. With the number of 
possible predictor variables within each component narrowed down, it was then possible 
to conduct a logistic regression on all variables that had been found to significantly 
predict vaccine behaviours. The only variable that was excluded from this analysis was 
relationship length, because its inclusion resulted in too small of a sample size to 
adequately test for effects. The following variables were entered as possible predictors of 
HPV vaccine obtainment: whether an individual had had vaginal intercourse, perceptions 
of the severity of HPV treatment (Treatment Severity), Vaccine Effectiveness, Vaccine 
Positive Beliefs, HPV Vaccine Safety Fears, Fear Doctor Stigma, whether the vaccine is 
covered by insurance, STI Stigma and Shame, Positive Cues to Action, and Subjective 
Norms. The results of the analysis revealed that the model was predictive, Model χ2 (10, 
N = 340) = 197.71, p < .01. Predictive success of the model was 87.9%.  The variables 
that maintained their predictive power were: Treatment Severity, HPV Vaccine Safety 
Fears, Fear of Doctor Stigma, and whether the vaccine was covered by insurance. Positive 
Cues to Action also approached significance as a predictor. As perceptions of the severity 
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of HPV treatment and positive cues to action increased, individuals were more likely to 
get the vaccine. As fear of doctor stigma and vaccine safety concerns increased, the 
likelihood that an individual would get vaccinated decreased. And finally, individuals 
who had insurance were more likely to get the vaccine. Please see Table 6 for a summary 
of the model statistics.  
Predictors of Intentions to Receive the HPV Vaccine for Those Who are Not 
Vaccinated 
Participants who had not received any HPV vaccine shots (N = 269) were asked 
two related questions to assess their intentions to obtain the HPV vaccine: (1) how much 
would you like to get the HPV vaccine (regardless of whether you think you actually 
will), and (2) How likely are you to actually get the vaccine? Participants could respond 
on a five-point likert scale that ranged from one (definitely not like to/very unlikely) to 
five (definitely would like to/very likely). The mean responses to both questions, in 
general, revealed a lack of interest in obtaining the vaccine. Individuals were more likely 
to want to get the vaccine (M = 2.88, SD = 1.19), than they were to actually think they 
would get it (M = 2.48, SD = .08). In order to verify that these two outcome measures 
were indeed measuring separate constructs, a Pearson correlation analysis and t-test was 
conducted. The two items were found to have a high correlation, r = .79, p < .001. The 
students t-test was also significant, t(265) = 8.55, p < .001, indicating that although the 
items are related, they do assess unique aspects of intentions to vaccinate.  
Desire to Get the Vaccine.  
 Due to the large number of possible predictor variables proposed in this study, the 
first step in investigating predictors of participants’ desire to get the HPV vaccine was to 
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Table 6 
 
Logistic Regression Results: Predictors of Actual HPV Vaccination Behaviour (N = 340) 
 
  95% CI for Odds Ratio 
 B (SE) Lower Odds Ratio Upper 
     
 
Constant 
 
 
0.30 (2.02) 
   
     
Vaginal intercourse 
 
-0.33 (0.47) 0.29 0.72 1.80 
Severity of HPV treatment 
 
0.99 (0.36)** 1.33 2.68 5.42 
HPV vaccine effectiveness 
 
0.39 (0.25) 0.91 1.48 2.39 
Vaccine benefits 
 
-0.10 (0.26) 0.54 0.91 1.52 
Vaccine safety 
 
-1.46 (0.27)** 0.14 0.23 0.39 
Fear stigma from doctor 
 
-1.20 (0.36)** 0.15 0.30 0.61 
Insurance covered 
 
-2.37 (0.39)** 0.04 0.09 0.20 
STI stigma and shame 
 
0.38 (0.23) 0.93 1.46 2.31 
Cues to action  
 
0.15 (0.08)* 1.00 1.17 1.37 
Subjective norms 
 
0.07 (0.34) 0.55 1.08 2.10 
Note. Model χ2 = 197.71, p < .01, Hosmer & Lemeshow R2 = 7.56, p > .05, .44 (Cox & 
Snell), .64 (Nagelkerke). * p = .057. ** p < .01.  
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conduct various multiple regressions in an effort to narrow down the number of predictor 
variables before a final regression model combining the various theoretical components 
was tested. These initial regressions were organized to test the variable(s) assessing each 
theoretical component. For most of the model components, one multiple regression 
analysis containing all of the possible predictor variables in that component was run. 
However, for the Susceptibility component, because the variables had varying sample 
sizes, various regressions had to be run for each of these possible predictor variables.  
 In order to investigate the predictive ability of the Knowledge component of the 
theoretical model being tested, a regression was run with HPV Knowledge scores as the 
predictor, and Desire to Get the HPV Vaccine (on a scale of 1 to 5) as the outcome. The 
regression was not significant, F(1,265) = 0.52, p > .05. 
To investigate the Susceptibility component of the theory, various linear 
regression analyses were conducted. Because variables assessing this component include 
a lot of dichotomous predictors that represent life experiences (e.g., ever having had 
vaginal intercourse, ever having had an abnormal pap, relationship status), in order to 
ensure an adequate sample size for the analyses, separate regressions were run for each 
predictor.  A regression was run with each of the following variables as a predictor, and 
desire to get the HPV vaccine as the outcome: Relationship status (single or in a 
relationship), Pap test status (ever have an abnormal test or not), vaginal intercourse 
status (have had or have not had), anal intercourse status (have had or not had), number of 
vaginal sexual partners, number of anal sexual partners, Susceptibility Scale scores, and 
relationship length. Two susceptibility variables were found to be predictive of a  
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desire to get the HPV vaccine: Susceptibility Scale scores, F(1,265) = 8.05, p < .01, 
adjusted R square  = .03, and relationship length F(1,265) = 4.74, p < .05, adjusted R 
square  = .01. As susceptibility scores increase, desire to get the vaccine also increases (β 
= .17, p < .01), and as relationship length increases desire to get the vaccine decreases (β 
= -.13, p < .05).  
 Next, the impact of the variables assessing the Severity component of the theory 
was tested with one multiple regression, with Desire to Get the Vaccine as the outcome 
variable and the following variables as predictors: Score on the General Severity scale, 
score on the Treatment Severity scale, score on the Social Severity scale, and score on the 
Fear of Cervical Cancer scale. None of the variables in this model were found to be 
predictive of participants’ desire to get the vaccine, F(4,259) = 0.38, p > .05.  
To test the variables assessing the Benefits component of the theory used in this 
study, a multiple regression was conducted with scores on the Vaccine Positive Beliefs 
scale, and the Vaccine Effectiveness scale as predictors. The model testing both of these 
predictors was significant, F(2,262) = 115.49, p < .001, adjusted R square  = .46. An 
examination of standardized beta values revealed that perceptions of the effectiveness of 
the HPV vaccine (β = .51, p < .001), and vaccine positive beliefs (β = .26, p < .001), 
predicted desires to get the HPV vaccine. As beliefs about the effectiveness of the vaccine 
and vaccine positive beliefs increase, desires to get the vaccine also increase. 
 The Barrier component of the theory was tested by running one multiple 
regression analysis using the following predictor variables: Pharmaceutical Company 
Trust, Physician Trust, STI Stigma and Shame, Fear of Doctor Stigma, Permissiveness 
subscale of the Sexual Attitudes Scale, regular healthcare provider status (have one or 
Factors that influence HPV vaccinations  101 
 
don’t have one), availability of insurance to cover costs, and perceptions about the cost of 
the HPV vaccine (Vaccine Costs). The model was significant, F(9,229) = 8.97, p < .001, 
adjusted R square  = .23. An examination of standardized beta weights revealed that the 
following were significant predictors: HPV Vaccine Safety Fears (β = -.30, p < .001), 
Pharmaceutical Company Trust (β = .22, p < .01), Vaccine Costs (β = .13, p < .05), and 
Fear of Doctor Stigma (β = -.12, p < .05). As Concerns about the safety of the vaccine 
and fear of doctor stigma increase, desires to get the vaccine decrease. As trust for 
pharmaceutical companies increase, desires to get the vaccine also increase, revealing that 
low levels of trust will lead to less desire to get vaccinated. And finally, as concerns about 
the cost of the vaccine increases, desire to get the vaccine also increases.  
 The remaining three components of the theoretical model being tested in this 
study, Cues to Action, Self-Efficacy, and Subjective Norms, were each tested with their 
own multiple regression analysis, each with one predictor variable: Positive Cues to 
Action for the Cues to Action regression, feeling of efficacy for the Self-Efficacy 
regression, and Subjective (Social) Norms surrounding HPV vaccination for the 
Subjective Norms regression. Each of the three regressions were significant: Cues to 
Action F(1,246) = 166.22, p < .001, adjusted R square  = .40, Self-Efficacy F(1,261) = 
49.20, p < .001, adjusted R square  = .16, and Subjective Norms F(1,265) = 107.99, p < 
.001, adjusted R square  = .29. As cues to action (β = .64, p < .001), self-efficacy (β = .40, 
p < .001), and subjective norms (β = .54, p < .001) increased, desire to get the vaccine 
increased.  
Multiple regression of all significant predictors. The significant predictors from 
each theoretical component that were identified in the regressions above, were then 
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entered into a final multiple regression model in order to investigate which variables 
would still significantly predict Desire to Receive the HPV Vaccine, when all possible 
contributing variables were taken into account. Using the Enter method, a significant 
model emerged F(11,212) = 37.15, p < .001, adjusted R square  = .64. Variables that were 
found to still significantly predict participants’ desire for the HPV vaccine were:  beliefs 
about vaccine effectiveness, thoughts about HPV vaccine safety, Positive Cues to Action, 
Vaccine Positive Beliefs, and Subjective Norms. Results revealed that as beliefs about the 
effectiveness of the HPV vaccine (β = .31, p < .001), Positive Cues to Action (β = .29, p 
< .001), social norms encouraging the vaccine (β = .14, p < .01), and Vaccine Positive 
Beliefs (that vaccines in general are useful) (β = .13, p < .05) increased, so too did a 
desire to get the HPV vaccine. Meanwhile, as worry about the safety of the HPV vaccine 
increased (β = -.18, p < .001), desire to get the vaccine decreased. See Table 7 for a 
summary of these findings.  
Actually Think they Would get the Vaccine 
An analysis of predictors of whether participants believe they will actually get the 
vaccine was conducted next. The analysis was conducted in the same fashion as the 
analysis of the question assessing desire to get the vaccine, with various initial regressions 
being run to test predictors for each model component, and then conducting a final 
multiple regression with all significant predictors.  
To begin, a regression testing whether HPV Knowledge is predictive of 
participants’ belief they would actually get the vaccine was conducted. This regression 
was not significant, F(1,265) = 1.23, p > .05, indicating that HPV knowledge was not 
predictive of these vaccination intentions.
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Table 7 
 
Multiple Regression Results: Predictors of a Desire to Obtain the HPV Vaccine (N = 
224) 
 
 B SE B β sr2 
     
Constant 
 
0.28 0.63  
 
     
HPV vaccine effectiveness 
 
0.37 0.07 .31** .05 
Vaccine safety 
 
-0.26 0.07 -.18** .02 
Cues to action  
 
0.16 0.03 .29** .05 
Susceptibility scale 
 
0.09 0.06 .07 .00 
Vaccine positive benefits 
 
0.18 0.07 .13* .01 
Pharmaceutical trust 
 
0.06 0.10 .03 .00 
Fear stigma from doctor 
 
0.01 0.08 .01 .00 
Vaccine cost 
 
0.04 0.04 .04 .00 
Vaccination efficacy 
 
0.06 0.07 .04 .00 
Subjective social norms 
 
0.29 0.10 .14** .01 
Relationship length 
 
-0.00 0.00 -.05 .00 
Note. R2=.66. *p<.05. ** p < .01.  
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To investigate whether certain life experiences and perceptions of susceptibility 
predict beliefs about whether one would actually get the vaccine or not, separate 
regressions were run with each of the following variables as the predictor, and beliefs that 
one would actually get the HPV vaccine as the outcome: relationship status (single or in a 
relationship), Pap test status (ever had an abnormal test or not), vaginal intercourse status 
(have had or have not had), anal intercourse status (have had or not had), number of 
vaginal sexual partners, number of anal sexual partners, Susceptibility Scale Score, and 
relationship length. Three susceptibility variables were found to be predictive of 
participants’ beliefs that they would actually get the vaccine: abnormal pap test status 
F(1,145) = 4.51, p < .05, adjusted R square  = .02, relationship length F(1,265) = 9.59, p 
< .01, adjusted R square  = .03, and having ever had anal intercourse F(1,265) = 5.15, p < 
.05, adjusted R square  = .02.  Those who had had an abnormal pap test (β = -.17, p < 
.05), and those who had ever had anal intercourse (β = -.14, p < .05) were less likely to 
think they would actually get the vaccine. Similar to other analyses, longer relationship 
length was associated with lower belief that one would actually get the vaccine (β = -.19, 
p < .01). 
 The Severity component variables were tested next. Participant scores on the 
General Severity Scale, the Treatment Severity Scale, the Social Severity Scale, and the 
Fear of Cervical Cancer scale were entered into the regression as possible predictors, with 
participants’ belief that they would actually get the vaccine as the outcome variable. Only 
one of these variables, general perceptions of the severity of HPV, was found to be 
predictive F(1,265) = 5.15, p < .05, adjusted R square  = .02. As perceptions of the 
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severity of HPV increased, thoughts that one would actually get the vaccine also 
increased (β = .15, p < .05).  
The predictive ability of the Benefit component variables were tested in one 
regression. Scores on the Vaccine Positive Beliefs scale and the Vaccine Effectiveness 
scale were entered as predictors of participants’ beliefs they would actually get the 
vaccine. Both variables were found to be predictive F(2,262) = 85.87, p < .001, adjusted 
R square  = .39. As beliefs about the effectiveness of the HPV vaccine (β = .55, p < .01) 
and vaccine positive beliefs (β = .14, p < .05) increased, thoughts that one would actually 
get the vaccine also increased.  
 To investigate which Barrier component variables were predictive of actual beliefs 
that one would get the vaccine, one regression analysis was conducted using the 
following predictor variables: Pharmaceutical Company Trust, Physician Trust, STI 
Stigma and Shame, Fear of Doctor Stigma, Permissiveness subscale of the Sexual 
Attitudes Scale, regular healthcare provider status, perceptions of the cost of the HPV 
vaccine (HPV Vaccine Costs), and availability of insurance to cover costs. The model 
was significant, F(9,229) = 5.21, p < .001, adjusted R square  = .14. An examination of 
standardized beta weights revealed that the following were significant predictors: HPV 
Vaccine Safety Fears (β = -.18, p < .01), Pharmaceutical Company Trust (β = .16, p < 
.05), and Physician Trust (β = .19, p < .01). Worry about stigma if asking a doctor for the 
vaccine approached significance (β = -.12, p = .064), as did whether the vaccine was 
covered by participants’ insurance (β = .12, p = .055). As vaccine safety concerns and 
fears about doctor stigma increase, thoughts that one would actually get the vaccine 
decrease. As trust in pharmaceutical companies and physicians increase, thinking that one 
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would actually get the vaccine increases. And finally, having insurance increases thoughts 
that one would actually get the vaccine.   
 The remaining three components of the theoretical model being tested in this 
study, Cues to Action, Self-Efficacy, and Subjective Norms were, again, each tested with 
their own multiple regression analysis, each with one predictor variable: Positive Cues to 
Action for the Cues to Action regression, feelings of efficacy for the Self-Efficacy 
regression, and subjective social norms surrounding HPV vaccination for the Subjective 
Norms regression. The three regression analyses were significant: Cues to Action 
F(1,246) = 142.50, p < .001, adjusted R square  = .36, Self-Efficacy F(1,261) = 46.65, p < 
.001, adjusted R square  = .15, and Subjective Norms F(1,265) = 97.75, p < .001, adjusted 
R square  = .27. As cues to obtain the vaccine (β = .61, p < .001), feelings of self-efficacy 
(β = .39, p < .001), and subjective norms (β = .52, p < .001) increase (become more 
positive), so do thoughts that one would actually get the vaccine.  
Multiple regression of all significant predictors. All of the variables that were 
found to be significant predictors in these initial regressions, except for pap test normality 
status and number of anal intercourse partners, were then placed together into a final 
multiple regression model in order to determine which variables would still emerge as 
predictive of beliefs that one would actually get the HPV vaccine. Pap test normality 
status and number of anal intercourse partners could not be placed into the regression 
analysis because the number of individuals who never received an HPV vaccine shot and 
who had reported their pap test status or anal intercourse status was too small to be 
reliably used in the regression analysis.  The final multiple regression model that was run, 
using the Enter method, was found to be predictive of participants’ beliefs that they 
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would actually get the vaccine F(10, 233) = 27.79, p < .001, adjusted R square  = .52. 
Variables that were found to still significantly predict participants’ desire for the HPV 
vaccine were:  Vaccine Effectiveness, Positive Cues to Action, Self-Efficacy, and 
Subjective Social Norms. Results revealed that as beliefs about the effectiveness of the 
HPV vaccine (β = .31, p < .001), positive cues to action (β = .29, p < .001), self-efficacy 
(β = .10, p < .05), and  social norms encouraging the vaccine (β = .17, p < .01) increased, 
so too did beliefs that one would actually get the HPV vaccine. See Table 8 for a 
summary of these findings. To see a summary of the final significant predictors of all 
three outcome measures please see Table 9. 
Testing a Model of HPV Vaccination Intentions 
While it is important to identify variables that have a direct effect on HPV 
vaccination decisions, it is likely that more complex relationships exist between the 
variables assessed in this study. In order to examine more complex relationships between 
the study variables and HPV vaccination intentions, a model was tested through structural 
equation modeling (SEM). The proposed model is displayed in Figure 1. Readers are 
reminded that in SEM, squares indicate observed variables (a variable that has been 
measured directly), while ovals represent latent variables (a construct that is inferred 
based on multiple measured variables). As Figure 1 demonstrates, it is proposed that 
vaccination intention decisions begin with an individual having a certain level of 
knowledge about HPV, and with an individual receiving positive cues to action 
(prompting to receive the vaccine). Knowledge and Cues to Action then affect 
perceptions of HPV Severity, HPV Susceptibility, and HPV vaccine Subjective Norms. 
Perceptions of Severity, Susceptibility, and Subjective Norms then impact
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Table 8 
 
Multiple Regression Results: Predictors of Beliefs Participants Would Actually get the 
HPV Vaccine (N = 244) 
 
 B SE B β sr2 
     
Constant 
 
-.49 .65  
 
     
Severity General 
 
0.07 0.09 .04 .00 
HPV vaccine effectiveness 
 
0.33 0.07 .31** .05 
Vaccine safety 
 
-0.07 0.08 -.05 .00 
Cues to action  
 
0.15 0.03 .29** .05 
Vaccine Positive benefits 
 
0.07 0.07 .05 .00 
Pharmaceutical Trust 
 
-0.10 0.10 -.05 .00 
Physician Trust 
 
0.07 0.06 .06 .00 
Vaccination Efficacy 
 
0.13 0.06 0.10* .01 
Subjective social norms 
 
0.34 0.10 .17** .02 
Relationship Length 
 
-0.00 0.00 -.07 .00 
Note. R2=.54. *p<.05.  ** p < .01. 
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Table 9 
Significant Regression Predictors for each of the Three Outcomes 
 
Actual Vaccinations 
Severity of Treatment 
Vaccine Safety Concerns 
Fear of Doctor Stigma 
Insurance Coverage 
Cues to Action 
 
Desire to Obtain the Vaccine 
Vaccine Effectiveness 
Vaccine Positive Beliefs 
Vaccine Safety Concerns 
Cues to Action 
Subjective Norms 
 
Actually Think Will Get the Vaccine 
Vaccine Effectiveness 
Cues to Action 
Self-Efficacy 
Subjective Norms 
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individuals’ assessments of HPV vaccination Benefits and Barriers. Because the Self-
Efficacy measure used in this study measures participants’ ability to overcome barriers to 
be vaccinated, it was predicted that Self-Efficacy would also impact assessment of 
Barriers. Finally, it was predicted that perceived Benefits and Barriers would impact 
desire to receive the vaccine.   
Assessing the fit of a model tested by SEM is done through the use of fit indices. 
These indices provide information about the fit of the overall model, and because no one 
index is able to assess the accuracy of the model, various indices need to be examined. In 
order to assess fit in the current study the following fit indices were used: CFI, RMSEA, 
IFI, and SRMR. In order to demonstrate good model fit, CFI and IFI values should be 
over .90 (although the CFI value must also remain under 1.0). RMSEA values are said to 
represent good fit when the value is .05 or less. If the value is above .05 but below .10 the 
model is said to have adequate fit, and if the value is over .10 the model has bad fit. And 
finally, values of the SRMR index below .08 are considered to indicate good fit. 
CFA Measurement Model 
As recommended by Kline (2005), before a test of the proposed model could 
begin, it was necessary to perform a CFA analysis of the measurement model. This step 
was necessary because of the unvalidated nature of some of the measures used in this 
study, and the lack of prior research into the relationship between these measured 
variables and the latent variables they are anticipated to represent. The purpose of the 
CFA is to determine if the variables assessed in this study are indeed associated with the 
latent variables they are predicted to measure. Per Kline, in order to assess a CFA model, 
all latent variables are assumed to covary with each other, and thus their associations are 
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left unanalysed. Observed variables that did not serve to measure a latent variable but 
instead directly represent a component of the model (e.g., knowledge, self-efficacy) were 
also added into the CFA model and were allowed to covary with one another, and with 
the latent variables. Thus, all of the model components were free to covary. Per Kline, the 
variance of all of the latent variables was fixed to one for this analysis (Kline, 2005).  
Please see Figure 2 for a diagram of the original measurement model tested with CFA.  
As the diagram illustrates, four variables were believed to assess perceptions of 
Susceptibility: The HPV Susceptibility Scale score, relationship length in years, number 
of vaginal sex partners, and a composite score developed from summing various life 
experiences that would impact participants’ assessment that they were susceptible to HPV 
infection (e.g., ever having an abnormal pap, ever having an STI). Eight variables were 
believed to assess the latent Barriers variable: Comfort Talking with a Doctor, HPV 
Vaccine Safety Fears, the SAS Permissiveness subscale, the STI Stigma and Shame 
Scale, Trust in Pharmaceutical Companies Scale, Trust in Physicians Scale, Vaccine 
Costs, and Fear of Doctor Stigma (if asking for the vaccine). It was believed that two 
variables would assess perceived Benefits of the HPV vaccine: Vaccine Effectiveness and 
Vaccine Positive Beliefs. And finally, perceptions of General Severity, Treatment 
Severity, and Social Severity were thought to assess the Severity component of the 
model. In addition, four observed variables, each measuring a model component 
(Knowledge, Self Efficacy, Social Norms, Positive Cues to Action), were also included in 
the CFA model. Finally, participants’ rating of their intention to receive the HPV vaccine 
was included as the final outcome variable in the model.
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Figure 2:  
Original CFA Measurement Model 
 
 
Figure 2. SLE = Susceptibility Score Based on Life Experiences. SusSc = Susceptibility 
Based on Life Experiences. RLYear = Relationship Length Years. SexPV = Number Sex 
Partners Vaginal Intercourse. VEff = Vaccine Effectiveness. VPB = Vaccine Positive 
Beliefs. SevG = Severity General. SevT = Severity Treatment. SevS = Severity Social. 
VSaf = Vaccine Safety Concern. SASp = Sexual Permissiveness. STISS = STI Stigma 
and Shame. CTDr = Comfort Talking to Dr. PhT = Pharmaceutical Company Trust. 
AskSt = Fear Doctor Stigma. DrT = Physician Trust.  VCost = Vaccine Cost. 
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The results of the CFA indicated that the measurement model had reasonable-to-
poor fit, χ2(178, N = 269) = 553.36, p < .001; Goodness of fit indices: CFI = .735, 
RMSEA = .089 (CI = .080-.097), IFI = .745, SRMR = .099. In an effort to increase model 
fit, possible modifications were sought out. The first step was to examine variable 
normality. It was found that the variable Number of Vaginal Sex Partners departed from 
normality (kurtosis = 25.54), and so the decision was made to remove this variable from 
the model. Because the main focus of this analysis is to test the basic structure of the 
theoretical model being investigated, and because there are numerous other susceptibility 
variables that can be used in this analysis, the decision was made to drop this variable 
rather than to transform it. The next step was to examine model regression estimates. Four 
variables were found to be non-significant measures of the latent variables they were 
presumed to assess. These variables were: Relationship Length in Years, Vaccine Cost, 
Pharmaceutical Company Trust, and Physician Trust. It was decided that these four 
variables would also be removed from the model.  
The second version of the CFA model was run and it had improved fit,  χ2(71, N = 
269) = 214.32, p < .001.; Goodness of fit indices: CFI = .886, RMSEA = .073 (CI = .061-
.086), IFI = .891, SRMR = .068.  All CFA model regression weights were significant. 
Modification index recommendations were examined to determine if any changes to the 
model would improve model fit. No significant change recommendations were made. 
According to Kline (2005), a model can be said to have good fit if the RMSEA value is 
.05 or less. Any RMSEA value over .10 indicates a model with bad fit. Values in between 
these cut-offs are said to have reasonable fit. Kline also recommends that the lower and 
upper RMSEA confidence intervals be examined. Ideally, the lower CI value should fall 
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below .05 and the upper value should fall below .10. Because of the range of values 
included in the confidence intervals of this CFA model, it was decided that this 
measurement model had reasonable fit and would be used in the SEM analysis.  
Structural Equation Model: HPV Vaccination Intentions 
The next step to test the proposed model of HPV vaccination intentions was to 
take the measurement model that was assessed with the CFA analysis, and to add the 
paths indicating the proposed relationship directions between the model variables. Please 
see Figure 3 to view the full version of the model that was tested. When the model was 
tested, it was found to have reasonable-to-bad fit, χ2(109, N = 269) = 394.46, p < .001.; 
Goodness of fit indices: CFI = .743, RMSEA = .099 (CI = .088-.109), IFI = .750, SRMR 
= .108.  In order to improve model fit, regression weights were examined to determine if 
any of the proposed model paths were non-significant. Three paths were found to be non-
significant. The path leading from Cues to Action to Severity, the path leading from HPV 
Knowledge to Social Norms, and the path leading from Susceptibility to Benefits. These 
three paths were removed from the model. Regression modification indices also 
recommended the addition of a path from Positive Cues to Action to Benefits. Because it 
makes sense that receiving positive cues to get vaccinated would encourage women to 
think about the benefits of vaccination, the decision was made to add this path. This new 
version of the model was then tested. 
The second version of the SEM model had improved, reasonable, fit, χ2(111, N = 
269) = 329.72, p < .001.; Goodness of fit indices: CFI = .803, IFI = .808, RMSEA = .086 
(CI = .075-.097), SRMR = .010.  An examination of the model regression weights 
revealed that the path between perceptions of Severity and Benefits was no longer
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Figure 3 
Original SEM Model Tested 
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significant. Thus, the decision to remove this path from the model was made. An 
examination of modification indices for regression weights did not find any 
recommendations that would significantly improve the fit of the model. A rerunning of 
the model (model version 3) with the deletion of the path between Severity and Benefits 
found little change in the fit of the model. The model still had reasonable fit, χ2(112, N = 
269) = 332.79, p < .001.; Goodness of fit indices: CFI = .802, IFI = .806, RMSEA = .086 
(CI = .075-.096), SRMR = .101.  An examination of the regression weights revealed that 
all paths were significant. A review of changes suggested by the modification indices 
showed that allowing the error terms of the Benefits latent variable and the Vaccine 
Safety Concern variable to covary would improve model fit. In SEM, error terms may 
need to be  correlated for various reasons. These include the two variables assessing 
similar constructs, a variable missing from the model that if included would have effects 
on both variables, and finally, because of method bias such as socially desirable 
responding on both variables (Garson, 2012). Because it makes sense that these benefit 
and vaccine safety beliefs could have a mutual influence in common, these two error 
terms were allowed to covary. No other modification indices provided useful information 
for improving the model.  
The fourth version of the model was run, and it was found that model fit did 
improve, χ2(111, N = 269) = 296.87, p < .001.; Goodness of fit indices: CFI = .833, IFI = 
.837, RMSEA = .079 (CI = .068-.090), SRMR = .094. An examination of the model 
regression weights revealed that all paths were significant. Modification indices revealed 
three rational modifications that would improve model fit. Modification indices 
recommended that the Self Efficacy variable be allowed to covary with the error term of 
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three variables: Positive Cues to Action, Benefits, and Social Norms. Because it seems 
possible that these four variables may have a common influence that is not assessed in 
this model (e.g., Optimism, Trust), but which may impact all of these variables, the 
decision was made to allow these error terms to covary. These changes were made and 
the model was run again. 
The fifth version of the model was found to have improved fit, χ2(108, N = 269) = 
232.38, p < .001.; Goodness of fit indices: CFI = .888, IFI = .891, RMSEA = .066 (CI = 
.054-.077), SRMR = .069. All model regression weights were significant and no 
modification indices had suggestions for significant model improvement. In light of this, 
the decision was made to cease modifying the model, and to determine that this is the 
final version. Please see Figure 4 and Figure 5 for the final version of the model. Figure 5 
contains only the model component variables so that standardized regression weights can 
be viewed.  
Supplemental Analyses 
Scale score mean differences between HPV vaccinators and non-vaccinators. 
To aid in the interpretation of the study results, mean outcome scale differences between 
those who received the vaccine and those who did not were investigated with t-tests (see 
Table 10). Results revealed that these two groups had significantly different average 
scores on the following variables: Treatment Severity, with those who obtained the 
vaccine believing that treatment would be more severe than those who did not get it; 
Vaccine Effectiveness, with those who obtained the vaccine believing the vaccine is more 
effective; Vaccine Positive Beliefs, with those who obtained the vaccine believing it is 
more positive than those who did not get it; Vaccine Safety Concerns, with those who
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Figure 4  
Final SEM Model  
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Figure 5 
Final SEM Model Components with Standardized Regression Weights 
   
.18 
.47 
-.12 .30 
.56 
-.66 
-.16 
.63 
.84 
.52 -.26 
-.19 
Note. Model covariances and error terms are not shown in this depiction. All regressions are significant at at least .05. 
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Table 10  
 
T-tests Comparing Outcome Scale Scores of Vaccinated and Unvaccinated Participants 
 
 Vaccinated Unvaccinated  
 
 
Measure  
 
M SD M SD t 
 
p 
Susceptibility Scale 1.91 .84 1.87 .89 -.30 >.05 
Severity General 4.47 .54 4.47 .57 .077 >.05 
Severity Treatment 4.40 0.55 4.23 0.70 -2.37* < .01 
Severity Social 4.13 .88 4.03 .97 -.90 >.05 
Fear of Cervical Cancer 3.59 .89 3.49 .95 -.85 >.05 
Vaccine Effectiveness 4.07 0.76 3.10 1.01 9.91* < .001 
Vaccine Positive Beliefs 4.20 0.76 3.53 0.86 -6.82* < .001 
Vaccine Safety Concerns 2.70 0.85 3.63 0.78 9.98* < .001 
SAS Permissiveness  2.13 .76 1.98 .83 -1.55 >.05 
STI Stigma and Shame 2.39 .80 2.43 .83 .43 >.05 
Physician Trust 3.72 0.72 3.48 0.88 2.44*  < .05 
Pharma. Company Trust 3.00 0.55 2.79 0.58 -3.22* < .001 
Cost Concern Scale 1.91 .98 2.19 1.27 2.13* <.05 
Fear Doctor Stigma 1.52 0.55 1.92 0.66 5.38* < .001 
Self-Efficacy 3.85 .91 3.52 .90 -1.69* <.05 
Social Norms 3.72 0.64 3.10 0.58 -8.50* < .001 
Positive Cues to Action 4.36 3.047 1.57 2.22 -8.14* < .001 
Note. *p < .05
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obtained the vaccine believing it is more safe; Fear of Doctor Stigma, with those who 
obtained the vaccine fearing stigma less than those who did not obtain the vaccine; Dr. 
Trust, with those who obtained the vaccine having more trust in their physician; 
Pharmaceutical Company Trust, with those who obtained the vaccine having more trust in 
pharmaceutical companies; Cost, with those who obtained the vaccine having less 
concern about cost than those who did not get the vaccine; Subjective Norms, with those 
who obtained the vaccine reporting more positive norms for the vaccine than those who 
did not get it; And Positive Cues to Action, with those who obtained the vaccine having 
received more positive cues to action. 
Physician sex and patient comfort. Research on doctor-patient communication 
has found that the gender of a doctor and patient can impact their communication. In light 
of this, a linear regression was conducted in order to determine if the sex of participants’ 
doctors influenced their fear of experiencing stigma if asking for the vaccine. The 
regression investigating this relationship was not significant, F(1,329) = 0.81, p < .001, 
adjusted R square  = -.001, indicating that fears of stigma were not related to the gender 
of the doctor. This lack of significance also held true when this possible relationship was 
examined for just women who received the vaccine, and just those who had not received 
the vaccine. An additional analysis was then conducted to determine whether health care 
provider gender influenced participants’ level of comfort in talking with their health care 
provider in general. The regression investigating this relationship was significant, 
F(1,329) = 22.61, p < .001, adjusted R square  = .062. With individuals feeling more 
comfortable with female doctors (M = 3.88, SD = .93) than male doctors (M = 3.35, SD = 
1.06).  
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 Recommending the HPV vaccine to male and female friends and family 
members. In addition to the main outcome items used in this study, participants were also 
asked some additional outcome items that were not a main focus of the current 
investigation. Two of these items examined whether participants would recommend the 
HPV vaccine to their male or female friends and family members. Responses to each 
question were recorded on a 5-point scale that ranged from 1 (definitely would not) to 5 
(definitely would). A t-test to investigate whether participants would make different 
recommendations for male and female friends was significant, t(370) = 8.47, p < .001. 
Participants were more likely to recommend that their female friends and relatives get the 
vaccine (M = 3.24, SD = 1.39) than they were to recommend their male friends and 
relatives to get it (M = 2.79, SD = 1.35). Additional analyses also revealed that 
participants’ vaccination status was related to whether they would recommend the 
vaccine to female friends or family members, F (3,367) = 28.80, p < .001, and to male 
friends or family members, F (3,364) = 15.89, p < .001. Post hoc tests revealed that 
participants who had received two or three of the vaccine shots were more likely to 
recommend vaccination to their female friends and family members than were individuals 
who had not had any vaccinations. For males, those who had had three shots were more 
likely to recommend the vaccine than those who had no shots. 
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Chapter IV 
Discussion  
When girls and women obtain the HPV vaccine they are protecting themselves 
against a virus that can lead to cancerous cells and genital warts, and all of the negative 
psychological and social implications that these illnesses can have for them. A vaccine for 
HPV was first released in 2006, and while many studies that had investigated anticipated 
obtainment of the vaccine reported that it would most likely be obtained by the majority 
of the targeted population, actual vaccination rates have not reached anticipated levels, 
especially for girls and women who are not eligible for the school-based vaccination 
program. There are many possible factors that could explain why girls and women choose 
to obtain the vaccine or not. This study used a modified version of the Health Belief 
Model to examine the relationship between psychosocial variables and HPV vaccination 
in a sample of women residing in Canada. Direct relationships between the study 
variables and actual and anticipated HPV vaccinations were investigated through logistic 
and multiple regression. While past research has examined the direct relationships 
between many of the components/variables used in this study and HPV vaccinations,  
many of the model’s components have not been sufficiently researched to date. Some 
variables have received little attention in the research literature or have not been 
measured adequately (e.g, perceived susceptibility, self-efficacy, cues to action), while 
the effects of others have been found to be inconsistent (e.g., knowledge, perceived 
severity). Another model component, perceived barriers, has repeatedly been found to be 
predictive of vaccine related outcomes, but due to the large number of factors that can be 
classified as potential barriers, additional novel  barriers to HPV vaccination had yet to be 
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investigated (e.g., medical establishment variables, sexuality variables). This study 
attempted to remedy some of these shortcomings.   
In addition to analyses investigating direct effects, in order to investigate more 
complex relationships, a modified Health Belief model of HPV vaccination intentions 
was tested using Structural Equation Modeling. Few studies in this area have tested 
complex models of health behaviour.  In addition, those that have explored the match 
between health behaviour change theories and HPV vaccinations have not used structural 
equation modeling to test possible models. Instead, these studies have used regression 
analysis, which limits the types of relationships between the model variables that can be 
explored. This study is novel in that the complex interrelationships between the model 
components were tested with SEM, providing a clear and complex picture of the decision 
making process as it related to HPV vaccination intentions.  
 This discussion describes the major findings of this study, beginning with an 
examination of vaccination and health behaviour rates. Next, support or lack of support 
for the study hypotheses are described, so that a clear picture of the usefulness of each 
model component can be determined. After this, a discussion of the results organized by 
type of outcome (actual vaccinations, desire to get vaccinated, and actual thoughts on 
whether one would obtain the vaccine) can be found. Finally, as the last step in describing 
the results of this study, a discussion of the model that was tested was undertaken. 
Following the various descriptions of the study results, a discussion of practical 
implications, limitations, and recommendations for future research is presented.   
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Vaccination and Health Behaviour Rates 
 Not surprisingly, this study found that the majority of participants had not 
received the HPV vaccine, with 72% of participants reporting they never received it, and 
27% of the sample reporting they had received at least one shot. While studies conducted 
prior to the release of the vaccine reported that high proportions of young women 
believed they would obtain it, uptake rates after its release were lower than anticipated, 
especially in non-school-based settings. The results found in the current study are in line 
with rates found in other studies that were conducted after the release of the vaccine. For 
example, Caskey, Lindau and Alexander (2009) found that 30% of 13 to 17 year olds, and 
9% of 18 to 26 year olds had received the HPV vaccine. As these rates demonstrate, 
vaccination rates after the release of the vaccine were lower than anticipated, and have 
stayed low over time.   
 In order to assess participants’ sexual risk taking and sexual health behaviours, the 
women in this study were asked to provide information such as their age of first 
intercourse, the number of sexual partners they had, their STI status, and whether they 
had ever had a pap test.  When asked about their sexual experiences, 84% of study 
participants reported that they had engaged in some form of sexual activity. When vaginal 
intercourse was investigated specifically, it was found that 73% of the women in this 
study had had vaginal intercourse, that the average number of sexual partners the women 
had had was four, and that the average age of first intercourse was 17 years old. When 
anal intercourse was investigated, it was found that  almost 20% of the women had 
engaged in it, with the average age of first experience being higher than for vaginal 
intercourse, at 19 and a half years. Individuals also reported having fewer anal intercourse 
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partners, with the average being 1.39. These values correspond roughly to Canadian 
sexual experience statistics, although the women in this study appear to engage in sexual 
intercourse a year later than the national average. Nationally, the average age of first 
vaginal intercourse is 16.5 years (Rotermann, 2005), and 86% of youth have had sex by 
the age of 24 (Rotterman, 2012). The difference in age of first intercourse may be related 
to the educated sample used in this study, or may be due to regional differences, as a large 
proportion of this sample came from Ontario. Ontario youth seem to be slightly less 
sexually experienced compared to national averages, with fewer Ontario youth engaging 
in sex than the Canadian average (Rotermann, 2005).  
 To date, Pap testing has been the most effective preventative action that a woman 
can take to avoid cervical cancer. This study found that 60% of the women who 
participated had ever received a Pap test. While this number at first seems low, further 
examination found that almost 80% of women who had had sexual intercourse had 
received a Pap test. Because physicians may not recommend Pap tests to women who 
have not yet engaged in sexual intercourse, these statistics are not surprising. For 
example, in a national health survey it was found that 77% of heterosexual Canadian 
women report having had a Pap test within the last three years (Tjepkema, 2008). As 
these results indicate, then, the women involved in this study were proactive about 
protecting their gynecological health through the traditional method of Pap testing. 
Participants were asked to indicate if they had ever had an abnormal Pap test, and almost 
13% of the sample had had an abnormal test. This rate is slightly higher than national 
abnormality rates, as 8% of Pap tests done in Canada require follow-up due to 
abnormality (The Canadian Women’s Health Network, 2007). This difference may be a 
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reflection of the age range of the study participants (younger women are more likely to 
have abnormal Pap tests), or it may be due to self-selection bias, as young women who 
have experienced an abnormal Pap may have been more interested in participating in this 
study.  
The women in this study were also asked if they had ever had an STI. Results 
indicated that 4.5% of the sample had had an STI, and 3.7% of the sample had been told 
they have HPV. This is similar to rates of common STI diagnoses in the general Canadian 
population. For example, 4.3% of 15-29 year olds have had Chlamydia. Because HPV is a 
non-reportable STI, exact national rates are not available. However, given its prevalence, 
it is likely that symptomatic HPV rates in the Canadian population are similar or higher 
than those for Chlamydia. This suggests that the current study does not have an 
overrepresentation of women diagnosed with HPV.  
Overall, the HPV vaccination rates and sexual experiences reported in this study 
closely reflect those of women in the Canadian population. Because of this, the results of 
this study are likely to reflect the experiences of Canadian women from an educated 
background.  
Discussion of Regression Results Organized By Hypotheses 
Hypothesis 1:  Perceived susceptibility to HPV infection will predict HPV 
vaccination. It was predicted that feeling susceptible to HPV would predict HPV 
vaccinations. When actual vaccine obtainment was investigated, two susceptibility 
variables were initially found to be predictive: relationship length in years, and whether 
an individual had ever had vaginal intercourse. As relationship length increased, 
participants were less likely to get the vaccine, and women who had never had sexual 
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intercourse were less likely to be vaccinated. These results coincide with results found in 
previous research, which found that individuals in monogamous relationships, and 
individuals who had never had sexual intercourse, were less likely to want the HPV 
vaccine (Buchanan, 2008; Caskey, Lindau & Alexander, 2009; Marshall, Ryan, Roberton, 
& Baghurst, 2007). From the perspective of women, the finding that those who have not 
had intercourse are less likely to obtain the HPV vaccine makes sense. These individuals 
likely believe they are not at risk of acquiring an STI, and thus they do not believe they 
need to be vaccinated. Unfortunately, this is the group of women for whom the vaccine is 
most protective. While the initial regression investigating the susceptibility variables and 
actual vaccine obtainment found a significant relationship, when the susceptibility 
variables were entered into the regression investigating all significant predictors of actual 
obtainment, they were found to no longer be predictive. Thus, while a relationship exists, 
it appears to be small, with other variables accounting for actual obtainment decisions.  
For women who had never been vaccinated, belief in susceptibility to HPV 
infection influenced desires to get vaccinated. Susceptibility scale scores and relationship 
length predicted desires. Women who felt more susceptible to infection were more likely 
to desire the vaccine, while the longer a woman was in a relationship, the less likely she 
was to desire it. As noted in the literature review section of this document, few studies 
have used a measure to assess actual feelings of susceptibility to HPV infection. The 
finding here, that a desire to get the vaccine is related to feelings of susceptibility, is one 
of the only studies (see Kuitto, Pickel, Neumann, Jahn & Metelmann, 2010, for another 
example) that shows that actual feelings of susceptibility (as assessed with a measure and 
not inferred based on demographic data such as relationship status) can be related to a 
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desire to be vaccinated. When the significant susceptibility variables discussed here were 
placed into the regression with other significant predictors of a desire to get the vaccine, it 
was found that they were no longer significant. Thus, while a small relationship might 
exist, again, other variables such as perceptions of vaccine effectiveness, positive cues to 
action and subjective norms have been found to be more predictive of desire to be 
vaccinated.  
Finally, when women who had never been vaccinated were asked if they actually 
thought they would get the vaccine, regardless of whether they wanted it or not, it was 
found that abnormal pap test status, relationship length, and ever having anal intercourse 
were predictive of beliefs that one would actually get the vaccine. Similar to the other 
regression findings, the longer a woman was in a relationship, the less likely she was to 
think she would actually get the vaccine.  Surprisingly however, women who had had an 
abnormal pap test in the past, or who had ever had anal intercourse, were less likely to 
think they would actually get the vaccine. These findings were surprising because 
previous research has found that women who have engaged in more sexual risk taking, 
such as having multiple sex partners (more than 5 partners versus 1-5), or having ever had 
an STI, were more likely to want to be vaccinated (Jones & Cook, 2008). Previous 
research has also found that women who had had an abnormal pap test in the past were 
more likely to want the HPV vaccine after an educational intervention than were women 
who had not had an abnormal Pap test (Ferris, Waller, Owen & Smith, 2008). Seemingly 
incongruous findings as they relate to risk and health behaviours are not completely 
unheard of in the health care field, however. For instance, research has shown that some 
women who are at risk for breast cancer are less likely to be screened for it, and that this 
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lack of screening behaviour is related to anxiety about finding a problem (Rimer, 
McBride & Crump, 2001).  
The reason for the surprising findings in this study may relate to how this 
particular question was worded. In the current study, number of anal intercourse partners 
and abnormal Pap test status were not found to be predictive of desire to get the vaccine. 
It is this type of intention (desire) that past research has investigated. Asking women if 
they actually think they would get the vaccine (regardless of whether they want it or not) 
may activate a more complex thought process. While a woman may recognize that she 
wants the vaccine, certain factors, such as knowledge of her Pap history and sexual risk-
taking/experience, may influence her perception of her HPV infection likelihood and thus 
her thoughts on vaccination. For example, women who have had an abnormal pap test 
may believe that they already have HPV, and thus they may decide that given the 
likelihood that they have HPV (high) they are less inclined to overcome barriers (e.g., 
time, cost) to actually get the vaccine, even though they may want it. It could also be that 
women who think they have already been exposed to HPV believe they are immune to it, 
or may not be aware that they can contract other strains of the virus. Thus, they do not 
realize that they would benefit from the vaccine. Similar to the previous two outcomes, 
however, when these susceptibility variables were entered into the regression with other 
significant predictors, they were no longer predictive, again indicating a weak 
relationship between susceptibility and the outcome.  
In conclusion, while it initially appears that susceptibility variables do influence 
actual and anticipated vaccinations, in interesting ways, it becomes clear with further 
analyses that susceptibility variables, when considered in the context of other predictors, 
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are not strong predictors of any of the HPV vaccine outcomes. Other factors play a much 
greater role in directly predicting vaccination behaviour.  
Hypothesis 2:  Perceived severity of HPV infection will predict HPV 
vaccination. Hypothesis two stated that participants’ perceptions of the severity of HPV 
would influence vaccinations, with the likelihood of wanting or obtaining the vaccine 
increasing as perceptions of severity increased. Various types of severity were assessed in 
this study: perceptions of the severity of treatment, of the social impact of having HPV, of 
HPV in general, and of fears of cervical cancer. Only perceptions of the severity of 
treatment were found to influence whether a woman got the vaccine or not. Women who 
were more concerned about treatment were more likely to want to get the vaccine. 
Concern about treatment severity proved to be a strong predictor of women’s actual 
vaccination decisions, as it maintained its predictive ability when all significant predictors 
of vaccine obtainment were placed into the final regression equation. 
For those who had not yet received the vaccine, severity was not found to be 
predictive of a desire to get the vaccine, although concerns about general severity were 
found to be related to actually thinking one would want the vaccine. This relationship was 
small, however, and when other factors that influence women’s vaccination decisions 
were taken into account, concerns about severity no longer had an impact on whether 
women would think they would get the vaccine or not. 
The results of this analysis parallel what has been found in previous research: 
mixed support for the influence that severity has on HPV vaccination decisions. 
Interestingly, previous research that has investigated whether severity is predictive of 
intentions to vaccinate also did not find a relationship (Buchanan, 2008; Dempsey, Zimet, 
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Davis & Koutsky, 2006; Jones & Cook, 2008). Thus, the lack of strong significant 
findings of a relationship between perceptions of severity and intentions in this study is 
not necessarily surprising. The interesting finding here, however, is that treatment 
severity was found to be predictive of actual vaccination behaviours.  
Hypothesis 3:  Perceived benefits will predict HPV vaccination. It was 
hypothesized that the more benefits an individual believed the HPV vaccine would 
provide, the more likely they would be to get vaccinated or to intend to get vaccinated. It 
was found that both beliefs about vaccine effectiveness and vaccine positive beliefs 
predicted actual vaccine obtainment when they were placed in the regression alone with 
vaccination status as the outcome. However, when they were entered into the regression 
model with other significant predictors, they were no longer predictive.  
The benefit variables proved to be more predictive of intentions to vaccinate. 
When desire to obtain the vaccine and beliefs that one would actually get the vaccine 
were assessed, both benefit variables were found to be predictive of each of these 
intentions. When placed into regressions with other significant predictors, the benefit 
variables were still predictive. Both vaccine effectiveness and vaccine positive beliefs 
continued to be predictive of a desire to get the vaccine, while beliefs about vaccine 
effectiveness continued to predict beliefs that one would actually get the vaccine. These 
results are similar to those of previous research, which found that perceived benefits 
predicted intentions (Buchanan, 2008). These previous studies also had found that 
women’s beliefs that the vaccine would help themselves or their children (similar to 
vaccine effectiveness in this study), or their community or society (similar to vaccine 
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positive beliefs in this study) were predictive of intentions (Dempsey et al., 2006; 
Gudmundsdottir et al, 2003).  
In summary then, it appears that beliefs about the benefits of vaccination are 
strong predictors of intentions to vaccinate, and yet are not the strongest predictors of 
actual vaccination behaviours. While little previous research in the area of HPV 
vaccinations has investigated these two benefit variables, this study suggests that these 
are important variables to consider when trying to understand what factors may influence 
women to think about obtaining the vaccine.  
Hypothesis 4: Perceived barriers will predict HPV vaccinations. It was 
predicted that more perceived barriers would negatively impact HPV vaccination 
behaviours. A large number of barrier variables were used in this study, and thus it was 
not surprising that for each outcome assessed, some barrier variables were predictive 
while some were not.  
When actual vaccine uptake was investigated, it was found that concerns about the 
safety of the HPV vaccine, women’s fears of experiencing stigma from their health care 
provider, and insurance coverage significantly impacted actual uptake.  These variables 
maintained their significance when entered into regressions with other variables, 
indicating that various barriers do play an important role in predicting actual vaccine 
uptake.  
 When a desire to get the HPV vaccine was investigated, concerns about vaccine 
safety, trust in pharmaceutical companies, cost, and fear of experiencing stigma from a 
doctor were associated with women’s desires to get vaccinated in initial analyses. 
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However, when other significant predictors were also taken into account, only vaccine 
safety concerns had a large enough influence on desire to maintain its significance.  
A similar lack of significance in the final regression model for barrier variables 
was also found when participants’ thoughts that they would actually get the vaccine were 
assessed. In the final regression investigating what barriers would influence whether 
women thought they would actually get the vaccine, no barrier variables proved to be 
predictive.   
 In summary, then, women’s concerns about the safety of vaccines, their fears of 
experiencing stigma from their doctor, and whether they had insurance, were the barriers 
that maintained their predictive ability for at least one of the outcomes. Interestingly, 
fears of experiencing stigma if asking a physician for the vaccine was one of the novel 
variables that was investigated in this study.  This finding indicates that the STI status of 
the vaccine may influence women’s decisions to vaccinate. Scale means revealed that 
while both vaccinated and unvaccinated women on average do not believe that their 
physicians would make negative judgements about them, women who got the vaccine 
disagreed more strongly that their doctor would judge them negatively. While the idea 
that patients do not want their doctors to view them negatively is not a new one in 
medical research, with medical research showing that patients give socially desirable 
information to their doctors because of concern with creating a desirable impression, 
fearing a loss of control, or even to avoid a lecture (Bilney & D’ Ardenne, 2001; Dew et 
al., 2007; Lewis, Matheson & Brimacombe, 2011), the fact that vaccination uptake is 
impacted by a fear of stigma from doctors is a unique finding in the area of HPV 
vaccination research. Even though the strength of the relationship between the fear of 
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stigma and vaccine uptake in this study was small, it will still be interesting to investigate 
this construct further in future research. It may be that fears of stigma are not as salient in 
questionnaire research, and that more complex experiments to investigate its effects in 
actual social interaction settings is needed. In summary, the finding that concerns about 
stigma may impact vaccination decisions is an important one to consider when experts 
look at ways to increase vaccinations, as some women may have concerns that they will 
be viewed negatively by others for asking for or obtaining this vaccine. Fear of stigma 
will also be an important variable to investigate in future STI vaccine studies, as other 
STI vaccines are currently in development. 
When the discussion turns to the other two barriers that were strong predictors of 
uptake, cost and concern about safety, their impact on vaccine obtainment was less 
surprising. Many media sources have documented (and fueled) public concern about the 
safety of the HPV vaccine, and about vaccines in general. In addition, past research into 
vaccination decisions, both about vaccines in general and the HPV vaccine specifically, 
have found that concerns about safety were related to uptake (Kahn et al., 2008; Prislin, 
Dyer, Blakely & Johnson, 1998). In this study, safety concern was one of the variables 
that had the largest difference in average scores when t-tests investigated differences 
between those who obtained the vaccine and those who didn’t. Those who obtained the 
vaccine had an average score of 2.7 out of 5 on the concern scale, while those who did not 
get vaccinated had an average score of 3.63 out of 5, revealing that those who did not 
obtain the vaccine actually reported that they did worry about the safety of the vaccine, 
while those who did get it reported a more neutral position. 
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Past research has consistently found that cost is a factor that individuals consider 
when thinking about the HPV vaccine (Caskey, Lindau & Alexander, 2009; Kahn et al., 
2008; Sauvageau, Duval, Cilca, Lavoie & Ouakki, 2007). Because of this it is not 
surprising that the insurance variable was found to be predictive of actual vaccination 
behaviours. It may be that those who have to pay for the vaccine simply could not afford 
it, or they may not have felt that they needed the vaccine enough to pay for it when it is 
rather expensive. Interestingly, the cost scale itself was not predictive of vaccination 
decisions in the final regression analyses This finding may be a true one, although the 
scale used in this study was not validated in other research, and so this finding could also 
be related to measurement error. The results from this study however, found that on 
average, participants reported that they were a little concerned about cost when they 
completed the cost scale; however, other variables such as benefits, cues to action and 
subjective norms proved to be more predictive of actual or intended vaccination 
decisions.  
Hypothesis 5: Knowledge will predict HPV vaccinations. HPV Knowledge was 
hypothesized to predict HPV vaccine obtainment and intentions. Surprisingly, knowledge 
was not directly related to any of the outcomes, neither actual nor intended vaccinations, 
assessed through the regressions conducted in this study. Previous research found mixed 
results when investigating the predictive ability of this variable, and thus while 
unexpected, the lack of support for this hypothesis is not entirely out of line with the 
findings from previous studies (Buchanan, 2008; Dempsey et al., 2006). While this study 
did not find that knowledge directly impacted vaccination related outcomes, knowledge 
did act upon other model variables, so that while it did not directly predict HPV vaccine 
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decisions and intentions, it was still indirectly related to these outcomes. Further 
elaboration of this result appears in the discussion of the structural equation model tested 
for this study that appears later in this section. In terms of the original hypothesis though, 
no support for the hypothesis was found. 
Hypothesis 6: Self-efficacy will predict HPV vaccination. It was theorized that 
feelings of self-efficacy for obtaining the vaccine would be related to intentions to 
vaccinate. Participants who had already received the vaccine were not asked to complete 
the items assessing self-efficacy, and so relationships between efficacy and actual 
vaccination decisions were not investigated. It was found that women with higher feelings 
of self-efficacy to obtain the vaccine were more likely to believe that they would actually 
get the HPV vaccine. This relationship between feelings of efficacy and thoughts that one 
would get the vaccine was significant, both in the individual regression investigating the 
relationship, and when it was placed in the final regression with other significant 
predictors. Feelings of self-efficacy were also initially predictive of desires to get the 
vaccine, although this relationship become nonsignificant when other, more predictive 
variables, were added into the analysis. Buchanan (2008) and Kahn et al. (2008) also 
found that self-efficacy predicted intentions to vaccinate.  
Hypothesis 7: Cues to Action will predict HPV vaccinations. It was anticipated 
that Cues to Action would be related to HPV vaccination behaviours. The results of this 
study revealed that Positive Cues to Action were indeed a strong predictor of actual 
vaccine obtainment, desire to get the vaccine, and thoughts that one would actually get 
the vaccine. Urgings to get the vaccine were predictive of each of these outcomes when 
assessed in initial regressions, and also when placed into regression equations with all 
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significant predictors, thus, revealing strong support for this hypothesis. While past 
research has found that cues from physicians and families do predict vaccinations 
(Caskey, Lindau and Alexander, 2009; Dempsey et al., 2006), the present study shows 
that cues from other sources also have a positive influence on vaccination behaviours. In 
this study, the number of cues an individual received, and their type, served as the cues 
variable. Cues could come from sources such as family, doctors, friends, advertisements, 
and romantic partners. Findings indicated that the more people or sources who talk to or 
educate women about the HPV vaccine, the more likely one is to be vaccinated, or to 
want the vaccine.  
Hypothesis 8: Subjective Norms will predict HPV vaccinations. Subjective 
norms were hypothesized to predict HPV vaccination behaviours and intentions. 
Women’s perceptions of the social norms surrounding the vaccine were found to predict 
actual vaccine obtainment when assessed apart from other significant predictors (although 
not when assessed with others), and to strongly predict both desire to get the vaccine, and 
thoughts that one would actually get it.  This significance held true for both outcomes 
when norm scores were entered into the regressions that included other significant 
predictors, indicating that what others think about the vaccine does influence women’s 
decisions. This supports findings by Buchanan (2008), who found that the subjective 
norms component of the Theory of Planned Behaviour was the only component from this 
model that was found to be predictive of intentions in her study. This idea, that the social 
discourse and norms surrounding certain vaccines influences uptake is not a new one, and 
has been discussed in research for other types of vaccines as well. For an interesting and 
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timely discussion of how public perceptions influence vaccination decisions (and in 
particular vaccine confidence), see Larson, Cooper, Eskola, Katz & Ratzan (2011). 
Because subjective norms were so predictive of desire and thoughts that one 
would actually want the vaccine, reasons for why norms were not predictive of actual 
vaccination behaviours were investigated further. Questionnaire items used to measure 
this construct were examined, and it appeared that these items may not have been worded 
adequately to assess this construct for individuals who had already received the vaccine. 
More specifically, the response options were not worded appropriately. An example item 
was “My romantic partner thinks…” and example response options were: “I definitely 
should not get the HPV vaccine”, and “Maybe I should get the HPV vaccine”. Because 
the wording of the items implies that a vaccination decision has not yet been made, 
individuals who had already been vaccinated may have been confused by this wording. If 
the items had been worded differently, the findings for this variable as they relate to 
actual vaccination behaviours may be more reliable. Future research in this area should 
aim to measure this variable more appropriately.  
Regression hypotheses overview. While many of the study variables were 
significant in initial regressions that only looked at the relationship between outcomes and 
each component, and the variable(s) that measured it, when all significant predictor 
variables from the various components were placed together into final regressions to 
assess each outcome, some variables lost their significance. Two of the modified Health 
Belief model components were not found to be directly predictive of any outcomes after 
the final regressions were conducted. These two components were perceived 
susceptibility and knowledge. Only one model component, cues to action, was predictive 
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of all three outcomes. The remaining model components were predictive of one or two 
outcomes. In summary, then, the majority of the hypotheses that predicted relationships 
between the model components and study outcomes were supported. However, specific 
hypothesis support varied across different outcome variables. In order to better 
understand the variables and model components that were predictive of different 
outcomes, a summary and discussion of the direct predictors of each outcome is presented 
next.  
Predictors of Actual Vaccinations 
Because this research is one of the few studies that has investigated factors that 
are related to actual vaccinations, the findings in this section may be particularly useful to 
health professionals. The model components that significantly predicted actual vaccine 
obtainment were: Severity (the severity of treatment variable), Barriers (vaccine safety 
concerns, fear of doctor stigma, insurance), and Cues to Action (positive cues to action). 
Fear of the severity of HPV treatment and cues to vaccinate are likely the factors that 
encourage women to get vaccinated, while the barrier variables discourage uptake.  
What do these significant findings mean?  While many barrier variables were 
hypothesized to predict actual vaccine uptake, only three were found to do so. Given past 
research findings that have reported concerns about the safety of the HPV vaccine, and 
given some individuals’ concern about vaccine safety in general, the fact that concerns 
about safety was one of the significant predictors of obtainment was not surprising. In 
addition, many past studies have found that cost is associated with HPV vaccination 
uptake, and so the significance of the insurance variable was also highly anticipated.  
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Perhaps the most interesting finding in terms of significant barrier variables, is the 
finding that women’s fears of experiencing stigma from a doctor was predictive of 
uptake. This is a novel variable in HPV vaccine research, and to this authors knowledge, 
is investigated here for the first time. Even though the statistical analyses from this study 
revealed that this variable had only a small impact on the outcomes, this finding is still 
important because it provides new information about a barrier to HPV vaccinations that 
health professionals need to recognize and research further. With this new knowledge, 
healthcare professionals can know to act to reassure their patients that obtaining the 
vaccine is a smart and healthy choice, and that they will not be negatively judged for 
doing so. Interestingly, given the relationship between Fear of Doctor Stigma and vaccine 
uptake in the current study, it is rather surprising that STI Stigma and Shame scores were 
not predictive of actual vaccination behaviours. This may be an interesting avenue for 
future research. 
While the hypothesis that perceived severity would predict uptake was supported, 
it is interesting that only one type of severity, treatment severity, was significantly related 
to behaviours. Treatment severity items asked participants how upset they would be if 
they had to receive treatment for certain medical issues associated with HPV. This is in 
contrast to other severity items, which intuitively may seem more likely to be predictive 
of behaviours (for example, items asking participants if they would be upset if they were 
told they have HPV, or genital warts, or abnormal cervical cells). It may be that 
pondering the actuality of treatment for an illness, which includes physical discomfort, 
time commitments, and social interactions, versus an illness in the abstract, is more 
powerful than pondering the severity of illness in general.  
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Finally, a surprising finding when looking at predictors of vaccine uptake, was the 
lack of a significant relationship between any of the benefit variables and vaccine 
obtainment. It appears that positive thoughts about the vaccine do little to directly impact 
actual vaccinations. While individuals’ own positive beliefs about the vaccine may not be 
a strong enough motivator to push them to get the vaccine, encouragement from others to 
get the vaccine (cues) was. This study shows that a mix of social (positive cues to action) 
and negative (perceptions of treatment severity) factors most strongly influence 
vaccination decisions.  
Predictors of Desire to Get Vaccinated, and Thoughts That One Will Actually Get It 
 While predictors of actual vaccine obtainment may be regarded as the most 
important variables to identify when it comes to investigating HPV vaccinations, it is also 
important to understand factors that predict intentions to vaccinate in those who have 
previously decided to forgo the vaccine. Interventions can and should target these 
individuals, especially considering the large number of women who fit into this category. 
Thus, understanding factors that will make these women consider getting vaccinated is 
important.  
For participants who had never been vaccinated, the variables that were found to 
be predictive of the two types of intentions were generally similar, although there were 
some differences. The model components that were predictive of a desire to get the 
vaccine were: Benefits (Vaccine effectiveness, Vaccine Positive Beliefs), Barriers 
(Vaccine Safety Concerns), Cues to Action, and Subjective Norms. Model components 
that were predictive of thoughts that one would actually get vaccinated were: Benefits 
(Vaccine effectiveness), Cues to Action, Self-Efficacy, and Subjective Norms. 
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  One of the most surprising findings here, is that barriers were not strongly related 
to either outcome. Only one barrier, concern about the safety of the vaccine, was 
predictive of desires, and no barriers were predictive of thoughts that one would actually 
get the vaccine. In contrast, three barriers were found to predict actual vaccine 
obtainment. 
 Subjective norms were found to influence both desires to get the vaccine, and 
thoughts that one would actually get it, indicating that women’s thoughts about the 
vaccine were influenced by what they perceived to be the social norms surrounding this 
issue. In light of this, it will be important that intervention efforts in this area focus on 
increasing societal acceptance of the HPV vaccine. This could be accomplished by means 
such as encouraging dating partners to both get vaccinated, or encouraging friends, or 
parents and children, to talk about the vaccine together.  The more sources that women 
receive encouragement from, the more likely they will be to get vaccinated. 
 The perceived benefits associated with vaccination were also found to be 
predictive of both intention outcomes. This is not surprising, and was predicted. It is 
logical that individuals who perceive benefits to vaccination will want to be vaccinated, 
and are more likely to think they actually will do so. It is interesting to note that benefit 
variables were initially found to be predictive of actual vaccination decisions, but that 
their predictive influence was not as large as the influence of other variables. For 
individuals who have not been vaccinated, however, perceived benefits are still a strong 
motivating factor to wanting the vaccine.  
Feelings of self-efficacy related to getting the HPV vaccine were found to predict 
beliefs that one would actually get vaccinated, but not desires to get it. Self-efficacy items 
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asked participants if they were confident that they could get the vaccine in light of things 
like cost, time, and potential barriers. This finding demonstrates that individuals who 
report that they are not likely to actually get the vaccine are aware that they lack the 
ability to overcome some of the barriers to obtainment that were listed in the efficacy 
questionnaire. This finding also highlights that researchers need to carefully word their 
outcome items when doing research, to ensure that items really ask what it is that 
researchers want to know. While desires to get the vaccine and thoughts that one actually 
will do so are closely related constructs, and do share many of the same predictors, there 
are some interesting differences between the two variables.   
Why Predictors May Vary for Actual and Intended Outcomes 
 One of the interesting questions that the results of this study raises, is why the 
variables that influence actual vaccination behaviours and intentions to vaccinate differ. 
These differences are likely related to barriers. While forming an intention to do 
something does not require one to become keenly aware of, and overcome barriers, acting 
or not acting requires one to acknowledge, think about, and then overcome obstacles (or 
not). This idea is clearly demonstrated by the current study finding that more barrier 
variables were predictive of actual vaccination behaviours then they were of intentions.  
Discussion of the Model of HPV Vaccination Intentions   
 The proposed model explaining the process through which HPV vaccination 
desires are formed, was found to have good fit to the data after a small number of 
modifications. In the original model, the decision process is depicted as beginning with 
the components HPV Knowledge and Cues to Action. It was hypothesized that the 
decision process begins with knowledge about the topic, and also when one is prompted 
Factors that influence HPV vaccinations  145 
 
to think about the topic at hand (in this case HPV vaccinations). These two components 
were both hypothesized to influence perceptions of Severity, Susceptibility, and 
Subjective Norms. These hypothesized relationships were supported for the most part, 
although some relationships were not present. Knowledge was not found to influence 
Subjective Norms, and Positive Cues to Action were not found to influence perceptions of 
Severity. In addition, an unanticipated relationship between Cues to Action and the 
Benefits variable was discovered. A discussion of each component and the relationships 
between them follows. 
For the Knowledge component, the results of the SEM confirmed that knowledge 
does influence how susceptible one feels to HPV and how severe one believes HPV is. 
Knowledge does not influence social norms, however. It was anticipated that HPV 
knowledge may impact social norms, because increased knowledge would allow one to 
be more aware and critical of the perceptions of others. This hypothesis was not 
supported, however.  
Examination of the relationships that were found, or not found, between positive 
cues to action and the three components believed to be influenced by them, revealed that 
cues to obtain the vaccine were related to women’s perceptions of their susceptibility to 
HPV. Prompts to obtain the vaccine were also found to be related to subjective norms, but 
were not found to be related to perceptions of severity. The lack of a relationship between 
Cues and Severity could be explained by the idea that receiving Cues does not necessarily 
mean that one understands HPV and the impact it can have on health. Receiving prompts 
to obtain the vaccine did appear to influence individuals’ feelings of susceptibility 
though, and they also made participants aware of the social norms surrounding the 
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vaccine. Positive Cues to Action was also, unexpectedly, found to be related to perceived 
benefits. This unanticipated relationship does make sense however, as the more positive 
cues one receives for the vaccine, the more likely they would be to perceive the benefits 
of vaccination. 
When looking at the original model that was proposed, the next set of anticipated 
relationships involved the components of Susceptibility, Severity, and Subjective Norms. 
These components were each hypothesized to be related to perceived benefits and 
barriers. Results revealed that the social norms surrounding the vaccine are related to 
women’s perceptions of both the benefits and the barriers of vaccination. Women’s 
perceptions of HPV severity and their susceptibility to HPV infection were both found to 
be related to perceived barriers to vaccination, but they were not found to be related to 
perceived benefits. The lack of a relationship between feelings of susceptibility and 
severity, and the perceived benefits of vaccination was surprising. It was anticipated that 
women with more worry (higher perceived severity and susceptibility), would believe 
there were more benefits to obtaining the vaccine because vaccination would lessen their 
worries. Instead, it appears that the potentially negative feelings of severity and 
susceptibility are related only to women’s perceptions of HPV vaccination barriers. It 
may be that once women’s thoughts about the unpleasant topics of HPV severity and 
susceptibility are activated, that they begin to worry about other negative things such as 
fears of vaccine safety, fear of stigma, and costs. 
Returning to the proposed model tested for this study, a relationship between 
feelings of self-efficacy and women’s perceptions of the barriers surrounding vaccination 
was predicted. This relationship was supported by the results of this study, an important 
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finding because it shows that participants may have the potential to overcome barriers 
that they believe stand in their way to vaccination. Due to the way that self-efficacy was 
assessed in this study, with items measuring women’s feelings that they could overcome 
various real-world obstacles (time, money) to getting vaccinated, it was not anticipated 
that feelings of self-efficacy would impact any other theoretical component.   
The final set of predictions made in the original model were that Benefits and 
Barriers would be related to desires to obtain the HPV vaccine. These predictions were 
supported in this study. Both components were found to be significantly related to the 
outcome. Interestingly, perceived benefits had a much stronger relationship with vaccine 
desires than did perceived barriers. This finding falls in line with the results of the 
regression analyses conducted earlier. While both types of benefits predicted desires to 
obtain the vaccine in the regressions, only one of many barriers proved to be predictive.   
 While the model tested in this study had good fit with the data, the women that 
make up the study sample represent a privileged group of women, with the majority of 
women having at least some university education and being Caucasian. It may be that if 
this model was tested on a less privileged group of women, minority, poor or uneducated 
women for example, that some of the component relationships would change. 
Underprivileged women face life challenges and develop perspectives about the world 
that privileged women do not necessarily develop. For example, underprivileged women 
often have lower levels of educational obtainment, which may impact how the knowledge 
component of the model would influence the study variables. In addition, these women 
would likely face more or stronger barriers to vaccination uptake. Cost may prove to be a 
much more important predictor of decisions for this group of women, as may fears of 
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stigma, or distrust of physicians or the healthcare system. Disadvantaged groups typically 
have experienced more stigma, and have less faith in healthcare and the altruism of 
healthcare professionals, and thus these factors may have an impact on what a model of 
HPV vaccine intentions looks like for these women. Of course, other model components 
and variables may also be impacted as well. Infection and treatment may be deemed more 
severe due to a lack of resources to deal with it, or women may feel more susceptible for 
example. The complex interactions between the variables may change in interesting ways 
when the model is tested on other groups of women. Thus, future research should seek to 
test the current model of HPV vaccine intentions, as well as alternate models, with other 
groups of women.   
In summary, the model of desires to obtain the HPV vaccine that was proposed in 
this study was supported with a few modifications. These modifications were all logical, 
and provide a deeper, and perhaps more interesting, understanding of the relationships 
between the model components. In addition, while the results of the regression analyses 
presented earlier seemed to suggest that certain model components are not related to HPV 
vaccine outcomes, the SEM  model reveals that all components are important to the 
decision making process. Not all components are directly related to the outcomes, but 
they do impact other components. Because no previously published research in the area of 
HPV vaccinations has tested a SEM model of decision making, this study provides an 
important starting place from which to research the decision making process related to 
actual and intended HPV vaccination decisions.   
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Limitations 
 As is true for all research, there were limitations to the current study that warrant 
discussion. While a substantial number of women participated in this study, a larger 
sample size would have allowed for a better analysis of the impact of some of the study 
variables on outcomes. More specifically, demographic or personal history variables that 
were only reported by a small number of participants (e.g., HPV status, HPV treatment), 
could not be analysed for their impact on the outcome variables. A larger sample size 
might have allowed for this. In addition, the sample for this study was predominantly 
white and college educated, and a more diverse sample would have been more 
representative of women in general. The final issue related to sample is the age of the 
women recruited for this study. While it is important to investigate predictors of 
vaccinations in women 18 to 30, it would also be very beneficial to conduct a study with 
younger girls and their parents.  
 Another limitation of the current study concerns some of the study measures. 
Because this investigation was based on a theoretical model that had not been extensively 
tested in this area, various study measures had to be created or modified. As a result, 
obtaining or creating alternative measures for some of the variables in this study may 
result in additional significant findings. An example of a measure in need of modification 
is the Subjective Norm measure. The items were not worded well for women who had 
already received the vaccine. Thus, analyses using this measure for this population may 
be less reliable in the current study. Research in the area of HPV vaccinations should 
continue to modify and evaluate the appropriateness of measures in order to confirm the 
findings found in this study. 
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 A related idea that also needs to be considered when contemplating the findings 
from this research, is the retrospective nature of the study, in that predictors of actual 
vaccinations were assessed after vaccination were or were not obtained. It may be that 
individuals who obtained the vaccine have different views and perceptions, as a result of 
having obtained the vaccine, than they did before they obtained it. Future research should 
address this limitation by assessing attitudes before an individual has obtained the 
vaccine, and then comparing the views of those who were vaccinated and not vaccinated.  
  Another aspect of the present study that some may consider to be a limitation, is 
the method used to recruit participants. Participants were recruited from two sources and 
completed the study online. The majority of the sample came from the Psychology 
Department participant pool. The participant pool is comprised of Introductory 
Psychology students, as well as individuals in various other psychology courses at the 
university. A large proportion of University of Windsor students take Introductory 
Psychology; thus, the students within the participant pool come from a variety of 
backgrounds and likely represent a diversified group of women within the university 
setting. In light of this, while using a participant pool may be a limitation, the diversity of 
the group makes it less of a concern then it may be otherwise. The second group of 
women who participated in this study were recruited through email and the social 
networking site Facebook. Because the email and Facebook recruitment advertisements 
originated with the author, the women who participated in this study and who heard about 
it through this method may be limited, in that they might constitute a more homogeneous 
group of women with some degree of connection to the researcher or her acquaintances. 
While the types of recruitment used in this study is a limitation, the examination of the 
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sample characteristics and the comparison made to an average Canadian sample revealed 
that in many respects this sample is similar to the average Canadian woman.  
Another possible limitation with this study is the fact that data was collected 
online. However, in this age of high computer usage, 79% of Canadian households have 
the internet (Statistics Canada, 2010), and especially among the age demographic 
recruited for this study, it is not anticipated that having to use a computer to complete the 
study would lead to problems with the integrity of the data collected. Thus, collecting 
data online likely had minimal impact on the external validity of the study.  
Implications 
 The results of this study have several important practical implications. This study 
clearly highlights the fact that previous research findings based on only the analysis of 
direct relationships between variables and HPV outcomes do not provide an accurate 
picture of all of the factors that influence vaccination decisions. Thus, it is important for 
health professionals and researchers who are designing interventions and educational 
programs related to HPV vaccinations to understand the complex range of variables that 
may have both direct and indirect relationships with HPV vaccination decisions. For 
instance, the regression results from this study might seem to suggest that HPV 
knowledge is not related to vaccine outcomes, and thus may lead to the erroneous 
conclusion that increasing knowledge will not have an effect on HPV vaccine outcomes. 
However, the results of the model testing in this study clearly show that knowledge does 
have an impact on outcomes indirectly, through its relationship to perceptions of severity 
and susceptibility, and thus educational efforts in this area would still be important.    
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 Another interesting implication that arises from the current study is related to the 
finding that concern about experiencing stigma from a health care provider if asking for 
the vaccine can impact vaccination decisions. This is an important finding, and should be 
taken into account by health professionals when they are offering women the vaccine. 
Professionals should plan an approach to offering the vaccine that indicates to women 
that they will not be judged negatively for accepting it. An intervention in this area would 
be an interesting next step. For example, a study investigating whether an intervention 
designed to decrease women’s fears of stigma increases vaccine acceptance could be 
conducted. Information could be provided through various methods in order to assess 
which is most effective. For example, a face to face discussion with a health care 
provider, an online program recommended by a reliable source, or printed educational 
materials provided by the healthcare provider or their support staff to patients. It should 
be noted that research into the usefulness of a Canada-based sexual health related website 
found that using the internet as a sexual health promotion tool is very effective, in that 
websites can have far reach, be cost-effective, and can be tailored so that they are 
interactive and engaging (Barak & Fisher, 2003). In addition to interventions targeted at 
the public, training could also be offered to health care providers so that they learn how to 
interact with patients in a way that makes women feel safe and free from stigma.  
 This study also revealed that concerns about vaccine safety do play a role in HPV 
vaccination decisions. Efforts to reduce vaccine concerns at both the individual level 
(e.g., when women are visiting with their health care providers), and at the societal level 
(e.g., through government and public health campaigns) are needed. 
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 Finally, another important implication of the current study was the finding that 
positive cues to action do influence vaccinations. Thus, the more types of positive cues 
that a woman receives, the more likely it is that she will be vaccinated. Positive public 
service messages, commercials, encouragement from doctors, and efforts to have women 
encourage each other, should be developed and investigated in order to encourage vaccine 
uptake.  
Suggestions for Future Research 
 One of the most important tasks for future research in this area is to focus on 
developing and validating scales to assess the model components and variables that were 
investigated in this study. While some variables were assessed with previously validated 
scales, others were not, and this inability to use well researched measures may have 
impacted the results of the current study. Thus, researchers looking at HPV vaccinations 
should focus on identifying variables that may have an impact on vaccine decisions, and 
how to measure them most effectively. 
 One of the more novel findings from this study is that women’s fear of stigma 
when asking for the vaccine can impact their vaccination decisions. Future research into 
possible interventions related to this would be valuable. Training health professionals to 
be aware of this barrier and how to overcome it in their discussions and education with 
women, and evaluating the impact of such training efforts, would be an interesting avenue 
of research.  
 Finally, future research in this area should also move away from the analysis of 
only direct relationships among variables and outcomes, and should begin to focus more 
on complex modeling. Because there were no previous SEM studies investigating HPV 
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vaccination decisions to my knowledge, the model tested in this study was exploratory. 
Additional research involving complex modeling is needed in this area, so that alternative 
models can be tested and compared. This will be the only way that a full understanding of 
the factors that influence vaccinations will be available. Continuing research in this area 
has the potential to positively impact women’s lives by increasing vaccinations. This 
might lead to fewer HPV infections, less distress from symptoms, and saved lives.  
Conclusion 
 This study investigated factors that predict actual and anticipated HPV 
vaccinations. Results revealed that the predictors of actual vaccine obtainment were 
women’s perception of the severity of HPV treatment, concerns about vaccine safety, 
whether one had insurance coverage for the vaccine or not, level of fear of experiencing 
stigma from their doctor, and positive cues to action. Factors that have an impact on 
intentions to receive the HPV vaccine were participants’ belief that vaccines are 
beneficial, beliefs that the HPV vaccine would be effective, concerns about vaccine 
safety, positive cues to action, self-efficacy, and social norms surrounding the vaccine. 
This study was beneficial to the area of HPV vaccine research, not just because it 
identified direct predictors of vaccination decisions, but also because it revealed that these 
predictors are different for actual versus intended vaccination decisions, and that even 
predictors of certain types of intentions vary somewhat, as desires to get the vaccine had 
some different predictors than did actually thinking one will get the vaccine. Finally, this 
study was also beneficial because it tested and found support for a complex model of 
HPV vaccination intentions and is the first study to use theory to successfully build and 
find support for a model of HPV vaccination intentions using SEM.   
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Appendix 
Questionnaires Developed for This Study 
 
Perceived HPV Susceptibility 
 
Rated on a five-point scale: 1 (very unlikely) 2 (somewhat unlikely) 3 (50/50 chance) 4 
(somewhat likely) 5 (very likely) 
 
1. Do you feel at risk of being infected with HPV? 
2. Do you feel at risk of getting cervical cancer? 
3. Do you feel at risk of getting genital warts? 
4. Do you feel at risk of having an abnormal Pap test? 
 
 
Perceived Severity of HPV Infection 
 
Rated on a five-point scale: 1 (not at all) 2 (a little) 3 (somewhat) 4 (quite a bit) 5 (very 
much) 
 
General Severity Questions 
 
1. How upset would you be if / were you when you were told that you have the HPV 
virus? 
2. How upset would you be if / were you when you were told that your Pap test was 
abnormal? 
3. How upset would you be if / where you when you were told that you have genital 
warts? 
4. Would you / did you worry about the impact of an HPV infection on your body? 
5. Would you / did you worry about your future fertility if you had HPV? 
 
Treatment Severity Questions 
 
1. How upset would you be / were you if you had to have treatment to remove genital 
warts? 
2. How upset would you be / were you if you had to have treatment to remove abnormal 
cervical cells? 
3. How upset would you be / were you when thinking about the impact of HPV on your 
body? 
4. Do you believe treatment for genital warts is/ was painful? 
5. Do you believe treatment for abnormal cervical cells is/was painful? 
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Social Severity Questions 
 
1. How upset would you be / were you if your doctor knew you had HPV? 
2. How upset would you be / were you if your sexual partner knew you had HPV? 
3. How upset would you be / were you if your friends knew you had HPV? 
4. How upset would you be / were you if you had to tell future sexual partners that you 
had HPV? 
5. If you were single and dating would you worry / did you worry about telling future 
sexual partners that you had HPV? 
 
 
HPV Vaccine Effectiveness 
 
Rated on a five-point scale: 1 (not at all) 2 (a little) 3 (somewhat) 4 (quite a bit) 5 (very 
much) 
 
1. In general, how effective do you think the HPV vaccine is?  
2. In general, I believe the HPV vaccine would benefit me. 
3. I believe the HPV vaccine would benefit me because it would reduce my risk of HPV 
infection. 
4. I believe the HPV vaccine would benefit me because it would reduce my risk of 
Genital Warts 
5. I believe the HPV vaccine would benefit me because it would reduce my risk of 
developing cancer. 
6. I believe the HPV vaccine would benefit me because it would protect my future 
fertility 
7. I believe the HPV vaccine would benefit my current or future romantic relationship(s) 
8. I believe the HPV vaccine would benefit my current or future sexual relationship(s) 
 
 
HPV Vaccine Safety Fears 
 
Rated on a five-point scale: 1(strongly disagree) 2 (disagree) 3 (neutral) 4 (agree) 5 
(strongly agree) 
 
1. I worry about the safety of the HPV vaccine 
2. I worry the HPV vaccine has not been out long enough to properly judge its safety.  
3. I worry about side effects from the HPV vaccine 
4. I worry about the safety of vaccines in general 
5. I worry about side effects from any type of vaccine 
6. I believe vaccines are safe.  
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Fear of Dr. Stigma 
 
Rated on a five-point scale: 1(strongly disagree) 2 (disagree) 3 (neither agree nor 
disagree) 4 (agree) 5 (strongly agree) 
 
If I asked my doctor for the HPV vaccine, the doctor would think…: 
1. That I sleep around 
2. That I am responsible 
3. That I will cheat on my romantic partner 
4. That I have poor morals 
5. That I don’t trust my romantic partner 
6. That I am protecting myself 
7. That my relationship is on the rocks 
8. That I am loose 
9. Nothing of it (*removed before analysis) 
10. That I want to protect my sexual partner(s) (*removed before analysis) 
11. That I am smart 
12. That I am a bad person 
 
 
Pharmaceutical Company Trust 
 
Rated on a five-point scale: 1(strongly disagree) 2 (disagree) 3 (neutral) 4 (agree) 5 
(strongly agree) 
 
1. I trust pharmaceutical companies 
2. The only thing pharmaceutical companies care about are profits 
3. I feel like I have to do my own research about whether certain drugs or vaccines are safe. 
4. Pharmaceutical companies properly test their drugs before they are made available to the 
general public. 
5. The people who work for pharmaceutical companies are honest people. 
6. I worry that pharmaceutical companies do not tell the truth about all of the side effects and 
reactions that people have to their products. 
7. Pharmaceutical companies charge significantly more for their products than they need to make 
a reasonable profit.  
8. Pharmaceutical companies bribe doctors to recommend their products. 
9. Developing and testing new drugs and vaccines is a long and complex process and 
pharmaceutical companies do the best they can to make the process safe and fair. 
10. Pharmaceutical companies make false claims in their advertising 
 
 
Cost 
 
Rated on a five-point scale: 1(not at all) 2 (a little) 3 (somewhat) 4 (quite a bit) 5 (very 
much) 
 
1. Is/was cost a concern when you think about/thought about getting the HPV vaccine? 
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2. Is the HPV vaccine a fair price? 
3. Does/did the cost of the HPV vaccine influence your decision to get the vaccine? 
4. Can you/could you afford to get the HPV vaccine?  
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